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Summary
Introduction: The aim of this thesis was to critically evaluate the potential of 
photodynamic therapy (PDT), using a novel non-laser light source and a 
topically active photosensitizing agent, 5-aminolaevulinic acid (5-ALA), for 
use in the management of skin cancer. PDT primarily acts via the activation 
by visible light, of a photosensitizer located within the neoplastic tissue, to 
produce activated oxygen species, especially singlet oxygen, in order to 
promote tumour destruction.
Lasers have been the usual source of irradiation in PDT although 
coherence of light is not required. Recent developments in light technology 
have enabled the production of a relatively inexpensive non-coherent light 
source of similar intensity and wavelength to laser. The development of a 
topically active agent, 5-aminolaevulinic acid (5-ALA), converted within cells 
to the active photosensitizer, protoporphyrin IX, can now avoid prolonged 
generalized photosensitivity reactions which limited the development of PDT 
as a practical clinical therapy.
Published clinical data on ALA-PDT available at the commencement of 
this thesis related predominantly to the use of lasers in open studies, with 
short term follow-up. The potential of non-laser light had received only 
limited interest and no randomized comparison trials of PDT had been 
undertaken.
Methods: Local hospital ethical committee approval was acquired for the 
clinical studies. A prototype light source, incorporating a 300W xenon short 
arc discharge source, (Cancer Research Campaign, U.K.), with a proven 
efficacy from in-vitro and in-vivo studies comparable to laser, was used in all 
U.K. studies. 5-ALA (20% w/w) was applied 4 or 6 hours (Bowen's disease 
and basal cell carcinoma) or 24 hours (cutaneous T-cell lymphoma) pre­
Xillumination. All studies using the prototype source were performed in the 
U.K. by myself. Two murine studies were undertaken by myself in Buffalo, 
NY where I also participated in a clinical study of ALA-PDT in cutaneous T- 
cell lymphoma (CTCL).
Chapter outline: Chapter 1 reviews the development of both the 
photosensitizers and light sources for PDT along with a detailed description 
of the photodynamic reaction and its acute and chronic effects. Chapter 2 
reviews the literature on the use of PDT in cutaneous malignancy with 
comparison of individual study protocols.
Chapter 3 summarizes the clinical trials of topical ALA-PDT using the 
prototype xenon source, with output filtered to 630±15nm. The studies and 
principal findings are listed below:
1. Actinic keratoses and Bowen's disease - Pilot study: 24 lesions, 100% 
initial clearance, 2 recurrences over 12 months, pain absent/mild during 
therapy in 22 lesions, local anaesthesia required in only one ulcerated lesion. 
This confirmed the clinical efficacy of ALA-PDT using the prototype lamp.
2. ALA-PDT vs. cryotherapy in Bowen's disease - Randomized comparison 
study: 40 lesions, PDT at least as effective as cryotherapy with a higher 
probability of clearance after one treatment with PDT. Cryotherapy was 
associated with more frequent adverse effects with ulceration and wound 
infection, effects not observed following PDT.
3. Effect of tumour thickness and time of 5-ALA application on BCC response 
- Comparison study, 53 lesions, tumour thickness predicted therapeutic 
response (p<0001). PDT most effective for BCC up to 1mm in depth (CR = 
100%) with a higher clearance rate for thicker lesions (1-2mm) when 5-ALA 
application was increased from 4 hours (CR = 43%) to 6 hours (CR = 100%).
4. Light dose/response study of ALA-PDT for Bowen's disease - Randomized
comparison study, 122 lesions, 25-125J/cm2 of red light (630±15nm) was
xi
more effective than lower doses in clearing lesions and minimizing 
recurrence (p<0.001).
5. ALA-PDT for large patch Bowen's disease - Open study, 40 lesions, 88% 
initial clearance after 1-3 treatment sessions, with inferior response for larger 
lesions. Four recurrences over 12 months of follow-up.
6. Red vs. green light for ALA-PDT in Bowen's disease - Randomized 
comparison study, 61 lesions, with complete response rate at 12 months 
using red light of 88%, compared with 48% using a theoretically equivalent 
dose of green light (p=0.002).
Chapter 4 examines the macroscopic and microscopic skin changes 
induced by ALA-PDT using the prototype lamp. Oedema and erythema 
developed during therapy and settled over 48 hours. Although occasional 
blister formation occurred, ALA-PDT only induced epidermal ulceration 
following therapy in one patient. Whilst there are no observed specific 
histological changes of ALA-PDT, both necrosis and apoptosis occur. 
Microscopic evidence of scar formation developed in a few basal cell 
carcinomas, but rarely occurred after PDT to other lesions.
In chapter 5, two murine studies were undertaken to determine 
whether a photoproduct of PPIX, activated by 670nm light, can be detected in 
vivo and alter PDT response. The initial study of cutaneous damage induced 
by 635 with or without 670nm light indicated phototoxicity attributable to a 
photoproduct at 670nm. Dual wavelength illumination appeared to be 
responsible for an improved tumour response to ALA-PDT in the second 
study. These pilot studies suggest a therapeutic benefit from inclusion of 
670nm in the light spectrum in ALA-PDT.
Chapter 6 summarizes the potential for ALA-PDT in the treatment of 
CTCL. Previously restricted to 2 case reports, this is described in detail for 
patch, plaque and tumour stage disease in patients with multiple lesions. 
Complete clearance was reported for 50%, 56% and 33% of 14 patch, 18
plaque and 21 tumours following 2 treatment sessions with increased 
response following further treatments. Five lesions recurred during a 12 
month follow-up period. This gives an overall response rate of 45% which 
requires comparison with existing modalities to determine the place of PDT in 
CTCL management.
Overview: This thesis progresses the development of ALA-PDT in
cutaneous malignancy. Randomized comparison or large open studies have 
permitted the refinement of protocols, assessment of clinical efficacy and 
adverse reactions, and monitored long term follow-up. Several studies 
confirm the efficacy of a compact non-laser source in PDT which, combined 
with topical application of photosensitizer and protocols to permit day/out­
patient therapy, endorses ALA-PDT as a practical clinical modality.
Topical ALA-PDT is confirmed as an effective therapy for certain non­
melanoma skin cancers, in particular, Bowen's disease and superficial BCC. 
PDT offers the advantages of being non-invasive, well tolerated in slow 
healing sites, and tissue sparing, leaving the skin surrounding the tumour 
intact and functional. ALA-PDT is demonstrated to be particularly useful for 
large superficial tumours and for lesions in anatomical sites where 
disfigurement from conventional therapies may be a particular risk. An initial 
assessment of ALA-PDT in CTCL also suggests that this may be a useful 
additional modality.
The poor efficacy of 4 hour ALA-PDT for lesions greater than 2mm in 
depth represents a major limitation for its use in nodular BCC and other 
potentially metastatic lesions, such as squamous cell carcinoma. New 
photosensitizers and the further refinement of treatment protocols may 
increase the depth of action of ALA-PDT. Utilizing the immunological effects 
of PDT may also allow improvements in response at tissue depths beyond 
that predicted by light attenuation and photosensitizer absorption.
The rising incidence of cutaneous malignancy and the requirement to 
provide effective, yet well tolerated therapy with good cosmesis, suggest that 
ALA-PDT, using a relatively inexpensive non-laser source, can be an 
effective additional modality, although its current clinical use should be 
restricted to in-situ squamous cell carcinoma and superficial basal cell 
carcinoma.
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1Chapter 1 - Photodvnamic therapy - development.
mechanisms of action and applications
1.1 -Introduction
Photodynamic therapy (PDT) is the activation of a photosensitizing 
drug by visible light to produce activated oxygen species within the 
neoplastic/dysplastic tissue. The photosensitizer or precursor requires to first 
be introduced into the dysplastic tissue and should be retained there at 
higher concentration than in the normal surrounding tissue to permit a 
disease-localizing therapeutic effect. This tissue is then exposed to light of a 
wavelength appropriate for absorption by the photosensitizer. Through 
several photophysical pathways, reactive oxygen species harmful to cell 
function, including singlet oxygen, are produced and eventual tissue 
destruction results.
Despite the concept of photodynamic therapy being first described 
almost 100 years ago, the development of PDT as a potential clinical 
modality has occurred only during the past 20 years with topical therapy first 
reported as recently as 1990. Section 1.2 outlines the history of the 
development of PDT.
A comprehensive understanding of the mechanisms involved in PDT 
tumour destruction has yet to emerge. Variations in treatment protocol are 
likely to determine the relative importance of the various cellular and vascular 
events occurring during PDT to achieve a therapeutic effect. Sections 3-7 of 
this chapter summarize current knowledge of these mechanisms with 
emphasis on those known to be relevant to the in-vivo PDT response.
PDT has been used to successfully treat a variety of cutaneous and 
non-cutaneous neoplasms with a few non-neoplastic applications also under 
assessment. World-wide, PDT has been approved for clinical use in one or 
more countries for the treatment of tumours of the bladder, lung, oesophagus,
2stomach and cervix. PDT is licensed for the treatment of early superficial 
neoplasia and the palliation of late disease of these organs. Section 1.8 
summarizes the potential non-cutaneous applications of PDT and current 
interest in its use for inflammatory cutaneous disorders.
1.2 The development of photodynamic therapy
The term 'photodynamic therapy' was first used in 1907 by von 
Tappeiner following experiments using eosin and a combination of natural 
and artificial light in the treatment of skin cancer, lupus of the skin and 
condylomata of the female genitalia.1 He realized the requirement for 
oxygen, describing the phenomenon as an oxygen-dependent 
photosensitization. Around this time, the first studies of the biological 
properties of haematoporphyrin were reported. Meyer-Betz2 observed 
photosensitivity of light-exposed sites which persisted for more than two 
months following self-injection of the agent. The subsequent observation of 
selective localization of porphyrins to tumours3 (1924) and the demonstration 
of a photodynamic action involving haematoporphyrin in tumours4 (1942) 
raised interest in PDT. However, large doses of the crude photosensitizer 
were required and the consequent phototoxicity limited development. Partial 
purification produced haematoporphyrin derivative (HpD) which had greater 
tumour-localising properties. PDT using HpD in human cancer was reported 
in 1967 by Lipson et a/5. The first human trial of PDT using HpD was 
performed by Dougherty et a/6 in 1978 in a variety of malignancies, with 
complete or partial response in 111 of 113 lesions. Tumours treated included 
carcinomas of the breast, colon, prostate, squamous cell, basal cell and 
endometrium, mycosis fungoides, chondrosarcoma and angiosarcoma. Many 
studies have subsequently reported the successful use of PDT with HpD or
3its more purified form, porfimer sodium (Photofrin II), in the treatment of 
various cutaneous and non-cutaneous malignancies.7"9
Whilst Hpd and porfimer sodium require systemic administration,
10Kennedy et al reported in 1990 a topically active agent, 5-aminolaevulinic 
acid (5-ALA), which is converted within cells to the active photosensitizer, 
protoporphyrin IX (PplX). This avoids the problem of generalized 
photosensitivity which followed the use of HpD and could last 6-10 
weeks.11,12 PDT using topical 5-ALA now offers the potential of a practical, 
out-patient based, alternative treatment modality for dermatology.
1.3 Mechanisms of action - Photosensitizers and their delivery
Photosensitizers possess the ability to transform absorbed light energy 
(photoexcitation) into chemical energy. The initial stage of PDT involves 
delivering the photosensitizer to the target tissue. Photosensitizers are 
distributed to and retained by both normal as well as neoplastic tissues.13 
There is considerable variation between agents in the time interval between 
administration and peak sensitizer tissue levels, and in the duration of 
sensitizer retention in tissues, although much of this work relates to in-vivo 
experiments in mice.14 Despite the wide distribution of systemically 
administered photosensitizer, rodent tumour models demonstrate a poorly 
understood, partially selective, tumour response. These responses appear to 
be even more pronounced in human malignant skin lesions. A gradient of 
differential sensitizer concentration between tumour and surrounding tissue 
has been demonstrated, but differs between sensitizer and tumour type. The 
photosensitizer chloraluminium phthalocyanine (AIPcSn) is found following 
injection into mice in a ratio of 2:1 tumour:normal tissue concentration in UV- 
2237 fibrosarcoma, but 10:1 for the Colo 26 carcinoma.14 Photofrin II 
tumour:skin ratios are usually less than 2:1 in transplantable rodent tumours
4and certain normal tissues (liver, spleen) may retain more photosensitizer 
than tumours.15"17
For skin tumours in humans, the topical route of application of 5-ALA 
permits an alternative method of tumour selectivity. 5-ALA is a precursor, in 
the haem biosynthesis pathway, of protoporphyrin IX (PplX), an endogenous
photosensitizer not normally present within tissue in therapeutically useful
18concentrations. Exogenous administration of 5-ALA, however, can increase 
the intracellular concentration of PplX as 5-ALA is the first precursor of haem 
after the feedback control point and the conversion of PplX to haem is 
relatively slow. Local application of 5-ALA is possible due to its increased 
passage, when in aqueous solution, through an abnormal epidermis thus 
restricting the photosensitization primarily to the tumour sites. This tissue 
selectivity in 5-ALA photodynamic therapy can be demonstrated by the
19detection of PplX-induced fluorescence. Svanberg et al report a 15:1 
tumournormal ratio in basal cell carcinomas (BCC) and in Bowen's disease 6 
hours following the topical application of 5-ALA.
5-ALA induced PplX accumulates, after topical or systemic 
administration, primarily in epithelia (epidermis, conjunctiva, oral, respiratory 
and vaginal mucosae, serosal surfaces, endometrium and urothelium) or in
glands and ducts (sebaceous, mammary, salivary glands and seminal
10vesicles), but not in mesodermal tissues. This may be due to different 
capacities of cells to synthesize haem or differences in feedback control. 
Proliferating, relatively iron deficient, tumour cells preferentially accumulate
PplX as iron is required for the final conversion of PplX into haem. This is
20described as the biological selectivity of 5-ALA for tumour tissue.
For exogenous photosensitizers, including Photofrin, where systemic 
administration is required, there remains only a limited understanding of the 
mechanism of increased tumour accumulation/retention. Porous tumour 
vasculature may favour accumulation and poor lymphatic drainage may
5promote retention of the photosensitizer. Increased low-density lipoprotein 
mediated endocytosis activity of tumour cells may provide a more specific 
mechanism for uptake.13 Selective retention may also be related to the 
decreased pH in tumours as sensitizers become more water soluble as pH is 
decreased and are thus less able to leave the tumour cell.21
The ideal photosensitizer should have a short half life, specific binding 
to the tumour, high quantum yield of singlet oxygen, and an activation 
spectrum between 700-800nm to optimise tissue penetration. Several new 
agents are under evaluation for photodynamic therapy; benzoporphyrin 
derivative monoacid (BpD-MA), meso-tetra-(hydroxyphenyl)-chlorin 
(mTHPC), N-aspartyl chlorin e6 (NPe6), tin etiopurpurin (SnET2), 
tetraphenylporphine sulphonate (TPPS4), zinc phthalocyanine (ZnPc) and 
sulfonated aluminium phthalocyanines (AIPcSn).22 Chlorins, which include 
BpD-MA, are reduced hydrophilic porphyrins and purpurins are chlorins with 
one reduced pyrrole group. Porphines and phalocyanines are synthetic 
porphyrins. These new photosensitizers are more potent than porfimer 
sodium and are more rapidly cleared following systemic administration, 
exemplified in BpD-MA which causes cutaneous sensitivity for only 3-5 days 
following systemic administration. Another group of photosensitizers are the 
cationic dyes, such as rhodamine 123, which are lipophilic, penetrating 
plasma membranes easily and accumulating less in skin than porphyrin-
23derived agents. They thus have a potential to treat tumours and spare 
overlying epidermis. However, some of these agents exhibit toxicity in the 
absence of light, limiting their suitability.
The in-vivo pharmacokinetics and biodistribution of photosensitizers 
are affected by their water solubility, with hydrophilic agents requiring a 
suitable vehicle (e.g. oil in water emulsions) to facilitate their delivery, usually 
via serum components, to the tumour tissue. Lipophilic (hydrophobic) dyes , 
such as porfimer sodium, PplX, HpD and the aluminium phthalocyanine -
6AlPcS^ localize to membrane structures (mitochondrial membranes, plasma 
and nuclear membranes and membranes of the endoplasmic reticulum), 
whereas more hydrophilic dyes, such as the aluminium phthalocyanines 
AIPcS2a, and AIPcS4, and NPe6, localize to lysosomes. Both the 
phthalocyanines and porphyrins increase in hydrophilicity as the number of 
sulphonated groups increases. Amphiphilic photosensitizers have 
hydrophobic and hydrophilic regions and include the most potent PDT 
agents, mTHPC and BpD-MA, with respect to direct activity on neoplastic 
cells24,25
The predominant mechanism of action of PDT is presumed to be direct 
tumour cell kill although in PDT with systemically administered 
photosensitizers, an important contribution to tumour destruction is achieved 
via damage to the vascular supply. Topical ALA-PDT, however, would 
appear to rely on direct tumour cell destruction to achieve a therapeutic 
effect, with a recent study demonstrating no direct vascular damage following 
this type of PDT.26
Most photosensitizers, given appropriate excitation, can be made to 
fluoresce, so that their distribution can be studied by fluorescence 
microscopy. Although naturally occurring PplX contributes to the 
autofluorescence of normal skin, exogenous ALA-induced PplX offers a 
means of enhancing contrast and its detection affords a valuable method of 
evaluating its method of action in PDT.16 Fluorescence detection can also be 
used as a method of detecting neoplasia.
1.4 Mechanisms of action - Light delivery
Light of appropriate wavelength for activation of the photosensitizer is 
required in the target tissue. A 'therapeutic window' between 600-800nm 
exists with shorter wavelength light undergoing significant absorption by
7endogenous chromophores in the skin, primarily haemoglobin, and longer 
wavelengths having insufficient energy to participate in photochemical 
reactions.27
Light fluence in tissue decreases exponentially with distance, affected 
by optical scattering and absorption by endogenous chromophores, both 
parameters differing between tissues. Whilst 630nm light may penetrate up
28 29to 6mm, compared to 1-2mm for light at 400-500nm, ’ the therapeutically 
effective maximum depth of PDT will depend on sufficient light dose being 
delivered to the tissue to achieve a photodynamic reaction. The 
therapeutically effective depth of PDT in the skin is therefore likely to be 
considerably less, at 1-3mm at 630nm, depending on the tissue.13
Most clinical applications of PDT have used red light of 630nm to 
achieve adequate penetration. 5-ALA-induced photosensitivity has a 
porphyrin-like spectrum with maximum excitation at 410nm and three smaller
30peaks at 510, 545 and 580nm. Using shorter wavelength light could thus 
achieve more efficient activation of PplX, but at the expense of depth of 
therapeutic effect. The new photosensitizers listed above have peak 
absorption wavelengths beyond 650nm and an extinction coefficient 
(measure of their ability to absorb light) at their maximal long wavelength 
absorption, at least 10-fold greater than porfimer sodium at 630nm 22
The biological effect in PDT is proportional to the amount of light 
energy reaching the tissue multiplied by the absorption coefficient of the 
photosensitizer.31 As the concentration of photosensitizer in tissue and the 
light dose absorbed by the photosensitizer are often not known, dosage is 
usually estimated from the energy fluence. This assumes that a given dose 
of photosensitizer will be distributed in a tissue in the same way and that 
tissue oxygenation does not become a limiting factor in the photodynamic 
process.
8A further complication in calculating the 'photodynamic dose' relates to 
the dosimetry of the light source used. To permit comparison of the light 
dose used from different laser and non-laser sources, the concept of total 
effective fluence has been developed. Total effective fluence rate ( Ed ) is 
defined at a specified tissue depth , d , by the equation:
E„ = J I(X)Td(X) A(X) d(A) 
where: I(X) is incident spectral irradiance from light source at wavelength 
Td(X) is optical transmission through tissue to depth d at wavelength X and A( 
X) is absorption by sensitizer at wavelength X 32 As the emission spectra of 
laser and non-laser sources are very different, measurements of total power 
or irradiance are insufficient to characterize each source as they do not 
quantify the dose of appropriate wavelength light at the required depth in 
tissue available for photodynamic therapy. This model has been used to 
compare the non-laser lamp used in this thesis with other sources including 
laser (Chapter 3).
Calculation of the requirements for light in PDT are further complicated 
by self-shielding and photo-bleaching. Self-shielding concerns the 
absorption of light by superficially placed photosensitizer thus limiting further 
tissue light penetration. Photo-bleaching is the process of photo-destruction 
of the sensitizer during light exposure, a helpful event in counteracting self- 
shielding. As there appears to be a threshold photodynamic dose to produce
33 34tissue necrosis, photo-bleaching may also be useful if it occurs in normal 
tissue before this threshold is reached, but is undesirable in tumour tissue. 
Although the ratio of photsensitizer in tumour:normal tissue may not always 
exceed unity, selective tumour treatment can still be realized by selective 
light delivery.
Most studies of PDT have used laser sources to provide light of 
sufficient intensity and at the appropriate wavelength for drug activation, with 
the opportunity of delivery to internal body surfaces via fibre optics, which
9can also allow for the illumination of thick tumours via implanted applicators. 
The most widely used lasers for PDT have been argon ion- and copper 
vapour-pumped dye lasers.7"9 They can produce 1-3 watts of red light (at 
630nm) for use in PDT. However, their expense, specialist support 
requirements, size, and limited availability has stimulated a search for 
cheaper, portable light sources that could be easily used in clinical practice. 
Laser diode arrays may provide a cheaper source of a fixed intense 
narrowband light. However, although they are able to produce 3-4 watts of 
light between 670-690nm, they cannot currently produce sufficient intensity of 
light in the 630nm region.
10The recent development of topical ALA-based PDT, has accelerated 
the need for an effective simple method of light delivery in PDT. Most 
noncoherent sources are based around incandescent or arc lamp sources. 
Modified slide projectors, by filtering out light below 600nm, have been used 
by several groups,35,36 although the light filtered out may account for over 
60% of the light energy available, leaving relatively inefficient sources of 
light, particularly if light of narrow-wavelength is desired. Sziemes et a/37 
recently described a new source, a 1200W metal halogen lamp, although this 
also emits a relatively broad band of light between 600-800nm. The lamp 
which I evaluate in this thesis, incorporating a xenon short arc source, 
represents a novel approach to this requirement for a powerful, yet portable 
non-coherent source of light which is tuneable over a wide wavelength range 
and can provide therapeutically effective levels of power output within a 
narrow bandwidth.
1.5 - The photodynamic effect
The rationale of the therapeutic efficacy of PDT is based on the 
cytotoxic action of products generated by excited photosensitizers. The
10
excited photosensitizer can react directly with tissue constituents through the 
so-called type I process, yielding radicals or radical ions, or through the type 
II process in which energy is transferred to singlet oxygen. When a 
photosensitizer absorbs light of the appropriate wavelength it is converted 
from a stable electronic structure (ground state) to an excited singlet state. 
This short-lived singlet state may undergo conversion to a longer-lived 
excited triplet state (lifetime 10'3-10s), which is the photo-active species 
responsible for the generation of cytotoxic products. This may either directly 
react with substrate by hydrogen atom or electron transfer to form radicals 
(type I reaction), or the triplet state can transfer its energy to oxygen directly 
to produce singlet oxygen (lifetime 0.6x1 O^s in a cellular environment), which 
is highly reactive in biological systems (type II reaction), causing photo-
38 39oxidation and cell death. Evidence for the involvement of the superoxide 
ion in some aspects of PDT damage suggest that both Type I and Type II 
reactions occur with ratio dependent on the photosensitizer, substrate and 
oxygen concentrations.40
Whilst the most important path leading to tumour necrosis in PDT 
appears to be that of singlet oxygen (type II), direct measurement in complex 
biological systems is difficult. The complete process, with excitation of 
photosensitizer, transfer of energy through intersystem crossings, to 
excitation of oxygen from its triplet state and the subsequent quenching of 
singlet oxygen through cytotoxic mechanisms, takes place in a time scale of 
microseconds.
1.6 - Acute effects of photodynamic therapy on tissues
The effect of photodynamic therapy on cells depends on the 
concentration and localization of the sensitizer and its efficiency in that 
environment, the light dose reaching the cell and the oxygen supply.
11
As the diffusion distance of singlet oxygen in cells is estimated to be
on
only 0.1 jam, cell damage is likely to be close to the site of its generation. 
The intracellular distribution of the photosensitizer will therefore influence the 
target sites and depends on their relative lipophilicity/hydrophilicity and 
polarity.24
For lipophilic photosensitizers, including Photofrin, protoporphyrin IX 
and the phthalocyanines, inhibition of mitochondrial enzymes may be the key 
event in PDT cell death. However, the inactivation of membrane transport 
systems, depolarisation of the plasma membrane and inhibition of DNA repair 
enzymes may precede inactivation of the mitochondrial, cytosolic and
39 41 -42lysosomal enzymes. 1 The release of lysosomal hydrolytic enzymes are 
presumed the main event in promoting cell death for hydrophilic agents such 
as the sulphonated phthalocyanines, tetraphenylporphine, and mono-l- 
aspartyl chlorin.43 Certain cationic sensitizers accumulate preferentially in 
mitochondria due to electrical potential gradients across the membrane.23,44
Following in vitro PDT using photofrin II, several inflammatory 
mediators are released including several eicosanoids (PGF2a, 6-keto-PGF1a, 
arachidonic acid) and histamine 45-47 These substances may contribute to 
the vascular effects of PDT in-vivo. The level of circulating photosensitizer is 
the main determinant for vascular photosensitivity with tumour cures reported 
in mice after exposure to light immediately after photosensitizer injection
48when blood drug levels were high and tumour cell localization absent. No 
significant differential in sensitivity between normal and tumour vessels has 
been reported with vascular shut-down in rodent tumours only preceding that 
of the surrounding tissue at sub-therapeutic PDT doses.49 Vascular 
photosensitivity has been observed in-vivo with several anionic agents, 
including porphyrins, purpurins, phthalocyanines and chlorins.50-52 Activation 
of these photosensitizers results in the reduction of blood flow both via 
vasoconstriction, thrombus formation and embolization, with a low rate of
12
reperfusion observed.50 The resulting tumour hypoxia may limit the cellular 
photodynamic process. The initiating events in PDT-induced vascular 
damage in humans remains unknown.
Lymphocytes, plasma cells and histiocytes infiltrate PDT-treated tissue 
suggesting an immune response. However it remains unclear whether this 
represents a specific PDT response, or is simply related to the degree of
53inflammation present. At present, it remains unclear whether cytokines 
(Interleukin 1-beta, Interleukin 2 and tumour necrosis factor-alpha) noted for 
up to 50 days following bladder PDT treatment were merely a function of the
54associated inflammation or a specific PDT response.
1.7 - Late effects of photodynamic therapy
Generalized photosensitivity up to 6-10 weeks following injection of 
Photofrin has been reported11,12 although newer systemic photosensitizers 
under development are likely to have shorter intervals of skin sensitivity with 
murine studies reporting loss of skin sensitivity within 2 weeks for AlPcSn, 9 
days for SnET2 and by 24 hours for NPe6.55"57
Preservation of the structural and function of collagen after Photofrin- 
and AIPcSn-PDT is superior to that after hyperthermia58 and probably 
contributes to the good cosmesis after PDT of skin lesions.
Nuclear damage has been observed in PDT with single strand breaks, 
alkali-labile lesions, DNA-DNA and DNA-protein crosslinking and sister 
chromatid changes. In-vitro studies with haematoporphyrin derivative and 
phthalocyanines, whilst demonstrating nuclear damage, have shown no
59mutagenic activity above background levels. The mutagenic potential of 
PDT appears to be much lower than for x-ray or UVC treatment. While 
nuclear damage can be induced by PDT, as there are also many cytoplasmic 
and membrane targets for photooxidation, cell death is presumed to occur
13
rather than the induction of mutagenic or carcinogenic phenotypes. The 
importance of nuclear effects in cell killing in PDT thus appear to be minor, 
with membrane disturbance probably having a predominant role in porphyrin- 
mediated cell inactivation. To date, only one tumour, a melanoma, has been 
reported, arising on the scalp of an 82yr. old female with extensive actinic 
damage and several squamous cell carcinomas,60 who had 1 year previously 
received 4 sessions of ALA-PDT to that site. Whether or not PDT was 
causative or coincidental to melanoma development is unknown, but it 
emphasizes the need for careful review of study patients following PDT to 
establish the frequency of late complications and in particular any neoplastic 
effects.
1.8 Applications of photodynamic therapy
A wide variety of potential applications for PDT in medicine are now 
emerging. Clinical studies have reported the therapeutic action of PDT in 
various cutaneous and non-cutaneous neoplasms.7-9 PDT can be used for 
the curative treatment of early, superficial neoplasia, especially tumours 
lining body surfaces which can be accessed by light either directly or via an 
endoscope. It may also be applications as an adjunct to surgery or in the 
palliation of advanced malignancy.
Cutaneous applications
Non-melanoma skin cancer, Kaposi's sarcoma and cutaneous T-cell 
lymphoma can all respond to PDT (Chapter 2). Improvement in plaques of 
psoriasis following photodynamic therapy have been reported using systemic
61 f iohaematoporphyrin derivative and ultraviolet light, 630nm laser light, or 
broadband visible non-laser light.63 Boehncke et a/64 have also reported 
treatment of chronic plaque psoriasis in three patients using ALA-PDT, with
14
an outcome comparable to that achieved using dithranol. However, a recent 
dose-response study65 has failed to demonstrate a regime that provides for a 
predictable efficacy, possibly related to variation in photsensitizer uptake 
between plaques in the same patient and between patients despite standard 
quantities of agent being applied.66
Two patients with alopecia areata have also been reported as 
responding to haematoporphyrin plus UVA light after 8-10 weeks of thrice
87weekly therapy with coarse terminal hair regrowing after 12-16 weeks. 
Control sites treated with UVA alone showed no response.
Non-cutaneous applications
Phase l-ll trials of PDT have shown complete eradication of tumour in 
around 90% of patients with early stage lung cancer with disease-free 
survival of up to 11 years.68"70 PDT may also convert inoperable into 
resectable tumours, and reduce the extent of surgery required.71
PDT for squamous cell carcinomas of the oesophagus, confined to the 
mucosa/muscularis mucosa, achieves a 5-year survival of 90-100%.72 It may 
also be superior to laser therapy for the palliation of advanced oesophageal 
carcinoma.73 Complete remission of 34/207 inoperable or recurrent 
advanced tumours of the oesophagus and stomach using haematoporphyrin 
has been reported.74 PDT has been observed in several centres to be 
effective in promoting the clearance of metaplasia and dysplasia in Barrett's 
oesophagus.75
Although PDT is effective for in-situ carcinoma of the bladder, early 
experiments, using haematoporphyrin and dihaematoporphyrin, were 
associated with high recurrence rates and the risk of reduction in bladder 
capacity which usually resolved by 3 months, but could be permanent.76"80
As an in-vivo study with ALA suggests detrusor muscle damage and fibrosis
80is less likely , ALA-PDT may be preferable for bladder tumours.
15
Small clinical studies indicate a primary, adjuvant or palliative role for 
PDT in gynaecological neoplasia, head and neck tumours, and even as 
adjunctive therapy following surgical debulking of cerebral gliomas and 
pleural mesotheliomas.8
The use of lethal photosensitization to kill microorganisms, although 
not a new concept, is receiving renewed attention with the development of 
PDT for clinical applications. The prerequisite for photosensitization of a 
microbial cell is the binding of porphyrin to the cytoplasmic membrane. Gram
positive bacteria appear particularly susceptible, including methicillin
81resistant Staphlococcus aureus and Propionobacterium acnes The gram-
negative bacteria Helicobacter pylori, has also been shown to be successfully
82killed in-vitro by PDT. The susceptibility of the bacteria and yeasts
83responsible for periodontal disease and the inactivation of parasites and 
viruses , including human immunodeficiency virus, by PDT in the sterilisation 
of blood components84,85 extend the possible applications of this modality.
The development of PDT for the indications outlined above will depend 
not only on efficacy in both open and randomized clinical trials, but also on 
assessment of ease of administration, adverse effects and outcome of PDT in 
comparison with existing therapies.
16
Chapter 2 - The use of photodvnamic therapy in cutaneous malignancy
2.1 - Introduction
The accessibility of the skin to light-mediated therapy and the high 
prevalence of cutaneous neoplasia led Dougherty et a/6 to treat non­
melanoma skin cancer in the first human trial of PDT in 1978. Several further 
trials have show the efficacy of PDT in a variety of primary cutaneous 
neoplasms and cutaneous metastases. A detailed review of these open 
studies is given in this chapter. Haematoporphyrin derivative, Photofrin and 
more recently, 5-aminolaevulinic acid, have been the main photosensitizing
agents used. The description in 1990 of PDT using topically administered 5-
10ALA, thus avoiding the prolonged generalized photosensitivity that followed 
the systemic administration of HpD and Photofrin, has stimulated interest in 
the clinical potential of PDT for cutaneous neoplasia. Lasers have been the 
predominant light source in these studies, although there are a few reports of 
the use of incandescent sources, including adapted slide-projectors.
2.2 - Actinic Keratoses and Bowen's disease
Actinic keratoses and Bowen's disease can be treated with 
cryotherapy, curettage and electrodessication, topical 5-flourouracil or 
surgical excision although no therapy is completely curative and each has 
potential complications. Radiotherapy can be used for Bowen's disease 
although full tumour doses are required. These therapies may be impractical 
for patients with numerous or large lesions, or lesions in anatomically difficult 
areas. As photodynamic therapy is tissue-sparing, it is potentially very useful 
in these circumstances.
Bowen's disease appears to respond well to PDT using HpD or 
Photofrin. Three of the four trials included in Table 2.1 reported a 96-100%
17
initial complete clinical response. However, the number of lesions treated
87was small (2-8) in three of these studies. Robinson et al reported two 
patients treated using the active component of HpD, di-haematoporphyrin 
ether (DHE). At a drug concentration of 2mg/kg and 25J/cm2, 160/166 
lesions were observed to clear, but only 45/90 further lesions cleared with 
1 mg/kg DHE and 50J/cm.2 A pre-clinical hypothesis of a direct reciprocal 
relationship between photosensitizer dose and light dose was thus not 
confirmed. There was also an absence of any reduction in generalized skin 
photosensitivity in this latter group.
The 10 studies performed since 1990 using 5-ALA as the source of 
photosensitization for the treatment of actinic keratoses and Bowen's disease
(Table 2.1) emphasize the interest that PDT using a topically active agent
10has generated in treating pre-malignant cutaneous lesions. Kennedy et al 
was first to use 5-aminolaevulinic acid, applying it to the tumour surface in an 
oil-in-water emulsion to promote absorption. He used a Kodak slide projector 
(containing a 500W tungsten lamp) modified only by the inclusion of a long­
wave pass colour filter to eliminate wavelengths less than 600nm. A high 
irradiance, between 150-300mW/cm,2 however suggests that heating of 
superficial tissue may have occurred with an unknown effect upon the PDT 
treatment. Hyperthermia has been reported as being an effective 
monotherapy for Bowen's disease96 and thus may have contributed to the 
therapeutic effect as 150mW/cm2 is considered to be the threshold intensity 
above which hyperthermic injury may occur.97
35Wolf et al also used 5-ALA, a slide projector (a Leitz Pradovit 
incorporating a 250W tungsten lamp) and filtered wavelengths less than 
570nm. Individual lesions were irradiated at 50-100 mW/cm,2 with all treated 
lesions still clearing. Infra-red emissions from these projector sources, 
despite the incorporation of heat rejection filters in the beam path, may 
contribute to tissue heating independent of the irradiance intensity. Stables
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et al recently compared the visible and infra-red power output of a Leitz 
Pradovit projector, and reported over 60% of the total power output was infra­
red, in the spectral range 900-1800nm. In addition, the remaining visible 
output (400-660nm) is unlikely to include wavelengths all suitable for PDT 
with those bandwidths around the absorption peaks of protoporphyrin IX of 
greatest importance. Incandescent tungsten-halogen lamps are thus 
relatively inefficient sources of light for PDT.
Cairnduff et al90 and Calzavara-Pinton91 treated Bowen's disease and 
actinic keratoses by PDT, using 630nm laser light. Dosimetry differed 
although irradiance was less than 100mW/cm2 in each study. A high 
clearance rate on clinical examination was observed and longer follow-up 
periods (18 and 29 months respectively) indicated a recurrence rate of up to 
10%. Calzavara-Pinton excised 20 of the treatment sites (17 from treated 
actinic keratoses and 3 from sites of Bowen's disease) with histological 
examination showing tumour remnants in 3 AK sites, but in no Bowen's
92disease site. All the other studies listed in Table 2.1, except Figan et al 
(see below) defined clearance as the absence of clinically evident tumour 
and histological confirmation was not obtained.
92Figan et al used 5-ALA in combination with the iron chelator 
desferrioxamine in an attempt to improve efficacy via the induction of 
endogenous porphyrin synthesis. 20% 5-ALA was applied for 20 hours prior 
to illumination with an incandescent source (filtered output 540-720nm) at a 
light intensity of 150-250mW/cm 2 Histological conformation of clearance 
was obtained for all lesions of Bowen's disease, but not for actinic keratoses. 
Repeated treatments cleared only 5/10 sites of Bowen's disease with 2 
subsequent recurrences after 1 and 4 months. As no comparison was made 
using this protocol without 3% desferrioxamine (dissolved with 5-ALA in the 
oil in water emulsion), the influence of the chelator cannot be assessed.
20
95Szeimes et al compared the efficacy of PDT for actinic keratosis at
different body sites. Only 10% 5-ALA was used, applied 6 hours pre­
illumination with filtered light (580-740nm) from a 1200W incandescent 
source (Waldmann 1200) with a light intensity of 160mW/cm.2 12/17 actinic 
keratoses situated on the head healed following a single treatment in 
comparison with none of the 19 lesions on the arms and hands. This 
difference was probably due to an observed greater initial thickness of 
lesions on the arms and hands reducing 5-ALA and/or light penetration.
Stender and W u lf" treated three patients with actinic cheilitis using 
topical 5-ALA (20% in a basic cream, applied 3 hours pre-illumination) and a 
slide projector (individual lesions received 55J/cm2). No evidence of 
recurrence was evident over the following 12 months.
2.3 - Squamous cell carcinoma
Squamous cell carcinomas (SCC) can be treated by locally destructive 
therapy (curettage and cautery, cryosurgery), radiotherapy, or surgery. 
Unlike the treatment of potential pre-malignant lesions such as actinic 
keratoses and Bowen's disease where recurrent disease can be easily re­
treated, the ability of SCC to metastasize implies that inadequate initial 
treatment may affect prognosis. The highest achievable clearance rate is 
thus required. In experienced hands, all techniques are reported to give 5 
year cure rates of approximately 90%100. A new treatment modality requires 
to achieve at least this result. Currently, no 5-year follow-up studies of PDT 
for any clinical application have been published.
Experience of treating SCC with PDT has been limited to date with 
published studies listed in Table 2.2. Five studies used haematoporphyrin 
derivative or Photofrin, with light from argon lasers. Overall, 36/44 (82%) of
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squamous cell carcinomas treated by systemic photosensitizer cleared 
although a high recurrence rate was observed in the 2 largest studies.
Four studies using 5-ALA as a topically applied photosensitizer have 
treated a total of 15 SCC. Two of the three studies using an incandescent
35light source failed to clear any tumours. In the third study, by Wolf et al, 5/6 
early invasive tumours were successfully treated. All 5 squamous cell
105carcinomas treated by Heinritz et al by laser cleared, with histological 
confirmation and no recurrences during a 4-12 month review period.
Wolf et al106 has also used topical ALA-PDT for the treatment of one 
SCC on the hand of a patient with xeroderma pigmentosum (XP). Although a 
single treatment was curative, erythema of the exposed area persisted for 
more than 2 weeks (normal 2-4 days). Persistent erythema is well known 
after ultraviolet irradiation (UVR) in patients with XP, but UVR exposure was 
unlikely in this patient who was in hospital throughout the 2 weeks with an 
incandescent light source used for the PDT. The persistant erythema 
remains unexplained and may limit the usefulness of PDT in XP despite its 
theoretical advantage of targetting membranous structures rather than via 
DNA damage.
Thus, although current studies of PDT for SCC thus suggest that this 
modality can be effective, results overall indicate efficacy short of 90% even 
during the short follow-up periods reported. Larger studies with extended 
follow-up are required, with comparison of different protocols before PDT can 
be considered as an alternative therapy for SCC.
2.4 - Basal cell carcinoma
A variety of therapies already exist for basal cell carcinomas (BCC) 
including surgical excision, curettage and electrodesiccation, cryotherapy, 
radiotherapy and Moh's micrographic surgery. Although it is extremely rare
23
for BCC to metastasize, inadequate therapy can allow recurrence and deep 
invasion. Recurrent disease can also be less responsive to repeat therapy 
with one study observing a 50% recurrence rate after retreatment of tumours
107treated inadequately at first presentation. A review of studies published 
from 1947-87 on the outcome of the treatment of primary (previously 
untreated) BCC reported a cumulative 5 year recurrence rate between 1.0-
10.1% (Mohs': 1.0%, cryotherapy: 7.5%, curettage and electrodessication:
1087.7%, radiotherapy: 8.7%, and surgery: 10.1%). As cost and man-power 
limits Mohs' surgery to only to a few indications, an average non-Mohs' 5 year 
recurrence rate of 8.7% indicates the limitation of currently available routine 
therapies. Photodynamic therapy will require to demonstrate not only 
efficacy, but also a comparable and preferably lower recurrence rate.
A. PDT using Haematoporphyrin derivative and Photofrin
Table 2.3 summarizes the clinical experience of PDT for BCC using 
systemic photosensitizers. No study has published recurrence rates up to 5
103years, although Keller et al reported no recurrent tumours 4 years after 
PDT to 6 BCC.
The seven published studies of the treatment of BCC by PDT using 
haematoporphyrin derivative or Photofrin report widely differing initial 
clearance rates of 52-100%. Dougherty et al,109 Waldow et al,86 and Keller
103et al cleared all lesions (17 in total), many treated BCC already failures of
102conventional surgery, with only one recurrence. Pennington et al cleared 
only 11/21 BCC with all tumours recurring during the subsequent 6 months. 
Although failure in this study may have been due to the low dose of light 
employed, a similarly poor outcome was reported by Buchanan et al111 
despite a higher light dose at a previously effective concentration and 
duration of photosensitizer. The subtype of BCC treated in these early 
studies was not stated. A laser light source was used in all these studies
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109 110although Dougherty et al and Tse et al treated a few lesions with a 
broad-band xenon arc lamp with comparable success rates.
Wilson et al112 at Roswell Park Cancer Institute in Buffalo appreciated 
the possible impact on efficacy of the histological type of BCC treated. They 
treated 75 superficial, 52 morphoeic and 24 nodular BCC, with clearance of 
133/151 tumours. During a follow-up period of 29 months however, 80% of 
recurrences arose from morphoeic tumours, with only 4% of the superficial or 
nodular types recurring.
The Roswell Park Group have also treated 588 superficial and nodular 
BCC in 9 patients with basal cell naevus syndrome (BCNS).114 
Photodynamic therapy was undertaken using Photofrin 1 mg/kg 48-96 hours 
prior to illumination with an argon laser. Complete clinical response rates in 
the adults treated ranged from 82-98% (mean 95%) after a mean follow-up of 
28 months. The opportunity to treat multiple lesions at a single visit (4 
lesions/20 minutes and 40 per session) along with excellent cosmetic results 
encouraged the group to suggest that PDT might have a role in the 
management of such patients despite the generalized photosensitivity 
induced by Photofrin.
B. PDT using a topical photosensitizer
Santoro et al115 in 1990 evaluated the effectiveness of topical meso- 
tetraphenylporphinesulphonate in the treatment, by PDT, of 292 lesions with 
superficial BCC. They reported complete clearance of 94% although with a 
20% recurrence rate during the following 24 months. No further studies using 
this photosensitizer in cutaneous malignancy have been reported, possibly 
due to its major disadvantage of poor tumour selectivity when topically 
applied, necessitating its application strictly to the tumour only.
Since 1990, over 1000 basal cell carcinomas have been treated by 
PDT using topically applied 5-ALA (Table 2.4). Initial clearance rates for
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tumours classed as superficial was 88-100% and for nodular BCC a range of 
response between 10-80% was observed. In each study the subtype of BCC 
has been decided predominantly by clinical assessment with histological 
confirmation usually obtained only in one representative lesion in each 
patient. Clearance was determined only by clinical assessment of treated 
sites in the study of Kennedy et al10 whilst Wolf et al,35 Cairnduff et al,90
113 92Warloe et al and Figan et al only biopsied sites following treatment if
91they had clinical doubt over clearance. Calzavara-Pinton biopsied 11/23 
superficial and 18/23 nodular BCC four weeks after treatment with this 
representative sample of 29 lesions considered to be complete clinical 
responses at the time of biopsy. Histological examination revealed tumour 
remnants in 1/11 superficial and 7/18 nodular BCC sites suggesting a 
potential reporting error for clinical clearance of 9% and 39% for superficial
93and nodular lesions respectively. Lui et al excised all 8 superficial BCC 7- 
12 weeks following treatment and discovered tumour in 3/7 (43%) lesions 
initially considered clear (clinical grading at time of excision not stated) which 
they interpreted as early recurrence. The absence of histological evidence of 
clearance for many of the lesions treated in these studies therefore limit 
assessment of the efficacy of PDT and complicate interpretation of 
recurrence rates which probably include several tumours which were only 
partial responders initially.
Initial clinical response rates for superficial BCC do not appear to be 
affected by duration of photosensitizer application nor by the light source 
used. Most studies applied 5-ALA at a 20% concentration 3-8 hours prior to 
illumination including that by Warloe et al113 with 97% clearance after a 3
92hour application. Figan et al extended the duration of application to 20 
hours with an identical result. Four of these ALA-PDT studies used a laser 
light source with initial clearance of 88-100% of 487 superficial BCC, whilst 
88-97% of 159 superficial BCC cleared using modified slide-projector
2 8
tungsten sources. Similar recurrence rates are also reported with 17/487 
(3.5%) and 4/159 (2.5%) superficial tumours recurring after PDT with laser 
and non-laser sources respectively although duration of follow-up was shorter 
with those studies using tungsten sources (6-36 months and 2-12 months 
respectively).
1Q Q1 11?Laser-based PDT studies ■ ■ reported a superior outcome for 
nodulo-ulcerative BCC in comparison with the two studies using a tungsten 
incandescent source.35,92 Initial clinical clearance of 285/381 (75%) treated 
using a laser (range 64-80%) compares with clearance of only 14/32 (44%) 
tumours treated using non-laser light. This poor result includes 13/22
92tumours treated by Figan et al who combined 5-ALA with desferrioxamine 
and prolonged application time to 20 hours, two measures anticipated to
35improve efficacy of ALA-PDT. The study by Wolf et al which cleared only 
1/10 nodulo-ulcerative lesions in contrast to 36/37 superficial BCC suggested 
that inadequate light and/or photosensitizer dose in the deeper tumour tissue 
might have impaired response.
The poorer efficacy of broadband non-laser sources for thicker 
noduloulcerative disease may be due to inadequate penetration of light to the 
deepest section of the tumour. Light dosimetry cannot accurately be 
compared between studies published to date due to the different wavelength 
and intensity of light used and the difficulty in determining the actual effective 
light energy produced by broadband non-laser sources.
Warloe et al113 enhanced 5-ALA penetration using dimethyl 
sulphoxide (DMSO) either in combination with 5-ALA or as a pre-treatment in 
a large open study of over 700 BCC. He also used 
ethylenediaminetetraacetic acid (EDTA) as iron chelator to promote the intra­
cellular accumulation of the active photosensitizer protoporphyrin IX. 
Tumours were both superficial and nodulo-ulcerative with the latter group 
sub-divided into lesions estimated to be <2mm or >2mm, although grading of
29
thickness was approximate, undertaken usually by clinical inspection. He 
reported clearance without DMSO/EDTA of 92% (130/141) of superficial 
BCC, 67% (16/24) of 'thin' and 34% (19/56) of 'thick' nodular lesions after one 
treatment. PDT using 5-ALA (20% in an oil in water emulsion - Unguentum 
Merck) plus 2-20% DMSO and 2-4% EDTA for 3 hours prior to illumination, 
achieved clearance rates of 91% (114/125) for superficial BCC, 91% (59/65) 
of 'thin' and 55% (25/45) of 'thick' nodular lesions. The application of 50-99% 
DMSO as pre-treatment for 15 minutes before 5-ALA produced virtually 
identical results to the DMSO/EDTA combination. Repeat treatments in the 
DMSO/EDTA group achieved clearance rates of 93%, 95% and 60% 
respectively. Fluorescence microscopy performed on tissue samples excised 
prior to tumour illumination revealed 5-ALA-induced porphyrin fluorescence 
to be localized at 3 hours only to the superficial sections of nodulo-ulcerative 
tumours. The combination of 5-ALA with DMSO/EDTA greatly increased 
fluorescence in the deeper layers of the tumours although in several thick 
lesions fluorescence of the tumour remained incomplete. EDTA as a single 
additive had little effect on fluorescence. The inclusion of a penetration 
enhancer thus improved efficacy of ALA-PDT in nodular BCC. Recurrence 
rates of 2-5% are reported with no tendency to late recurrence after a follow- 
up period of more than 3 years.
Oseroff (personal communication) has also assessed the impact of 
altering duration of photosensitizer application on clearance. Whilst 
prolonging application from 4-5 hours to 24 hours had minimal effect on 
clearing superficial BCC (24 hour treatment group - 69/76 cleared, i.e. 91%), 
an increase in clearance rate from 78% to 90% was observed for nodular 
BCC (24 hour treatment group -18/20 cleared).
Despite the possible inadequate treatment of thicker lesions, 
surprisingly recurrence rates for nodular BCC do not appear to be higher 
than for superficial tumours with rates of 0-8%.
30
Cairnduff et al90 noted late recurrence of BCC following ALA-PDT, with 
a median time to recurrence of 11 months with 6/14 tumours recurring during 
a median follow-up of 17 months. Most other studies have followed patients 
for shorter intervals although Warloe et al113 report a low recurrence rate 
maintained for 3 years.
Warloe et al113 however did not achieve the same success using ALA- 
PDT in treating patients with basal cell naevus syndrome as did the Roswell 
Park Group who used Photofrin.114 Only 11/18 (61%) of superficial and 3/26 
(12%) nodulo-ulcerative BCC cleared in 4 patients. Inadequate 
photosensitizer penetration in the thicker tumours may partly explain the 
difference.
2.5 - Cutaneous lymphoma
Cutaneous T-cell lymphoma, characterized by the malignant 
proliferation of atypical helper T-cells (CD4+ T-lymphocytes) can be treated 
by topical steroids and UVB phototherapy, PUVA photochemotherapy ± 
interferon alpha-2a, topical nitrogen mustard, electron beam therapy, oral 
retinoids, or photophoresis. Efficacy of each therapy depends on the stage of 
disease and adverse effects can limit use.
Boehncke et al116 performed PDT using Photosan, a mixture of 
porphyrins, on cell lines established from patients with CTCL. PDT resulted 
in a dose-dependant inhibition of transformed T-cell proliferation. They 
subsequently undertook in-vivo fluorescence microscopy during PDT of 
plaques of CTCL in two patients to demonstrate photobleaching and thus the 
triggering of photochemical reactions by photodynamic therapy.
Dougherty et al6 first reported successful PDT for CTCL using 
haematoporphyrin derivative. However, as with other PDT applications, the 
opportunity to avoid prolonged photosensitivity by using 5-ALA led to Malik et
31
al117 to demonstrate by in-vitro studies preferential porphyrin accumulation 
within the lymphocytic infiltrate of CTCL lesions after 5-ALA 
photosensitization.
Topical 5-ALA has since been shown to promote the accumulation of 
protoporhyrin IX within malignant CD4+ T-lymphocytes with preferential 
uptake by relatively iron deficient cells expressing the transferrin receptor 
(CD71). PDT of these tumour cells after 5-ALA incubation demonstrated
preferential killing compared to normal, unstimulated peripheral blood
118lymphocytes.
19In 1994, Svanberg et al reported the treatment of two patients with 4 
plaques of cutaneous T-cell lymphoma (10-50mm in diameter) by topical 
ALA-PDT using a pulsed frequency doubled Nd:YAG laser (630nm). Laser- 
induced fluorescence was performed to monitor the accumulation of PPIX 
and a 5:1 concentration gradient was observed between the lymphomatous 
plaques and the normal surrounding skin. A complete response, confirmed 
on histology, was observed in two lesions after 2 treatments. In the same
119year, Wolf et al successfully used topical ALA-PDT in the treatment of two 
patients with plaque-stage CTCL, one (patient A) had a solitary 18x9cm 
plaque and the other (patient B) had 2 plaques (5x3 and 12.5x4cm). Using 
20% 5-ALA 4-6 hours prior to illumination with a non-laser source, clinical 
and histological remission was achieved after 4 treatments in patient A (over
7 weeks) and 5 treatments for both lesions in Patient B (over 18 weeks).
120Preliminary data from Oseroff et al , indicates that single treatments 
of ALA-PDT can achieve greater than 50% reductions in tumour mass in 
lesions up to 1.5cm thick. Repetitive treatments every 1-3 weeks improve 
response with complete clinical and histological clearance in certain lesions. 
This data has now been updated and is discussed in Chapter 6.
There are no published reports of PDT use in the treatment of other 
types of lymphoma.
a A Jots
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2.6 - Kaposi's sarcoma
Kaposi's sarcoma (KS), the most common malignancy in patients with 
AIDS, can present as a spectrum of disease from local cutaneous lesions to 
disseminated visceral involvement. Therapy for extensive disease is limited 
to chemotherapy, whilst cutaneous disease may respond to intralesional 
chemotherapy, cryosurgery or radiotherapy. Kaposi's sarcoma consists of 
spindle cells with an extensive vascular compartment and thus might respond 
to PDT using systemically administered photosensitizers with proven vascular
50 52photosensitivity. PDT may thus be effective in the palliation or cure of 
mucocutaneous KS lesions. A total of five patients with classical KS have 
been successfully treated in two centres by PDT, with complete clinical 
clearance of 17/23 (74%) and 2/2 lesions respectively.109,121 Four 
studies122-125 have reported an efficacy of Photofrin-mediated PDT in AIDS-
related Kaposi's sarcoma with control of tumours up to 4cm in diameter.
122Dougherty reported tumour clearance in 80% of over 100 cutaneous 
KS lesions in 5 patients (although the proportion of biopsy proven lesions is 
not stated) by PDT using either 3mg/kg haematoporphyrin derivative or 1.5- 
2.0mg/kg Photofrin and 20-70J/cm2 of 630nm laser light (superficial and 
interstitial treatments).
123Schweitzer et al treated 5 patients each with multiple oral KS 
lesions by PDT (Photofrin 2mg/kg - intravenous and interstitial) with partial 
(n=2) or complete clearance (n=3) achieved in all tumours (partial clearance: 
>50% reduction in measurable size for at least 4 weeks, complete response: 
clinical disappearance of lesion for at least 8 weeks). No recurrences were 
observed in the complete responders during 3-7 months of follow-up.
124Hebeda et al treated 83 lesions in 8 patients using 2mg/kg Photofrin 
injected intravenously 48 hours prior to illumination with 70-120J/cm2 from a 
630nm laser source. All patients had biopsy-proven KS restricted to the skin 
with the diameter of lesions 5-38mm. Size of individual lesions showed a
33
negative relationship with the probability of complete clearance (p=0.047). A 
complete response rate (absence of any measurable KS for at least 4 weeks) 
was achieved in 56/83 (67.5%) lesions with superior clearance for tumours 
localized to the head. The poor response rate may have been due to the 
absence of interstitial therapy and no repeat treatments for incomplete 
responses. The cosmetic result, however, was unsatisfactory due to the high 
prevalence of scars (41%) and of hyperpigmentation which lasted several 
months after PDT.
The poor cosmetic result in this study may have been due to the high
125dose of Photofrin used, with 1 mg/kg used by Bernstein et al at Roswell 
Park Cancer Institute, Buffalo, achieving excellent cosmetic results. This 
latter study of over 400 lesions in 20 patients cleared 23% (n=92) of lesions 
(clinically clear for at least 8 weeks) and partly cleared 46% (n=184) using 
intravenous photosensitizer (and interstitial if tumours over 5mm thick) and 
630nm light doses from 100-400J/cm 2
Topical ALA-PDT for KS has not been reported, but due to the 
apparent absence of vascular damage following ALA-PDT26 and the relatively 
poor absorption of 5-ALA through normal overlying epidermis, it is unlikely to 
be as effective as systemic/intralesional Photofrin for PDT in KS.
2.7 - Cutaneous metastases
PDT has been used for cutaneous metastases, predominantly from 
breast (Table 2.5) and melanoma (Table 2.6). Interpretation of these small 
open studies, based on clinical response and typically of patients with 
advanced disease and failed conventional therapies, can only, however, 
provide an indication of whether or not PDT is a potential therapy for such 
tumours.
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Clearance was observed to be complete in only 14-74% of breast 
adenocarcinoma metastases (Table 2.5), with a high recurrence rate 
observed in certain studies.
109Dougherty observed at least a 50% reduction in size of lesions 
following PDT in 34/35 patients with cutaneous metastatic breast carcinoma 
who already had received surgery, radiotherapy and chemotherapy. Patients 
had lesions ranging from a single 12x12cm lesion to multiple smaller 
metastases. Recurrence was high in those surviving long enough for 12 
month follow-up although retreatment often achieved a further response.
A penetration depth of red light (630nm) of 4mm in human breast
129cancer has been determined indicating the likely advantage of interstitial
109 121photodynamic therapy. Whilst the studies of Dougherty, Tumio et al,
127 104Schuh et a r , and McCaughan et al include interstitial treatment of 
larger/thicker metastatic breast tumours, clearance rates were not uniformly 
higher compared with the remaining studies which illuminated lesions only
130from the surface. Diffusing fibres were used by Lowdell et al to treat 50 
breast and squamous cell carcinoma metastases (number of each tumour 
type not stated) by Photofrin-mediated PDT. A complete clinical response 
was observed two months after treatment in 26/50 (52%) overall, but with an
81 % clearance for the highest light and photosensitizer doses.
10Kennedy et al used topical ALA-PDT to treat 4 patients with 
metastatic breast carcinoma. Although strong protoporphyrin IX fluorescence 
was induced in percutaneous nodules, there was no effect of PDT, using a 
tungsten source, on the lesions. Cairnduff et al90 treated 14 metastatic 
adenocarcinomas with ALA-PDT using a laser in 5 patients, all derived from 
primary breast carcinomas. Only 5/6 lesions in one patient demonstrated a 
complete clinical response which was maintained for 6 months.
Experience of the successful treatment of cutaneous metastatic 
melanoma deposits by PDT is more limited than with breast metastases
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(Table 2.6). Dougherty6 and McCaughan et al104 observed no clinical 
evidence of residual tumour after PDT to over 70% of treated lesions 
although recurrence rate was not stated in the former study and was 60% at 
12 months in the latter study (despite the interstitial illumination of tumours in 
this study).
Wolf et al35 failed to clear 8 cutaneous metastases of melanoma after 
topical ALA-PDT using an incandescent light source with only superficial 
tumour necrosis achieved in those amelanotic tumours and no response with 
melanotic metastases. The intensity of pigmentation of the tumours treated in 
the other studies is not stated although Dougherty6 comments on the inferior 
responsiveness of more intensely pigmented tumours. All studies using PDT 
in melanoma have used photosensitizers optimally activated by light of 410-
30635nm, within the range of wavelengths normally absorbed by melanin, 
hence probably limiting the potential for a photodynamic reaction to occur. 
The future development of photosensitizers with longer activating 
wavelengths beyond 700nm may thus improve the efficacy of PDT for 
metastatic melanoma.
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Chapter 3 - Topical photodvnamic therapy using a non-laser light source
3.1 - Introduction
Photodynamic therapy appears to be an effective therapy for certain 
cutaneous malignancies. However, the requirement to administer 
photosensitizers by the systemic route and their potential to induce prolonged 
generalized photosensitivity limit the ease with which PDT could be 
performed as a routine procedure. Topical administration of photosensitizer 
may permit PDT to become a practical out-patient therapy. However, 
published studies (reported in Chapter 2) have failed to determine the 
effective depth of action of PDT by this method and there remains no 
comparison of PDT with existing treatment modalities.
In addition, reliance on laser sources to produce sufficient high 
intensity light for PDT, restricts the availability of PDT. Whilst lasers can 
deliver light of sufficient intensity and at an appropriate wavelength for drug 
activation, their cost, complexity and limited availability has led to a search 
for alternative cheaper, yet effective, portable, light sources that can be easily 
used in clinical practice. Cheap incandescent sources used to date, 
however, have broad emission bandwidths, emit significant amounts of 
infrared radiation, and are inefficient sources of red light, which is considered 
to be optimal for porphyrin-based PDT.
The place of PDT in routine clinical dermatological practice thus 
remains to be established. Clinical studies of PDT have been of open 
design, often small, with a diverse array of protocols and frequently without 
histological confirmation of clearance. They often failed to assess dose- 
response outcomes, compare different wavelengths, and undertook only 
short-term follow-up of patients.
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3.2 - Aims
This thesis seeks to further define the clinical potential of PDT in the 
treatment of cutaneous malignancy and facilitate its clinical application by 
assessing a novel light source. The effect on treatment efficacy of alterations 
in light and photosensitizer delivery will also be assessed. The principal aims 
of this thesis are to:
1. Evaluate the efficacy for photodynamic therapy of a prototype non­
laser source which can emit light of a narrow bandwidth at intensities 
anticipated to be effective for PDT.
2. Compare, by randomized trial, PDT with cryotherapy, the current 
treatment of choice, for Bowen's disease.
3. Assess the influence of tumour thickness on the efficacy of ALA-PDT 
in the treatment of basal cell carcinomas.
4. Determine the influence of alterations in photosensitizer delivery and 
of light intensity, wavelength, lesion size and total dose on efficacy of 
ALA-PDT.
5 Assess the prevalence of adverse effects, cosmetic outcome and
recurrence rates for ALA-PDT in cutaneous neoplasia.
3.3 - Materials and methods
The overall design of studies described in this chapter are summarized 
below with particular emphasis on the light source and photosensitizer used. 
Details specific to the design of individual studies and the treatment protocols 
of individual case reports are noted under the relevant chapter sub-section.
Patients:
Ethical committee approval was obtained for the treatment of patients 
with non-melanoma skin cancer and its potential precursor disorders, by
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photodynamic therapy. Patients presenting to the Dermatology Department 
of the Western Infirmary, Glasgow, were invited to participate in the studies. 
No lesion had been previously treated. Histological confirmation of the 
diagnosis was acquired by performing a 4mm punch biopsy on all lesions.
The consent forms used for these studies are shown in Appendices 1-3.
PDT light source
The light source employed (Figure 3.1) was specifically designed for 
use in photodynamic therapy by Drs. C. Whitehurst and J.V. Moore of the 
Paterson Institute, Christie Hospital, Manchester, and funded by the U.K. 
Cancer Research Campaign. The prototype lamp incorporates a 300W 
xenon short arc plasma discharge (Laser Lines, Banbury, UK), producing a 
continuous wave broadband flat spectral output of 50mW/nm across the 
entire visible spectrum. A dichroic 'hot' mirror (Optical Works, Newquay, UK), 
for heat rejection, and a toughened, high efficiency filter (Glen Spectra, 
Stanmore, UK) select the appropriate wavelength and bandwidth before the 
output is focused into a flexible light guide (Ultrafine Technology, Brentford, 
UK) via coated aspherical optics (Ealing, Watford, UK), which couples the 
light to the light guide, and a programmable shutter. The prototype light 
delivers over 1.0W of photoactivating light directly or up to 0.8W via a light 
guide within a bandwidth of 30nm and can be filtered to emit any wavelength 
from 300nm-1.1|im. To broaden the treatment field and produce uniform 
irradiation of lesions (±2%), 25mm diameter distal optics were attached to the 
light guide.
Infra-red emission from the source was totally blocked by the 
wideband dielectric heat filter and the non-infra-red transmitting light guide. 
Zero infra-red emission up to 35j^m wavelength was verified with a 
calorimeter.
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Figure 3.1: Prototype lamp with timer unit and fibre bundle which has a
25mm distal optics apparatus attached. A. First prototype lamp. B. Modified 
lamp.
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Two prototype lamps of identical spectral output were used in the 
studies described below. They were of identical design except for minor 
internal modifications to boost power and reduce overall size, with changes in 
external casing and to the flexible fibre bundle used which in the first lamp 
delivered 0.5W (5mm guide) and in the second lamp, 0.6W (5mm guide) and
0.8W (8mm guide). The first lamp (measuring 30x30x20cm, Figure 3.1a) was 
used in the initial open study of actinic keratoses and Bowen's disease and 
the randomized comparison trial of PDT vs. cryotherapy for Bowen's disease. 
All remaining studies used the second lamp (Figure 3.1b) which measures 
30x15x15cm. As all light dosimetry was calculated from light delivery at the 
distal end of the fibre bundles, with irradiance individually calculated for each 
study treatment, no difference in the efficacy of PDT between the two sources 
was anticipated.
131Initial in-vitro assessment of the prototype lamp demonstrated an 
efficiency, using clonogenic cell assays, for HpD-induced cellular 
photoactivation close to that of an argon pumped dye laser with a relative 
biological effectiveness (RBE) of 87±3% (p<0.05) between 10-100mW/cm2. 
The lamp was superior to a copper vapour pumped dye laser with a RBE of 
150% at fluence rates above 50mW/cm.2
132In a subsequent in-vivo study which used tumour growth delay to 
quantify the relative efficacy of the prototype with an argon pumped dye 
laser, there was no significant difference in the extent of tumour (mammary 
carcinoma-T50/80) response between the two light sources.
Dosimetry was calculated at monthly intervals using the same power 
meter (Coherent 201 - calibrated by the manufacturer against a national 
standard source). Fluence rates were calculated for specified distances from 
the fibre-optic tip to the skin surface and a dosage chart derived as 
exemplified in Table 3.1.
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Table 3.1 Example of one fluence table used for the studies
using the prototype lamp (figures re-calculated monthly)
630+15nm Filter - Treatment times usina 5mm fibre Date:
Field diameter required (cm) 2.5 3 4 5
Distance (Light fibre-skin) (cm) 7 12.5 19 24
Area (cm2) 4.9 7.1 12.6 19.6
Fluence rate (mW/cm2) 122 86 48 30
Exposue time for 150J (sec) 1230 1744 3125 5000
Exposue time for 125J (sec) 1021 1448 2594 4150
Exposue time for 100J (sec) 820 1163 2083 3333
Exposue time for 75J (sec) 615 872 1562 2500
Exposue time for 50J (sec) 410 581 1042 1667
630±15nm Filter - Treatment times using 8mm fibre
Field diameter required (cm) 5 6 7 7.5
Distance (Light fibre-skin) (cm) 14 17 20 22
Area (cm2) 19.6 28.3 38.5 44.2
Fluence rate (mW/cm2) 40 28 21 18
Exposue time for 150J (sec) 3750 5357 7143 8333
Exposue time for 125J (sec) 3112 4446 5929 6916
Exposue time for 100J (sec) 2500 3571 4762 5555
Exposue time for 75J (sec) 1875 2678 3572 4166
Exposue time for 50J (sec) 1250 1786 2381 2778
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Photosensitizer
1. Preparation: 5-aminolaevulinic acid hydrochloride (Sigma Chemical
Co.) was prepared 20% w/w in an oil in water emulsion. The formulation 
used was 2g 5-ALA, 2ml distilled water and 6g Unguentum Merck (E. Merck 
Ltd. West Drayton,UK). 5-ALA was mixed with distilled water to achieve 
partial dissolution. This mixture was then rubbed down into the Unguentum 
Merck. The finished product was stored in glass jars (2g of finished product) 
in a refrigerator for use within 48 hours of manufacture. Gloves, goggles and 
a particulate mask were worn during preparation.
2. Application: Topical 5-ALA was applied to lesions 4 or 6 hours before 
illumination with the lamp. Surface crusts were removed from the lesions and 
the surface gently abraded prior to 5-ALA application. Approximately 50mg/ 
cm2 of cream was applied to the entire irradiation field, including the clinically 
disease-free margin. The cream was then kept in place under an occlusive 
dressing (Tegaderm, 3M) and screened from light for 4-6 hours, after which 
the 5-ALA cream remaining on the skin surface was carefully removed.
Adverse effects
Patients used visual analogue scales (Appendix 1) to record pain 
during treatment and over the 10 days following PDT (with subsequent 
interpretation of 0 < x < 3 as mild, 3< x < 7 as moderate and 7 < x < 10 as 
severe). Patients were offered local anaesthesic (1% plain lignocaine by 
intradermal injection) during treatment.
Clearance and recurrence
Lesions were examined on completion of therapy and 24-48 hours 
later, then at increasing intervals during the following 2 months. Clinical 
response to the first application of PDT was determined at 2 months and a 
second treatment administered if lesions persisted. Clearance was defined in
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Bowen's disease as clinical clearance with histological confirmation for all 
lesions where doubt over clinical clearance existed. Clearance was defined 
in basal cell carcinoma as clinical clearance with histological confirmation for 
all treated tumours (except where multiple tumours in same patient when a 
representative post treatment biopsy was performed) two months following 
either the first or, if required, second treatment. Monthly review of all patients 
was undertaken for a minimum of 12 months following clearance to observe 
for recurrence and assess scarring potential of the therapy. Post therapy 3- 
4mm punch biopsies were performed in all lesions.
Fluorescence/Photography
Fluorescence was detected on the surface of skin/tumour by an 
ultraviolet lamp (UV56 lamp, UVP, Upland, CA, USA), producing light with 
peak emission at 365nm. The presence of fluorescence was recorded prior 
to illumination of treatment sites and the subsequent reduction in intensity 
was recorded in the fluorescence decay studies (Section 3.7-9). Pre- and 
post- treatment clinical pictures of lesions were acquired in all studies with 
photography undertaken by CAM.
3.4 - Actinic keratoses and Bowen's disease - Pilot study
Aim: To assess the efficacy of the prototype light source for photodynamic 
therapy in the treatment of Bowen’s disease and actinic keratoses.
Patients: Patients presenting with lesions of Bowen's disease (in-situ
squamous cell carcinoma) or actinic keratoses, 21mm in diameter or less, 
were invited to participate in the study (for consent form see Appendix 2). 
Histological confirmation of the diagnosis was acquired by performing a 4mm 
punch biopsy on all lesions.
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Methods: Topical 5-aminolaevulinic acid was applied 4 hours before
irradiation. Using appropriate filters, the spectral output of the lamp was 
adjusted to a 30nm bandwidth centred at 630nm. To broaden the treatment 
field and produce uniform irradiation of lesions, an 11 mm diameter perspex 
rod or 25mm diameter collimating lens was attached to the 5mm fibre bundle. 
We included at least a 10% margin around lesions in our field of irradiation 
permitting us to treat lesions up to 9 mm in diameter using the rod, and 21mm 
in diameter using the lens with field size diameters of 11mm and 25mm 
respectively. At fluence rates of 158mW/cm2 for the rod and 55mW/cm2 for 
the lens, lesions received 94-156J/cm2 The treatment dose was centred on 
125J/cm2 as this dose has been shown previously to be effective in ALA-PDT 
using laser.90 Patients were reviewed at monthly intervals and treatment 
repeated if residual disease was present.
Statistics: Comparison of the size of lesions clearing and of those not
clearing after a single PDT treatment, was performed by a Mann-Whitney U 
test. Comparisons of clearance rates depending on dosage and the 
apparatus used to deliver the irradiation, were done using a chi-squared test.
Results - Clearance rates: Twenty lesions of Bowen's disease and 4
actinic keratoses (AK), in 12 patients (3M+9F, median age 65yrs., range 43- 
95yrs.), received photodynamic therapy. Sixteen lesions were sited on the 
leg and 6 on the forearm or hand, and two on the scalp. The median surface 
area of all treated lesions was 60mm2 (range - 9mm2- 400mm2).
Fifteen lesions (12 Bowen's and 3 actinic keratoses) cleared after a 
single treatment with PDT using this non-laser source. All 9 remaining 
lesions cleared following a second treatment, 2 months later. The median 
size of lesions clearing after 1 treatment was 56mm2 (range 9 - 400mm2), not 
significantly different from the size of those lesions requiring a second
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treatment (median 60mm2, range 9 - 380mm2). The clinical response to PDT 
of areas of Bowen's disease and actinic keratosis is shown in Figures 3.2 and
3.3 respectively.
The effect of light dose on clearance after a single treatment is shown 
in Table 3.2. The first five lesions entered into the trial received 94J/cm2, 
75% of our intended treatment dose in order to observe for side-effects. 
Subsequent lesions received 125J/cm2 except, as one patient had 7 lesions, 
two lesions received 94J/cm2, three 125J/cm2, and the remaining two, 
156J/cm2. Three lesions in this patient did not clear with a single treatment, 
one from each of the 3 dose regimens used. Although overall a higher 
percentage of lesions treated with 94J/cm2 cleared after 1 treatment, 
compared with those which received 125J/cm2, this difference was not 
statistically significant.
The perspex rod, with the higher fluence rate of 158mW/cm2, was 
attached to the fibre bundle for the treatment of 15 lesions, of which 10 
cleared (67%) on a single treatment. The collimating lens (fluence rate 
55mW/cm2) was attached to the bundle for the treatment of the 9 larger 
lesions, with 5 lesions clearing (56%) in this group after a single treatment. 
This difference in clearance rate, however, was not significant.
Results - Adverse effects: As treatment of our initial lesions (with
94J/cm2) was well tolerated, the study proceeded, with the increase in dose 
as described. Side-effects were similar in frequency and severity between 
the different dosage groups and are therefore listed together.
No pain was experienced by patients during the treatment of 12 
lesions. Pain during PDT was described as mild in a further 10, moderate in 
one, and severe in one lesion which was an area of Bowen's disease that had 
ulcerated prior to therapy. Only in this latter case was local anaesthesia 
administered. Over the 10 days following treatment, no pain was associated
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Figure 3.2 Bowen's disease on the upper and lower lip a) before and b) 
two months after a single treatment with ALA-PDT using the 
prototype lamp.
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Figure 3.3 An actinic keratosis on scalp a) before and b) two months
after a single treatment with ALA-PDT using the prototype lamp.
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Table 3.2 Clearance of lesions of Bowen's disease after a single
treatment depending on light dose. Treatment times, depending 
on which end attachment to the fibre bundle was used, are also 
shown.
Dose
(J/cm2)
Total no. of 
lesions treated
No. of 
tree
Rod
lesions
ited
Lens
Treatmi
(mi
Rod
snt time 
ns.)
Lens
Clear 
after 1 
treatment
94 7 5 2 10 29 5
125 15 8 7 13 39 9
156 2 2 0 16 49 1
51
with 21 treated lesions, with mild discomfort lasting around 7 days described 
in the remaining 3 lesions. Whilst erythema and oedematous swelling of the 
treatment sites were evident on completion of irradiation, only 3 lesions 
proceeded to blister (by 2 days) with one area of Bowen's disease 
subsequently ulcerating. No photosensitivity reactions were evident following 
PDT.
A visible scar in the treatment field, outwith diagnostic biopsy sites, 
was observed in only three treatment sites, all 3 areas of Bowen's disease 
treated on the ankle and overlying the achilles tendon.
Results - Recurrence rate: During the 12 months following clinical
clearance of the 24 lesions, two areas of Bowen's disease recurred, both at 8 
months, in lesions treated with 125J/cm2. Clearance of these two lesions was 
achieved with a further treatment session of PDT using the prototype lamp. 
This gave an overall complete response rate after 1 year of 92%.
Summary: Clearance was achieved with a single treatment in 15 lesions
(12 Bowen’s and 3 actinic keratoses) and in all of the remaining 9 lesions 
after a second treatment with ALA-PDT using the prototype light source. The 
treatment was well tolerated, with pain absent or mild during treatment in 22 
lesions, with only 1 lesion requiring local anaesthesia. Over the 10 days 
following treatment, no pain was associated with 21 treated lesions. During a 
12 month follow-up period, 2 Bowen's disease lesions recurred. The overall 
complete response rate was 92%. Scarring was evident following the PDT in 
only 3 lesions.
Photodynamic therapy using this portable non-laser light source, 
appears to be an effective and well tolerated treatment for Bowen's disease 
and actinic keratoses.
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3.5 - PDT vs. cryotherapy in Bowen's disease
Aim: To compare the efficacy and adverse effect profile of photodynamic 
therapy with that of cryotherapy in the treatment of Bowen's disease.
Patients: Ethical committee approval was obtained for the randomized
treatment of patients with Bowen's disease with cryotherapy or PDT. During 
the 5 month recruitment period, sequential patients attending the department 
with a clinical diagnosis of Bowen’s disease received a diagnostic 4mm 
punch biopsy. All patients with histological confirmation of the diagnosis and 
with individual lesions of <21 mm in diameter, were invited to participate in the 
study (for information sheet and consent form see Appendices 3+4). No 
lesion had been previously treated. Individual lesions were then randomized 
to receive either cryotherapy or PDT.
Methods:
Cryotherapy: Liquid nitrogen was applied to lesions via a hand-held ‘Cryac’ 
spray. After initial icefield formation, the freeze was maintained for 20 
seconds. A single freeze-thaw cycle technique was employed with a 2-3mm 
rim of clinically healthy tissue included in the treatment field.
ALA-PDT: 20% 5-ALA was applied to lesions four hours pre-illumination.
Using appropriate filters, the spectral output of the lamp was adjusted to a 
30nm bandwidth centred at 630nm. To broaden the treatment field and 
produce uniform irradiation of lesions, a 25mm collimating lens was attached 
to the 5mm fibre bundle. A minimum of a 10% margin around lesions was 
included in the field of irradiation permitting the treatment of lesions <21 mm 
in diameter using a field size of 25mm. At a fluence rate of 70mW/cm2 
(higher than in the pilot study following internal adjustment of the first 
prototype lamp), lesions received 125J/cm.
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Clearance and Recurrence: Clinical response was determined after two
months and repeat treatments administered if lesions persisted. Following 
clearance, all patients were reviewed at monthly intervals for 12 months to 
look for recurrence and late adverse effects. Following therapy, 3mm punch 
biopsies were performed in lesions where doubt over clinical clearance or 
recurrence existed.
Statistics: Comparison of clearance rates was performed using a chi-
squared test. To permit comparison of the effect of lesion size on success of 
clearing after a single treatment with each modality, a linear logistic 
regression analysis was performed. With the probability of a success 
denoted as p, the logit transform of p was logit (p) = log (^P, p) and this was 
modelled as a linear function of the log area. Comparison of pain scores in 
each group was performed by a Mann-Whitney test.
Results - Clearance rates Forty lesions of Bowen's disease in 19
patients (3 male, 16 female, mean age 76yrs., range 62-88yrs.) were 
randomized to receive treatment. The 20 lesions treated by cryotherapy were 
located on the legs (n=16), face (n=3) and hand (n=1), and lesions treated by 
PDT were also located on the legs (n=17), face (n=2) and hand (n=1).
Cryotherapy produced clearance in 10/20 lesions after one treatment, 
a further six lesions clearing after two treatments and the remaining four 
lesions required three treatments. PDT resulted in clearance of 15/20 lesions 
after one treatment and the remaining five lesions after a second treatment. 
Direct comparison of clearance rates revealed no significant difference 
between the two treatments (p=0.08).
Analysis of lesion size in each group revealed that, by chance, lesions 
treated by PDT had larger surface areas (median 150mm2, range 25- 
441mm2) than those treated by cryotherapy (median 82mm2, range 30-
54
360mm2). The larger lesions in each group also appeared to be the most 
likely to require more than one treatment with the lesions persisting after one 
treatment with PDT, of median size 378mm2 (range 150-441 mm2) and those 
persisting after one application of cryotherapy of median size 208mm2 (range 
50-360).
A further comparison of the success of clearing after a single treatment 
was therefore performed using linear logistic regression to model the effect of 
lesion size on clearance. As illustrated in Figure 3.4, the probability that a 
lesion of any size is completely cleared at the first treatment is significantly 
greater with PDT than with cryotherapy (p<0.01). For both treatment 
modalities it was also confirmed that lesion size affects the probability that it 
is completely cleared at the first treatment (p<0.002).
Results - Adverse effects Pain during cryotherapy was present in 19 lesions 
and described as mild in 12 and moderate in 7 lesions. Pain during PDT was 
present in only 11 lesions and was mild in six and moderate in five lesions. 
This difference was statistically significant (p=0.01). No local anaesthesia 
was requested by patients receiving PDT or cryotherapy. Over the 10 days 
following treatment, no pain was associated with 10 of the cryotherapy 
treated lesions and 15 of those that received PDT, with pain otherwise mild or 
moderate in severity in the remainder in both groups. All six patients who 
received both treatments due to having multiple lesions, reported PDT as 
being less painful.
Blister formation occurred after initial cryotherapy in seven lesions with 
subsequent ulceration in five. Systemic antibiotic was later commenced by 
the patient's general practitioner for cellulitis arising around two of these 
ulcerated lesions. In contrast, no blistering nor ulceration occurred following 
PDT, with no subsequent episodes of secondary infection. No 
photosensitivity reactions were observed following PDT.
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Figure 3.4 Comparison of the success of clearing Bowen’s disease after a 
single treatment with cryotherapy or PDT, using linear logistic 
regression to model the effect of lesion size on clearance.
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At final review 12 months following clearance, a visible scar in the 
treatment field, outwith diagnostic biopsy sites, was observed in four lesions 
treated by cryotherapy, whilst visible scarring was absent in all lesions 
treated by PDT.
Results - Recurrence rate: During the 12 months following clinical
clearance, only two areas of Bowen's disease recurred, at 6 and 8 months, 
both from the cryotherapy group. This gives an overall complete response 
rate after one year of 90% in the cryotherapy group and 100% in the PDT 
group.
Summary: In a randomized comparison trial of ALA-PDT vs. cryotherapy in
the treatment of 40 lesions of Bowen’s disease, cryotherapy produced 
clearance in 10/20 lesions after one treatment, the remaining 10 lesions 
requiring two or three treatment applications. PDT resulted in clearance of 
15/20 lesions after one treatment and of the remaining five lesions after a 
second treatment. The probability that a lesion cleared after one treatment 
was greater with PDT than cryotherapy (p<0.01). Cryotherapy was 
associated with ulceration (5/20), infection (2/20) and recurrent disease 
(2/20); no such complications occurred following PDT.
PDT, using a non-laser light source and topical 5-ALA, appears to be 
at least as effective as cryotherapy in the treatment of Bowen's disease with 
fewer adverse effects.
3.6 - Basal cell carcinoma - Open Study
Aim: To determine the efficacy of topical ALA-PDT using the prototype light 
source in the treatment of superficial basal cell carcinomas. In particular, this 
study sought to assess the influence of tumour thickness on the efficacy of
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ALA-PDT by comparing tumour response with histological thickness. The 
effect of altering the duration of photosensitizer application on clearance of 
BCC was also examined.
Patients and Methods: Patients attending the department with a clinical
diagnosis of superficial basal cell carcinoma received a diagnostic 4mm 
punch biopsy and those with histological confirmation of BCC were invited to 
participate in the study (for information sheet and consent form see 
Appendices 5+6). No lesion had been previously treated.
The spectral output of the lamp was adjusted with filters to 630±15nm. 
A 25mm collimating lens was attached to the light guide to produce uniform 
irradiation of lesions. A minimum of a 10% margin around lesions was 
included in the field of irradiation. Alteration of the distance of the collimating 
lens from the skin surface achieved field diameters of 3-7.5cm (5mm fibre - 3- 
4cm fields; 8mm fibre - 5-7.5cm field) at fluence rates of 20-86mW/cm.2 
Individual lesions received 150J/cm.2 Patients recruited during Year 1 
received 20% 5-ALA application 4 hours pre-illumination, whilst patients 
entering during Year 2 received photosensitizer 6 hours pre-illumination. The 
patients were offered local anaesthetic during treatment, if required.
The thickness of the tumour, measured from the granular layer to the 
deepest tumour cell in the dermis, was determined from examination of the 
diagnostic 4mm punch biopsy, which was performed by the same clinician 
(CAM) who sampled the thickest clinically evident part of all lesions. Adverse 
effects were recorded for all patients, including pain during treatment which 
was assessed using visual analogue scales.
Statistics: Clearance rates were compared using a two-sided Fisher's
exact test. The effects of tumour thickness and lesion size on clearance were 
modelled through a linear regression analysis.
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Results - Clearance rates: Fifty-three basal cell carcinomas in 31
patients (14 male, 17 female, mean age 68yrs., range 29-96yrs.) received 
PDT. Of these patients, 24 had one BCC, three had two, two had three, one 
had four and one patient had 13 tumours.
The complete response rate (Table 3.3) after 5-ALA application for 6 
hours was significantly higher than for the 4 hour group (p=0.005). Although 
multiple lesions in the same patient were all treated on different occasions, 
there might be slight departure from independence of the dataset, particularly 
due to the patient with 13 lesions. Statistical analysis of the remaining 40 
lesions continued to demonstrate a significant difference in response
(p=0.008).
Only 3/6 facial BCC in the 4 hour group cleared , whilst 4/6 limb 
lesions and 13/15 lesions on the trunk resolved (Figure 3.5). Basal cell 
carcinomas treated after 6 hours were situated on the face (n=2), limbs (n=7) 
and trunk (n=17).
The size of lesions treated in each group were similar (median sizes: 
4hr., 288mm2;6hr., 235mm2). However, the median size of lesions requiring 
two treatments was larger in both groups (4hr.: 775mm2, range 288- 
4480mm2; 6hr.: 1312mm2, range 140-4500mm2) than for lesions clearing 
after one treatment (4hr.: 399mm2, range 50-2400mm2; 6hr.: 150mm2, range 
50-2500mm2).
Results - Tumour thickness: The effect of tumour thickness on response
rate is shown in Table 3.3b. It is important to note that the calculated values 
of tumour thickness may be an underestimate of the in-vivo depth due to 
tissue shrinkage in biopsy tissue preparation. Whilst all tumours less than
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Table 3.3: Complete response (CR) rate following PDT for all 53 basal cell
carcinomas (a) depending on duration of photosensitizer 
application, and (b) depending on tumour thckness. All lesions 
received 150J/cm2
(a) Photosensitizer duration 4 hour(n=27) 6 hour(n=26)
CR after 1 treatment 16 20
CR after 2 treatments 3 6
Total CR - no./rate 19(70%) 26(100%)
Recurrence 3* 0
Follow-up period -mean and range (months) 24(17-27) 10(6-16)
Overall response rate 59% 100%
(b) Tumour thickness CR rate - 4 hour CR rate - 6 hour
<1mm (n=36) 16/16 20/20
1-2mm (n=13) 3/7 6/6
>2mm (n=4) 0/4 _
* Recurrence at 5, 18, 22 months (Tumour thickness, 1.0, 0.3, 0.4mm respectively).
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Figure 3.5. Basal cell carcinoma on the back (a) 7.2x5.6cm lesion before 
photodynamic therapy ( 0.7mm thick) and (b) the same site 4 
months after 2 treatments with ALA-PDT.
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1mm thick cleared in each group, only 3/7 tumours 1-2mm in depth cleared in 
the 4hr. group, in comparison with all 6 tumours in the 6hr. group (p=0.09). 
No tumour greater than 2mm in thickness cleared, although all 4 such lesions 
belonged to the 4 hour group.
The median thickness of tumours clearing after one treatment was 
identical for both study groups at 0.4mm (range: 4hr. 0.3-1.0mm, 6hr. 0.3- 
1.5mm). The median thickness of lesions clearing after two treatments in the 
4hr. group was 0.7mm (range 0.5-0.8mm) compared with 0.9mm in the 6hr. 
group (range 0.6-1.2mm). The 8 lesions in this study which did not clear 
were overall thicker (median 1.6mm, range 1.0-3.5mm) and included the four 
lesions that were over 2mm thick.
Basal cell carcinoma thickness was an important determinant of 
tumour response in the 4 hour group (p<0.0001) on linear logistic regression 
analysis. After allowing for thickness, lesion size did not affect clearance in 
this group. The 6 hour group was not analysed in view of the 100% CR rate.
Results - Adverse effects: Pain during PDT in each group was absent
in 10, mild in 14, moderate in 2 and severe in 1 lesion in the 4hr. group and 
absent in 5, mild in 16, moderate in 4 and severe in 1 in the 6hr. group. The 
2 patients experiencing severe pain on initiation of therapy received local 
anaesthesia and pain subsided. These were the two largest lesions 
(4480mm2 and 4500mm2) in this study with no other patient requiring local 
anaesthesia.
Blister formation occurred following PDT in 6 patients which resolved 
by day 5, but neither ulceration nor infection of treatment sites was observed. 
No photosensitivity reactions were recorded following PDT. Cosmetic 
outcome was excellent for all tumours (Figures 3.5 and 3.6) with minimal scar 
formation. Initial pigmentary changes post-therapy (both hypo- and hyper-
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Figure 3.6 Basal cell carcinoma on back (6.7x4.1cm, 0.8mm thick) 
(a) before and (b) two months after one treatment with 
photodynamic therapy.
182531
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pigmentation) resolved within 6 months. Hair loss was noted to persist in one 
large BCC treated in the pubic area (Figure 3.7)
Results - Recurrence rate: Three basal cell carcinomas have recurred
after 5, 18 and 22 months (tumour thickness 1.0, 0.3 and 0.4mm respectively) 
in the 4hr. group (Table 3.3), with no recurrences in the 6 hour group. The 
recurrent lesions were successfully re-treated by PDT. These patients 
continue on follow-up.
Case report:
Thirteen of the basal cell carcinomas treated in this study were from a 
65 year-old male Caucasian. He had received radiotherapy for acne at 26 
years of age. He gave no history of arsenic ingestion. His first BCC was 
diagnosed when 45 years old and he has subsequently developed many 
further lesions on his trunk and upper limbs, but not face, requiring frequent 
surgery ± grafting. The extent and multiplicity of BCCs (Figure 3.8) led to his 
referral from the plastic surgery unit.
The size of the lesions treated ranged from 270mm2-2795mm2 
(median=1500mm2). PDT resulted in clearance of 12/13 lesions (Figure 3.6), 
6/7 in the 4 hour group and all 6 in the 6 hour group, and reduction in size of 
the remaining BCC which facilitated direct surgical excision without grafting.
Summary: The efficacy of topical ALA-PDT using the non-laser source was
demonstrated in an open study of the treatment of 53 superficial basal cell 
carcinomas. 5-ALA application 4 hours pre-illumination cleared 19/27 BCC, 
whilst 6 hour application cleared 26/26 BCC (p=0.005). All 36 tumours <1mm 
thick cleared following PDT. Four hour application of 5-ALA cleared only 3/7 
tumours 1-2mm thick, in comparison with 6 hour application which cleared 6/6 
BCC in this category. All 4 BCC >2mm thick and treated at four hours, failed
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Figure 3.7 Basal cell carcinoma (7.5x6.0cm, 0.6mm thick) in the groin of a 
45 year old female (a) before and (b) 12 months after two 
treatments with photodynamic therapy.
I l l l l l l l l l l l l l l l l l l ,
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Figure 3.8 Multiple basal cell carcinomas on the back, several ulcerated.
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to clear. Tumour thickness was an important determinant of clearance in the 
4 hour group (p<0.0001).
Tumour thickness appears to closely predict the therapeutic response 
of BCC to PDT. Increasing the duration of application of 5-ALA from 4 to 6 
hours may improve tumour clearance by increasing the efficacy of PDT for 
intermediate thickness tumours. PDT may therefore be a useful therapy for 
superficial basal cell carcinomas <2mm thick.
3.7 - The effects of light dose, fluence rate and lesion size on
response of Bowen’s disease to ALA-PDT
Aim: To determine the optimal dosage schedule using the prototype lamp 
for topical ALA-PDT by assessing the response of areas of Bowen's disease 
to different light dose and fluence rate regimens. Efficacy of ALA-PDT in the 
treatment of large patches of Bowen's disease was examined to further 
assess the influence of lesion size on outcome. The rate of decay of 
photosensitizer during PDT was also assessed via monitoring of surface 
fluorescence to assist in refining the dosage schedules.
Patients and Methods: Patients with histologically proven areas of
Bowen's disease were invited to participate in the dose-response studies, 
providing no lesion had been previously treated. ALA-PDT used 20% 5-ALA 
applied 4 hours prior to illumination by the techniques outlined above and 
clearance was determined after two months in each case with one repeat 
treatment administered if lesions persisted. Following therapy, 3mm punch 
biopsies were performed in lesions where doubt over clinical clearance or 
recurrence existed. Following clearance, all patients were reviewed at 
monthly intervals for 12 months. Those parameters unique to each part of 
the dose-response assessment are summarized below:
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(a) Light dose/response study - Lamp output was 630 ± 15nm, delivered via 
a flexible light guide and collimating lens. Irradiance was maintained at 55- 
86mW/cm2 permitting a 3cm diameter field size ( the variation being due to 
the fall-off in lamp output during the 2 year period of the study). Lesion size: 
a maximum diameter of 25mm was permitted to allow for a minimum 10% 
margin around lesions. A light dose of 50, 75, 100 or 125J/cm2 was randomly 
allocated with the intention to recruit 30 lesions in each category. Six further 
lesions subsequently received 25J/cm2.
(b) Large patch Bowen’s disease study - Patients with patches of Bowen's 
disease >21 mm in maximum diameter were recruited into an open study of 
ALA-PDT with study design identical to that outlined in Section 3.6 except 
that 5-ALA was applied 4 hours prior to illumination with a subsequent total 
light dose of 125J/cm 2 In view of earlier experience indicating that larger 
lesions are more likely to require repeat treatments, up to three treatments 
were permitted within this study protocol before reversion to conventional 
therapy. Pain during and over the 10 days following treatment was assessed 
as described in Section 3.3. Patients were offered local anaesthesia during 
treatment.
(c) Fluence rate/response study - Lamp output was 630 ± 15nm, delivered 
via a flexible light guide and either the perspex rod (for lesions up to 9mm in 
maximum diameter and used in the pilot study - Section 3.4) or the 
collimating lens apparatus. Irradiance varied between 18-158mW/cm2 
depending on whether the rod (158mW/cm2) or collimating apparatus was 
used and the field size with which lesions were treated (2.5-7.5cm - Table 
3.1). As data is included from the early pilot and the PDT vs. cryotherapy 
studies, certain additional irradiance values are included to those listed in
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Table 3.1 due to the differences in power output between the prototype lamps 
used. Only lesions which received 125J/cm2 were included in this analysis.
(d) Rate of decay of surface fluorescence - Fluorescence at the skin surface 
due to the presence of protoporphyrin IX was detected using a hand-held 
ultraviolet lamp with a peak emission at 365nm. This lamp was used 
throughout the clinical trials of PDT to confirm the initial presence of PplX 
and its subsequent surface clearance post-PDT. For a randomly selected
o
group of lesions the fluorescence was also detected at intervals of 10J/cm 
during PDT to detect changes in the intensity of fluorescence using the scale 
noted below (all assessments by CAM): Fluorescence intensity: 0 - not 
detectable; 1 - just visible; 2 - moderate; 3 - strong; 4 - very intense.
Statistics: A stepwise logistic regression procedure was used to assess
the influence of dose on the success of PDT. The probability of failure was 
modelled with success defined as clearance by 2 treatments with no 
recurrence within one year. As well as lesion size, 3 indicator variables, < 
100J/cm2, <75J/cm2 and <50J/cm2 were included. The same procedure was 
used to assess the influence of irradiance on clearance with lesion size and 
fluence rate as explanatory variables. Comparison of fluorescence decay 
rates was by a Mann-Whitney analysis, adjusted for ties.
Results:
(a) Light dose/response study: A total of 120 lesions in 72 patients initially 
entered the trial, although 4 lesions (in 3 patients) were subsequently lost to 
follow-up and not included in the analysis. Clearance rates are summarized 
in Table 3.4. Whilst 125 and 100J/cm2 achieved initial complete response 
rates of 100 and 93% respectively, during the 12 months of follow-up, three 
recurrences in the 125J/cm2 group (at 5, 7 and 8 months) and one recurrence
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Table 3.4: Dose-response comparison for the treatment of (a) Bowen's
disease and (b) basal cell carcinoma by ALA-PDT.
i § ) _________^ ^ ^ ^ ^ _____
Dose
J/cm2
No. of 
lesions
Clear on 1 
treatment
Clear on 2 
treatments
No. of 
recurrences 
over 1 year
Median
size
(mm2)
Range 
of size 
(mm2)
Overall 
clearance 
rate (%)
125 30 23 7 3 171 36-462 90 (n=27)
100 27 22 3 1 195 25-590 89 (n=24)
75 29 23 3 7 100 25-374 66 (n=19)
50 30 17 10 6 196 25-462 70 (n=21)
25 6 0 0 216 64-540 0
M
150 16 13 3 1 405 50-2795 94 (n=15)
100 16 12 4 1 400 81-3000 94 (n=15)
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in the 100J/cm2 group (at 7 months) reduced the clearance rates to 90 and 
89% respectively. Seven recurrences in the 75J/cm2 group (after 3,3,6,6,8,9 
and 10 months) and five recurrences in the 50J/cm2 group (after 5,5,6,7,9 
and 11 months) reduced overall clearance rates in these groups to 66 and 
70% respectively.
Statistical analysis of these results confirmed a significant reduction in 
the probability of successful clearance at 1 year for lesions receiving less 
than 100 J/cm2 (p<0.001) with larger lesions overall less likely to clear than 
smaller ones (p=0.02). The odds ratio (95%CI) for this reduction in efficacy 
after 75 or 50 J/cm2 was 6.73 (2.33-19.4) and for the influence of size (in 
mm2) on clearance was 1.004 (1.001 -1.007).
In view of the positive response of the majority of lesions to 50J/cm,2 a 
further six lesions received 25J/cm,2 but no complete response was observed 
although a partial response was noted in three of the lesions.
(b) Large patch Bowen’s disease study - 40 patches of Bowen's disease in 
36 patients received ALA-PDT, with clearance of 17 after one treatment and 
a further 13 clearing after a second and 5 after a third, giving an initial 
complete response rate of 88%. Five lesions (1 ulcerated pre-treatment, 4 
clinically thicker plaque than other lesions), failed to clear during three 
treatments although all showed a partial response. Figure 3.9 shows one 
lesion that has successfully responded to one treatment and a second area of 
Bowen's disease demonstrating a partial response after three treatments. 
During the 12 month follow-up period, 4 patches recurred, three at 3 months 
and one at 7 months, giving an overall clearance rate of 78%. The median 
size of lesions clearing within 2 treatments was 623mm2 (range 405- 
2236mm2), on a third treatment was 930mm2 (range 700-1750mm2), and was 
1600mm2 (range 868-2530mm2) for those areas of Bowen's disease which 
did not clear.
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Figure 3.9-a+b Response of large patches of Bowen's disease to PDT.
(a) 40x40mm patch on right leg prior to and (b) 2 months 
following a single treatment.
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Figure 3.9 c+d Response of large patches of Bowen's disease to PDT.
(c) 62x40mm patch on right knee before and (d) 2 
months following 3 treatments with PDT.
^86174
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Treatment was well tolerated with initial oedematous swelling at the 
lesion site, present on completion of ALA-PDT, and subsiding over 24 hours. 
Ulceration and infection of treatment sites were not observed. Eschars 
formed over lesions which separated after 4-6 weeks. During treatment, pain 
was absent in 14, mild in 12, moderate in intensity in 6, and graded as severe 
in 8. However, local anaesthesia was requested only in 3 lesions with 
median size 875 mm2 (range 460-3850mm2). Following treatment, pain 
persisted only in the 8 patients describing pain as severe until day 2 in three, 
day 7 in three and up to 10 days in the remaining two patients.
(c) Fluence rate/response study: Clearance rates for the range of fluence 
rates used are summarized in Table 3.5. Logistic regression demonstrated 
that larger lesions were associated with a lower overall clearance rate 
(p=0.007). After correcting for this influence of size, a significant 
improvement in response was apparent at fluence rates at or below 
48mW/cm2 (p=0.0097). Odds ratios (95%CI) were 1.003 (1.001-1.005) for 
size and 0.019 (0.0007-0.501) for failure of clearance at fluence rates of < 
48mW/cm2.
(d) Rate of decay of surface fluorescence: For all lesions of Bowen’s
disease which received a dose of 50J/cm2 or greater, surface fluorescence 
(grade 3 or 4) was present prior to therapy and was absent on cessation of 
therapy. This excludes the 6 lesions of Bowen's disease treated with 25J/cm2 
(Table 3.4) in which fluorescence was detectable (grade 1) in 4/6 and not 
detectable in the remaining 2 lesions post-PDT. The pattern of fluorescence 
decay at 10J/cm2 increments is shown in Table 3.6 for 11 randomly selected 
lesions of Bowen's disease with loss of fluorescence by 30-50J/cm2 in all 
lesions.
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Table 3.5: Fluence rate-response comparison for the treatment of Bowen's
disease by ALA-PDT. All lesions received 125J/cm2
Fluence
rate
mW/cm2
No. of 
lesions
Clear on 1 
treatment
Clear on 2 
treatments
No. of 
recurrences 
over 1 year
Median
size
(mm2)
Range 
of size 
(mm2)
Overall % 
clearance 
rate
158 15 13 2 0 42 9-81 100
122 4 3 1 1 37 16-94 75
86 14 10 2 2 140 9-460 71
70 13 9 4 0 210 HO-
462
100
55 9 3 6 3 256 195-
576
67
48 22 12 6 3 580 351-
1122
68
40 8 3 4 0 1225 525-
1360
88
30 1 1 0 0 1050 100
18 4 1 1 0 2358 1431-
2530
50
Total 90 55 26 8 _ _
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Table 3.6: Fluorescence decay at lesion surface for Bowen's disease and
basal cell carcinomas during ALA-PDT.
Case
No.
Diagnosis Fluorescence intensity at incremental light doses (J/cm2)
0 10 20 30 40 50 Loss by
1 Bowen's 4 2 2 1 1 0 50
2 Bowen's 4 3 2 1 0 0 40
3 Bowen's 3 2 1 0 0 0 30
4 Bowen's 4 2 1 1 0 0 40
5 Bowen's 4 3 2 1 0 0 40
6 Bowen's 4 2 1 0 0 0 30
7 Bowen's 4 2 2 1 0 0 40
8 Bowen's 3 2 1 0 0 0 30
9 Bowen's 3 2 1 1 0 0 40
10 Bowen's 4 3 1 0 0 0 30
11 Bowen's 3 2 1 1 0 0 40
Mean: 37
12 BCC 4 2 2 1 1 0 50
13 BCC 4 3 3 2 1 0 50
14 BCC 3 2 1 1 0 0 40
15 BCC 4 2 1 1 1 0 50
16 BCC 4 2 1 1 0 0 40
17 BCC 4 2 1 1 0 0 40
18 BCC 4 3 1 1 0 0 40
Mean: 44
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Summary: A randomized study of light dose for Bowen’s disease using
filtered red light and a 5-ALA application time of 4 hours showed a superior 
efficacy for doses of 100 and 125 J/cm2 when recurrence rates over a 12 
month period were included in the overall clearance data. Overall, larger 
lesions were associated with a lower clearance rate. Fluence rates of < 
48mW/cm2 were associated with an improved response despite the larger 
size of the lesions treated. Fluorescence decay assessments support a 
minimum light dose of 50J/cm2 to ensure clearance of visible surface 
protoporphyrin IX in lesions of Bowen's disease.
3.8 - The effects of light dose, fluence rate and lesion size on
response of BCC to ALA-PDT
Aim: To determine the influence on outcome of ALA-PDT for BCC of 
alterations in light dose, fluence rate and lesion size. The rate of decay of 
photosensitizer during PDT was also assessed to assist in refining the 
dosage schedules.
Patients and Methods: Patients with histologically proven areas of
superficial basal cell carcinoma were invited to participate in the dose- 
response studies, providing no lesion had been previously treated. ALA-PDT 
using 20% 5-ALA applied 4 or 6 hours prior to illumination by the techniques 
outlined above and clearance was determined after two months in each case 
with one repeat treatment administered if lesions persisted. Following 
clearance, all patients were reviewed at monthly intervals for at least 12 
months.
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(a) Light dose/response study - Lamp output was 630±15nm. Alteration of 
the distance of the collimating lens from the skin surface achieved field 
diameters of 3-7.5cm at fluence rates of 20-86mW/cm 2 Individual lesions 
from two patients were randomized to receive either 100 or 150J/cm2 with 5- 
ALA applied 6 hours pre-illumination. Only lesions with a tumour thickness < 
1mm were included.
(b) Fluence rate/response study - The lamp characteristics are as described 
in (a) above. Only lesions treated with 150J/cm2 with 5-ALA application 6 
hours pre-illumination were evaluated.
(c) Lesion size/response study - Data from all lesions treated in Section 3.6 
was combined with that derived from BCC treated in this section.
(d) Rate of decay of surface fluorescence - Fluorescence detection at the 
skin surface due to protoporphyrin IX was as described in Section 3.7(d). 
The fluorescence noted 6 hours following 5-ALA application is shown in 
Figure 3.10 which also demonstrates how this technique can assist in 
delineating tumour margins.
Statistics: Logistic regression analysis was used to assess the influence of
lesion size on the success of PDT in BCC, with tumour thickness also 
entered as an explanatory variable. The probability of failure was modelled, 
with success defined as clearance by 2 treatments with no recurrence within 
one year. The same procedure was attempted to compare the two dosage 
regimens and to assess the influence of irradiance on clearance with lesion 
size and tumour thickness as explanatory variables. Comparison of 
fluorescence decay rates for BCC was by a Mann-Whitney analysis, adjusted 
for ties.
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Figure 3.10 (a) A superficial (0.4mm) BCC on the scalp with poorly 
defined margins, (b) The same lesion demonstrates 
fluorescence as detected by a UV lamp 6 h. after 5-ALA 
application.
^    V
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Results:
(a) Light dose/response study: basal cell carcinomas were treated in two 
patients with 12 and 20 tumours, who had 6 and 10 lesions respectively 
treated by each of the light doses studied. The results are summarized in 
Table 3.4. Although there is insufficient data for formal statistical analysis, no 
difference in response was noted between the two dosage levels 
administered.
(b) Fluence rate/response study: Table 3.7 summarizes the results of 33 
BCC treated by the same light dose and 5-ALA application duration. 
Although there was insufficient data for formal analysis, fluence rate had no 
discernible effect on outcome.
(c) Lesion size/response study - Table 3.8 outlines all 76 BCC which 
received ALA-PDT by one of three treatment regimens outlined. For BCC 
lesions treated at 4 hours with 150J/cm2, size was not significant, although 
thickness was an important determinant of response (p<0.0001). For lesions 
receiving 150J/cm2 six hours following 5-ALA application, size was marginally 
not significant (p=0.06), although thickness was again an important 
determinant of response (p=0.012). BCC treated with 100J/cm2 six hours 
post-ALA showed no significant effect of size nor tumour thickness on 
outcome. This latter group was both the smallest and contained thinner 
tumours in comparison with the other groups.
(d) Rate of decay of surface fluorescence: For all BCC treated by PDT in this 
thesis, surface fluorescence (grade 3 or 4) was present prior to therapy and 
was absent on cessation of therapy. The pattern of fluorescence decay at 
10J/cm2 increments for 7 randomly selected BCC is shown in Table 3.6 with 
loss of all visible fluorescence by 50J/cm2. The median dose at which
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Table 3.7: Fluence rate-response comparison for the treatment
of basal cell carcinomas by ALA-PDT. All lesions received 
150 J/cm2
Fluence
rate
mW/cm2
No. of 
lesions
Clear on 
1
treatment
Clear on 2 
treatments
No. of 
recurrences 
over 1 year
Median
size
(mm2)
Range 
of size 
(mm2)
Overall % 
clearance 
rate
122 8 7 1 0 95 70-150 100
86 13 12 1 1 (3 mth) 225 100-495 92
48 2 0 2 0 510 425-594 100
40 3 1 2 0 1050 888-
1120
100
30 4 3 1 0 1788 1250-
2500
100
18 3 1 2 0 2795 2475-
4500
100
Total 33 24 9 1 - _ _
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Table 3.8: Lesion size/tumour thickness-response comparison for the
treatment of basal cell carcinomas by ALA-PDT.
Group Application 
time (hrs) 
/Dose (J/cm2)
No. of 
lesions
Clear by 2 
treatments, no 
recurrence
Median size 
(range) (mm2)
Median thickness 
(range) (mm)
1 4/150 27 16 288 (50-4480) 0.7 (0.3-3.5)
2 6/150 33 32 405 (50-2795) 0.5 (0.3-1.5)
3 6/100 16 15 400 (80-2475) 0.3(0.3-1.0)
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fluorescence is lost was higher for BCC than Bowen's (p=0.04) possibly due 
to the 6 hour pre-treatment 5-ALA application time for BCC in comparison 
with 4 hours for Bowen's disease.
Summary: A light dose of 100J/cm2 was as effective as 150J/cm2 in the
clearance of BCC, without fluence rate influencing outcome. Tumour 
thickness is the predominant variable affecting response over size for BCC 
although neither variable significantly altered outcome in the relatively thin 
tumour group treated with 100J/cm2. Fluorescence decay indicated a 
minimum light dose of 50J/cm2 to ensure surface PPIX clearance following 5- 
ALA application 6 hours pre-illumination.
3.9 - Red vs. green light - efficacy and temperature change
Aim: To assess the influence of wavelength on clearance of Bowen's 
disease by comparing red with green filtered light emitted from the prototype 
lamp. Differences in decay of surface fluorescence and maximum 
temperatures during therapy were recorded in addition to clinical clearance 
and recurrence rates.
Patients and Methods: Sequential patients each with two or more biopsy
proven patches of Bowen’s disease and with individual lesions of <21 mm in 
diameter, were invited to participate in the study. Individual lesions were 
randomized to receive PDT either with green or red filtered light. 20% 5-ALA 
was applied to lesions four hours pre-illumination. The spectral output of the 
lamp was adjusted to 540±15nm (green) or 630±15nm (red) using appropriate 
filters. A 25mm collimating lens apparatus was attached to the 5mm fibre 
guide. At a fluence rate of 86mW/cm2, lesions received 125J/cm2 of red light
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and 62.5J/cm2 of green light. This dose of green light was chosen as the 
quantum yield of protoporphyrin IX at 540nm is approximately twice that at 
630nm (Figure 3.11).133
Fluorescence decay was recorded in a random sample of 5 lesions 
receiving each wavelength by the method outlined in Section 3.7(d).
Temperature was recorded during PDT by an infrared temperature 
probe attached to a digital multimeter (80T-IR probe and meter, Fluke, 
Everett,WA) with recordings before, midway and during the last minute of 
illumination. Control recordings from the untreated side/limb were also noted.
Clinical response was determined after two months and a repeat 
treatment administered if necessary. Following clearance, all patients were 
reviewed at monthly intervals for 12 months to look for recurrence.
Statistics: Simple logistic regression was used to compare clearance rates
as most patients had only two lesions treated. The explanatory variables 
were light colour and size. No significant interaction between light, colour 
and lesion size was evident after fitting a full logistic model and hence the 
model was fitted without an interaction term.
Comparison of loss of fluorescence between the green and red-light 
treatment groups was complicated by the identical observations in the green 
group. The Mann-Whitney test thus failed due to the tied values and a chi- 
squared test failed due to the small expected numbers in many cells. A 
Fisher’s Exact test was therefore performed by grouping the observations in 
the 40 and 50 J/cm2 categories and comparing these observations with those 
in the 30 J/cm2 category.
A Mann-Whitney U test was performed to compare the median 
maximum temperatures and median rise in temperature during PDT.
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Figure 3.11 Absorption spectrum for protoporphyrin IX comparing the
extinction coefficient with wavelength (adapted from Konig K
and Auchter S). 133
Extinction
0.12
510
0.1
545
0.08
580
0.06
630
0.04
0.02
0
800450 500 550 600 650 700 750
Wavelength (nm)
85
Results: Table 3.9 summarizes the clearance rates during PDT using
each filter. A total of 61 patches of Bowen's disease in 26 patients received 
ALA-PDT with 8/29 lesions treated using the green filter failing to clear after 2 
treatments compared with only 2/32 lesions treated by red light. The 
difference in response was significant (p=0.002) with lesion size not a factor 
in achieving clearance at 12 months (p=0.403). Further analysis of the effect 
of size on clearance after one treatment was only marginally not significant 
(p=0.055) for red-light treated lesions and remained not significant for green- 
light treated lesions. A high recurrence rate was observed in the group 
treated by green light, with 7 recurrences, in comparison with only two lesions 
relapsing after PDT using red-filtered light. Comparing red with green light, 
the odds ratio is estimated to be 0.13 (95% Cl 0.04-0.48) in favour of red 
light.
Fluorescence decay was assessed in 5 lesions treated by green light 
with surface fluorescence initially very intense (n=2) or strong (n=3) with a 
reduction in all cases to moderate intensity by 10J/cm,2 to just visible by 
20J/cm2 and to not detectable by 30J/cm2. No surface fluorescence was 
evident on completion of PDT (after 62.5J/cm2) in all remaining lesions 
treated by green light in this study. Comparison of rate of loss of surface 
fluorescence with Bowen’s lesions treated by red light (Section 3.7 and Table 
3.6) suggests an earlier loss of fluorescence in green-light treated lesions 
although this was marginally non-significant on statistical assessment (p= 
0.057).
The temperature during PDT for all lesions and irradiances (28- 
122mW/cm2) showed an increase of 3.1°C (1.5-5.6°C) for red light treatments 
with a maximum value of 34.3°C (29.7-37.1°C). The maximum value was the 
highest value recorded - either mid-treatment or during the final minute of 
treatment (usually the higher). For lesions illuminated by green light the 
median temperature rise was 4.0°C (2.9-5.2) with a maximum value also of
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Table 3.9: Comparison of clearance rates for Bowen's disease
following ALA-PDT using red or green filtered light
Light No. of 
lesions
Clear on 1 
treatment
Clear on 2 
treatments
No. of 
recurrences 
over 1 year
Median
size
(mm2)
Range 
of size 
(mm2)
Overall 
clearance 
rate (%)
Red 32 24 6 2
(6,7 mths)
125 16-441 88 (n=28)
Green 29 18 3 7
(4,4,4,5,6,7,1 
0 mths)
100 25-400 55 (n=16)
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34.3°C (30.4-35.9°C). Subset analysis of those lesions treated at 
122mW/cm2 similarly demonstrated a slightly lower median temperature rise 
with red light treated lesions (n=6) of 3.8°C (1.9-5.7) than for green light 
illuminated lesions (n=9) of 4.2°C (2.9-5.4°C), but with an identical mean 
maximum value of 34.7°C (red: 31.6-37.1°C, green: 33.9-35.9°C). Neither 
maximum temperatures nor rise in temperature were statistically different 
between the red and green groups.
Summary: Green light-activated ALA-PDT using the prototype lamp
achieved a complete response rate at 12 months of 48% (14/29) in 
comparison with 88% (28/32) using red light. Green light thus appears less 
effective than red light at theoretically equivalent doses for protoporphyrin IX 
production (p=0.002). A more rapid bleaching of PPIX from the skin surface 
was evident with green compared with red light with a lower minimum 
dosage, of 30J/cm2, at which surface fluorescence became undetectable. 
Tissue temperature rise was slightly, but not significantly, higher with green 
than red light although no hyperthermic temperatures were recorded in either 
group.
3.10 - Squamous cell carcinoma, large ulcerated basal cell carcinoma, 
and metastatic melanoma
The case reports below relate to patients in whom ALA-PDT, using the 
prototype lamp, was undertaken due to the failure or inappropriateness of 
existing treatment modalities. Patients were fully informed of the 
experimental nature of photodynamic therapy.
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Case 1: Squamous cell carcinoma
Biopsy proven squamous cell carcinoma on the scalp of a frail 83 year- 
old female which had continued to grow and ulcerate despite repeated 
radiotherapy which had reached the limits of tolerance at the time the patient 
was assessed for ALA-PDT. Examination revealed an ulcer 5x4cm in 
diameter with an erythematous crusted margin.
PDT was performed using local anaesthesia with 5-ALA applied 4 
hours pre-illumination using 125J/cm2 red-filtered light and a field diameter of 
7cm. Although painful to the patient despite local anaesthesia (infiltration 
made difficult by tethering of the skin to the underlying tissues) treatment was 
completed and at review 4 weeks later the ulcer diameter had reduced to 
4x1.8cm. PDT was repeated with difficulty again in infiltration of anaesthesia. 
Whilst treatment was completed with only moderate discomfort experienced 
by the patient, pain became severe during the subsequent 6 hours 
necessitating opiate analgesia. Examination at this time showed marked 
localized oedema and erythema. Although by 24 hours pain had settled and 
erythema and swelling had reduced, the patient declined further treatment.
Case 2: Large ulcerated basal cell carcinoma
In addition to the partial response of an ulcerated BCC (50x30mm ulcer 
crater) treated in the patient with multiple lesions described in Section 3.6, 
with reduction in lesion size (as well as complete re-epithelialization) which 
facilitated direct surgical closure, a further large ulcerated BCC has been 
treated by ALA-PDT in an 87 year-old man. This patient had presented with 
a non-healing ulcer on his right calf of at least 8 months duration. Failure of 
response to conventional ulcer dressings precipitated his referral with 
subsequent histological confirmation of a BCC with a tumour thickness of 
2.1mm. ALA-PDT with 150J/cm2 of filtered red light and 5-ALA application 4 
hours prior to illumination achieved re-epithelialization of the ulcer within 3
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weeks (Figure 3.12). Residual tumour was evident on a biopsy 3 months 
after initial therapy and PDT was repeated. The ulcer remained healed with 
no surface evidence of recurrent BCC during the subsequent 3 months until 
the patient died from a myocardial infarction (known history of ischaemic 
heart disease). A repeat biopsy had not been undertaken by this time and 
hence tumour clearance cannot be confirmed. However, this patient had 
reported his satisfaction with the treatment in relieving him of thrice weekly 
ulcer dressing changes and bathing restrictions.
Case 3: Metastatic melanoma
A 76-year-old female who had had a superficial spreading melanoma 
(Breslow = 0.7mm, Clark level 4) excised from her right elbow two years 
previously, presented with a pigmented lesion on her right shin surrounded 
by a 2.4x2.0cm erythematous patch. Biopsy of this lesion revealed a partially 
regressed vertical growth phase melanoma of maximum thickness 0.95mm, 
Clark level 3. Staging revealed no evidence of other metastatic disease. The 
patient, who had previously had a deep venous thrombosis in her right leg, 
was reluctant to receive surgery which would require grafting and a single 
treatment of PDT (125J/cm2 red light 4 hours following 5-ALA) was 
administered to this residual, partly melanotic, lesion. No response was 
evident at 1 month with 4mm punch biopsy confirming persistent disease. 
The patient was finally persuaded to receive surgical excision of the nodule.
90
Figure 3.12 Ulcerated basal cell carcinoma on right leg (5.0x3.0cm), tumour 
thickness 2.1mm, (a) before and (b) 1 month after ALA-PDT.
fc.'
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3.11 -Conclusions
This prototype non-laser source is effective in promoting ALA-PDT in 
clinical practice in the treatment of pre-malignant non-melanoma skin cancer 
and superficial basal cell carcinomas.
A 100% initial clinical clearance was achieved in an open pilot study of 
actinic keratoses and Bowen's disease up to 21mm in maximum diameter, 
although two treatments with PDT were required to achieve clearance in 37% 
of lesions. The overall clearance rate at 1 year of 92% compares favourably 
with results from similar trials using laser light sources (Table 2.1).
In a subsequent open study of large patches of Bowen's disease, 
35/40 (88%) lesions >21 mm in diameter showed initial complete response 
after 1-3 treatments, although 4 recurrences during the following 12 months 
reduced the CR rate to 78%. All remaining lesions showed a partial 
response. Although the response rate was thus lower for the larger lesions, 
ALA-PDT may be particularly useful in this group and reduce the requirement 
for surgery.
ALA-PDT, using the prototype lamp appears to be at least as effective 
as cryotherapy when compared in a randomized trial for the treatment of 
Bowen’s disease and was associated with fewer adverse effects and a lower 
recurrence rate. PDT was superior to cryotherapy in clearing lesions 
following a single treatment after correcting for the effect of lesion size on 
clearance in each group.
Topical ALA-PDT using the lamp to treat superficial basal cell 
carcinomas confirmed tumour thickness as an important determinant of 
clearance for the 27 lesions treated after a 5-ALA application time of 4 hours. 
Although all 16 tumours <1mm cleared, 3/7 1-2mm and 0/4 >2mm thick 
cleared. Prolonging application time to 6 hours cleared all 26 BCC although 
all tumours in this group were <2mm thick and only 6 tumours were 1-2mm in
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tumour thickness. ALA-PDT using a 5-ALA application time of 6 hours would 
thus appear an effective therapy for BCC <2mm in thickness with tumours 
<1mm thick particularly likely to respond. Tumour thickness also had a 
significant effect on response when all BCC treated with 150J/cm2 at six 
hours were compared. As no lesions >2mm thick were treated at 6 hours, 
ALA-PDT may even be effective in this thicker group of tumours following the 
longer photosensitizer application time and requires further study.
An application time of 6 hours was the practical limit to facilitate day 
treatment of lesions by ALA-PDT. Evidence from fluorescence studies 
supports 4-6 hour application times for thin tumours, but 5-ALA uptake by 
thicker tumours may benefit longer application times. Szeimes et al134 
observed that 4 hours after topical application of 10% ALA, protoporphyrin IX 
flourescence was evident only in skin appendages, but at 12 hours was 
detectable in tumour cells in deep dermis. Martin et al135 observed only 
partial thickness protoporphyrin IX fluorescence in 4/9 nodular BCCs 
following application of 5-ALA in-vivo on average 6 hours prior to imaging. 
Whilst 6/7 superficial BCCs showed full thickness fluorescence, the absence 
of reproducible fluorescence marking of the overall thicker nodular lesions 
implied that ALA-PDT may not be reliable in treating this type of BCC. 
Roberts et al9 reported that 4 hours after 20% 5-ALA application using a 
different vehicle, protoporphyrin IX distribution in BCC did not appear to be 
affected by tumour depth and was most intense in those regions of tumour 
immediately adjacent to the dermis.
Superficial BCC lesions can present a particular management problem 
in view of their size and location. A 95% clearance rate at one year for all 36 
tumours <1mm treated suggests that this treatment is at least as effective as 
conventional therapies. Further study of noduloulcerative tumours is required 
to determine whether efficacy can be improved by alterations in 
photosensitizer administration (application time, concentration, lipophilicity,
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penetration enhancement) and light delivery (dose, fractionation, interstitial, 
wavelength).
Fractionation (discontinuous illumination) may improve tumour 
responsiveness by permitting tissue reoxygenation during 'black' periods 
although repair of sublethal tumour cell damage may reduce efficacy.136 
Equal on/off times of 30 seconds during treatment using systemic 
photosensitizers have clinically been associated with improved response 
although theoretically only 10 seconds at most should be required for oxygen 
distribution assuming a normal inter-capillary spacing of 100-400 pm. This 
suggests that vascular occlusion and areas of chronic hypoxia may influence 
tumour oxygen supply and hence susceptibility to PDT. The importance of 
fractionation in cutaneous malignancy with topical ALA-PDT is not known.
Interstitial illumination may be useful in thicker nodular lesions as 
demonstrated with Kaposi's sarcoma studies122,123 although systemic 
photosensitizer delivery may also be required, combining to make PDT an 
invasive therapy reducing its advantages over surgery.
The light source used is unlikely to limit efficacy in thicker tumours 
providing sufficient energy of appropriate wavelength can be delivered to the 
tissue. The effective fluence rate for light produced by the prototype lamp 
used in this thesis has been calculated by the formula described in Chapter 
1.4 which incorporates spectral irradiation, optical transmission through 
tissue and the anticipated absorption of the light by the photosensitizer at the
137wavelengths used. Previously published graphs of optical transmission 
and porphyrin absorption133 (Figure 3.11) were used. Effective fluence rate 
for the study lamp using the red filter (630±15nm) was almost identical to that 
of a 630nm dye laser32 for depths of 0.05mm (18.3W/m2 for lamp, 18.4W/m2 
for laser) and 2mm (2.69W/m2 for lamp, 2.81 W/m2 for laser). This supports 
the study observations that at least for lesions up to 2mm, the lamp achieved
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comparable results to previous laser based ALA-PDT studies (Tables 2.1 and
2.4).
Clinical study of light dose used in the treatment of cutaneous 
malignancy by ALA-PDT appears to have been based on previously reported 
results rather than dose-response. Following the treatment of 124 confirmed 
lesions of Bowen's disease each with 1 year follow-up (Section 3.7), a dose 
of 100-125J/cm2 is optimal for ALA-PDT using red-filtered light of 630±15nm. 
Lower doses, although initially as effective, were associated with a higher 
recurrence rate indicating that insufficient photodynamic damage was being 
achieved at these doses. Fluorescence decay assessment indicated a 
minimum dose of 50J/cm2 to clear surface PPIX in all studied tumours. These 
observations are supported by calculation of PPIX decomposition which 
estimates that the concentration of active photosensitizer is reduced to 10% 
after exposure to an optical dose twice as large as the bleaching fluence. As 
the bleaching fluence is in the range 20-50J/cm2 for PPIX, any increase of 
light dose above 100J/cm2 is unlikely to be clinically relevant.138
Due to ethical considerations, analysis of dose-response was more 
limited for ALA-PDT in BCC. Although both 100 and 150J/cm2 proved equally 
effective, only two patients with multiple tumours were studied and their 
pattern of response may thus be different due to those undefined factors 
predisposing them to develop multiple tumours. This initial comparison of 
dose/response, combined with fluorescence data demonstrating that at least 
50J/cm2 is required before surface PPIX is lost from all tumours, indicates 
that photodynamic activity can be induced within BCCs at least up to this 
dose and that the likely optimum therapeutic dose lies between 50-100J/cm2.
Apart from the initial pilot study, lesion size has been demonstrated to 
have a significant effect on the probability of clearance on a single treatment 
with PDT for Bowen's disease in the comparison study with cryotherapy, and 
was almost significant for red-light treated lesions in the red/green
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comparison study. Lesion size also was a significant determinant of overall 
outcome in the dose/response and fluence rate studies of Bowen's disease. 
This influence may be a function of lesion volume as size also influenced 
response with cryotherapy. Tumour thickness appears to have a
predominant effect over size for BCC, supporting this hypothesis.
Assessment of the effect of fluence rate on response for both Bowen's 
disease and BCC revealed no effect on outcome within the rates studied (18- 
122mW/cm2) for BCC, but a significant improvement in response was 
apparent at fluence rates at or below 48mW/cm2 for lesions of Bowen's. This 
apparent improvement in clearance at low irradiances despite the larger size 
of lesions in these categories requires cautious interpretation due to the 
study design. Fluence rate and lesion size are linked variables as irradiance 
intensity was reduced as a consequence of the larger fields of illumination 
required to treat larger lesions. Nevertheless, this effect of low fluence rate 
was despite the opposing influence of larger lesions which were 
demonstrated in the same study to overall have a poorer clearance rate than 
small lesions. The absence of this association for BCC raises further 
concern that this may not be a re-producible observation.
Several in-vitro and in-vivo studies indicate that high fluence rates of 
up to 200mW/cm2 reduce efficacy of p d t139'142 although others have failed to 
show this association.143,144 Whilst the rapid depletion of oxygen at very high 
irradiances is likely to limit PDT effect, its impact on clinical outcome, at the 
lower irradiances studied, may only be evident when other parameters 
(photosensitizer concentration, light wavelength and total dose) are sub- 
optimal for PDT. Although the PPIX concentration for topical ALA-PDT is 
presumed to be lower than by systemic administration, a study using systemic 
photosensitizer has demonstrated that oxygen depletion starts to effect 
outcome above 50mW/cm2.145 This would support our observation that 
irradiance intensities below this value within the range studied are optimal for
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clinical ALA-PDT although further assessment is required in a study designed 
to avoid linkage between size and fluence rates.
Temperature measurements, using the infra-red probe, revealed an 
absence of hyperthermia, confirming that at the fluence rates used in this 
thesis photodynamic, and not hyperthermic damage, is induced.
Green light appears less effective than red light at theoretically 
equivalent doses for protoporphyrin IX production suggesting that depth of 
penetration of green light might be inadequate for clearance of Bowen's 
disease in clinical practice. The rapid loss of fluorescence surface activity in 
green-light-induced PDT indicates that the PPIX was more susceptible to 
bleaching with green light than with red. Tissue temperature rise was slightly, 
but not significantly, higher with green than red light although no 
hyperthermic temperatures were recorded. The absence of any effect of 
lesion size for lesions of Bowen’s disease treated by green light, suggests 
that wavelength may have had the predominant effect on outcome in this 
study.
The light dose using the green filtered light was calculated by 
comparison of the quantum yield of PPIX at 540nm and 630nm.133 Using the 
recently described formula for estimating total effective irradiance32 (Chapter
1.4) indicates a three-fold higher effective fluence rate for green light at 
0.05mm depth (57.0W/m2) than with red light (18.3W/m2), but with similar 
values at 2mm (3.45W/m2 and 2.69W/m2 respectively). Thus 62.5J/cm2 of 
green-filtered light was probably a relatively higher dose than 125J/cm2 of 
red-filtered light. The reduced efficacy of green light in clinical study may 
thus have been influenced more by light distribution than dose. A model of 
optical distribution in Caucasian skin indicates that 635nm light peaks in the 
upper dermis (due to the addition of scattered light to the incident fluence) in
138comparison with 514nm light which peaks in the stratum corneum. An in- 
situ fluence equal to the incident unscattered fluence is attained at a depth of
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2.5mm at 635nm compared with 0.5mm at 514nm. Despite the superficial 
nature of Bowen's disease, this difference in penetration appears to be of 
therapeutic importance when red and green light is compared. The high 
recurrence rate with green light suggests that the deepest dysplastic cells 
may have been inadequately treated by green light.
ALA-PDT using the prototype lamp was well tolerated both during 
irradiation and in the follow-up period. Local anaesthesia was required only 
where the epidermis was not intact prior to irradiation or for certain larger 
lesions including 3 large patches of Bowen's disease and the two largest 
BCCs treated. The majority of patients presenting with Bowen's disease and 
BCCs were elderly, with Bowen's lesions often on the lower leg, a poor site 
for healing. Therefore, the avoidance of ulceration (except for 1 lesion in the 
pilot study) and treatment site infection following treatment was encouraging. 
The absence of generalized photosensitivity following PDT using topically 
applied photosensitizer permitted the patients to be easily managed on an 
out-patient basis.
The low incidence of clinically obvious scar formation is consistent with
the good cosmetic results reported following laser induced PDT for Bowen's
disease10,19,90. Cairnduff90 and Kennedy10 have used doses up to 250 and 
2540 J/cm respectively with no reported scar formation. Scarring was 
observed in three treatment sites, all overlying the achilles tendon in patients 
treated in the pilot study of Bowen's disease. Minimal visible scar formation 
was also observed following ALA-PDT for BCCs although temporary 
pigmentary change and permanent localized hair loss was noted in certain 
treatment sites, especially larger lesions on hair-bearing sites.
Individual cases of extensive SCC and metastatic melanoma did not 
show satisfactory response to ALA-PDT. However, treatment trials were 
probably inadequate to fully assess efficacy. The patient with a large SCC on 
her scalp may have continued to respond to PDT if localized 'sectional'
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treatments had been commenced which may have permitted more effective 
local anaesthetic coverage and less severe post therapy oedema and pain. 
The lack of response of a cutaneous metastatic melanoma deposit is 
compatible with the poor efficacy of ALA-PDT for this tumour reported by 
Wolf et al.35 Absorption of 630nm light by the melanin pigmentation may 
have been the main reason for the failure of PDT as well as possible 
inadequate penetration of the nodule by photosensitizer at 4 hours.
Although follow-up intervals remain short for observing 
tumourogenesis, no tumour appears to have been induced or promoted by 
PDT during any of the studies outlined above where a total of 263 lesions of 
Bowen's disease and 77 BCC received ALA-PDT.
This chapter has outlined studies confirming the efficacy of ALA-PDT 
using the prototype lamp in non-melanoma skin cancer, confirming an 
efficacy compatible with previous laser and non-laser studies. ALA-PDT may 
also have a role as an adjunctive/palliative therapy for extensive ulcerated 
BCC. The influence of duration of photosensitizer application, light dose, 
fluence rate, tumour thickness and lesion size have been assessed with 
clearance data in all cases incorporating at least a 12 month follow-up period 
(up to 24 months for BCCs). ALA-PDT using the prototype lamp was 
practical as an out-patient therapy and was well tolerated by patients with a 
low prevalence of adverse events.
PDT in dermatology offers the advantages of being non-invasive, 
relatively painfree, well tolerated in slow healing sites such as the lower leg, 
and tissue sparing, leaving the skin surrounding the tumour intact and 
functional.
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Chapter 4 - Morphology of the Skin following topical ALA-PDT
4.1 - Introduction
Although studies have indicated intracellular effects of PDT (Chapter
1), there is little knowledge of the histopathological changes that occur 
following topical ALA-PDT in clinical practice. Good cosmesis is reported 
following PDT although these observations have been based on clinical and 
not histopathological assessment. This chapter assesses the tissue changes 
following topical ALA-PDT for Bowen's disease and basal cell carcinoma with 
particular reference to histological evidence of scar formation and the 
presence of PDT-induced apoptosis.
Tissue response to PDT has been described as a rapidly developing 
coagulation necrosis and can be observed within hours of treatment. This 
necrosis is accompanied by an acute inflammatory response and affects 
normal as well as tumour tissues in the treatment field. These observations 
have been made in v/Vo50,146-148 following systemic administration of 
photosensitizer where PDT response may depend on damage to tumour 
vasculature as evident from endothelial cell swelling, blood cell aggragation 
and haemorrhage noted on light microscopy. Wang et a/26 recently reported 
that no direct vascular damage was observed following topical ALA-PDT in 
the treatment of 40 basal cell carcinomas and 6 patches of Bowen's disease. 
Laser doppler perfusion imaging was used with care taken to minimize the 
effects of spatial variation in perfusion by averaging values over the 
assessment area. Pre-treatment perfusion was higher in the lesion than 
surrounding skin in all tumours and increased immediately following 
illumination, falling to the level of normal skin only after healing. All tumours 
cleared with treatment indicating that direct tumour cell damage and not 
tissue hypoxia due to vascular impairment was responsible for tumour
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destruction. Topical ALA-PDT may thus produce a different pattern of tissue 
damage from systemic PDT with consequences in respect of healing as well 
as possibly favouring its use in sites of poor perfusion.
Preservation of the structure of collagen following PDT has been 
attributed to a relative resistance to photo-dynamic destruction.58 This may 
not only preserve the integrity of tissue, but promote a good cosmetic 
outcome in PDT treated tissue. Structural integrity of rodent colon has been 
assessed following PDT with aluminium phthalocyanine and compared with 
changes following thermal treatment.149 Despite full-thickness necrosis being 
induced by each therapy, the relative mechanical strength of the tissue, 
measured by the bursting pressure of colon, was unchanged following PDT, 
but greatly reduced following thermal treatment. Collagen fibrils were 
preserved in the submucosal collagen layer with PDT whilst thermally 
damaged collagen lost its fibrillary architecture. Clinical studies of ALA-PDT 
in the treatment of non-melanoma skin cancer and its precursor lesions 
indicate good cosmesis, but without confirmation of an absence of 
microscopic scar formation.19,91'5,105,113 Confirmation of a low scarring 
potential with preservation of tissue function would make topical ALA-PDT 
particularly useful for lesions on the eyelids, ears and nose where 
disfigurement can result from conventional treatment modalities.
Apoptosis is an active programmed process of cell death, in contrast to 
necrosis when cells appear to be passive targets of injury.150 Malignant cell 
proliferation is often associated with a reduced frequency of apoptosis and a 
concomitant loss of response to chemotherapeutic agents, which in a normal 
cell population, elicit an apoptotic response. The induction of apoptosis by 
PDT has been demonstrated both in vitro (including human squamous cell 
carcinoma lines151) and in vivo (in RIF-1 tumours in C3H mice,152 and HeLa 
cells in nude mice153) and may represent an important method of action of 
PDT. Evidence of apoptosis has been observed within 1 hour of PDT.154 The
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initiation of apoptosis has been shown to vary with photosensitizer and type 
of malignant cell. Photofrin-mediated PDT was observed to induce apoptosis 
in two of three malignant cell lines.155 The potential of ALA-PDT to induce 
apoptosis is not known.
4.2 - Morphological changes induced by ALA-PDT
Aims
To determine the macroscopic and microscopic changes in the skin 
induced by ALA-PDT using the prototype non-laser light source.
Patients and methods
Histopathological specimens were acquired from patients receiving 
topical ALA-PDT using the prototype non-laser light source by the protocols 
outlined in Sections 3.4-6. Observed macroscopic changes relate to lesions 
treated in all clinical studies described in Chapter 3. Post-therapy 4mm 
punch biopsies were undertaken at intervals up to 2 months following therapy 
in Bowen's disease and up to 1 year post-PDT for BCC. Post therapy 
specimens were not taken from the scar sites of earlier punch biopsies. 
Histopathological specimens in this analysis relate only to lesions of Bowen's 
disease treated 4 hours post-ALA application by 125J/cm2 of red light and to 
BCCs illuminated 4-6 hours post-ALA by 150J/cm2 of red light. 
Histopathological specimens were also acquired post-cryotherapy in the 
comparative study of therapy in Bowen's disease (Section 3.5).
Biopsy specimens underwent routine paraffin processing and were 
stained with haematoxylin and eosin.
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Results
(a) Macroscopic assessment of skin changes following topical ALA-PDT: 
Treatment of lesions of Bowen's disease and BCCs treated in the studies 
described in Sections 3.4-6 resulted in oedema and erythema immediately 
following ALA-PDT which settled over 48 hours. Blister formation was noted 
in 3/40 patches of Bowens disease and 6/53 BCC, all resolving within 1 
week. Lesions subsequently developed a light crust which could remain for 
up to 2 months. Ulceration of the skin and cellulitis were not observed 
following PDT. Post inflammatory hyperpigmentation was evident in a few 
BCC treatment sites which resolved within 6 months. Hair loss was observed 
where BCC's were located within scalp hairline (n=1), within pubic hair 
(n=1)(Figure 3.7b), or on particularly thick body hair (n=4). Whilst lesions of 
Bowens disease frequently assumed normal skin colour by 12 month review, 
BCC treatment sites retained a faint erythematous hue in approximately 25% 
of cases (Figures 3.5 and 3.6). Nevertheless, clearly visible lesion-wide scar 
formation was only seen on the 3 ankle sites (Section 3.4) and patients 
otherwise all found the cosmetic result of ALA-PDT acceptable. The small 
scars left from up to 2 punch biopsies made detailed assessment of PDT- 
induced scar formation difficult although minimal visible scar formation was 
evident in certain of the larger BCCs.
(b). Histopathology of the skin after PDT in Bowen's disease:
Post-therapy histopathological specimens were available from 20 
lesions of Bowen's disease and 4 patches treated with cryotherapy. 
Immediately following PDT, vacuolation of keratinocytes within dysplastic 
regions with spongiosis of intervening epidermis and oedema of the 
superficial dermis was evident in all 3 specimens studied. Multiple 
apparently apoptotic cells were visible in lesional epidermis in 2 specimens. 
Capillary dilatation with a mixed acute and chronic inflammatory cell infiltrate
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was also present in the dermis with red cell extravasation in the papillary 
dermis in one specimen. Similar features were noted in 4 biopsies 1 hour 
post-PDT with evidence of both coagulation necrosis of some superficial 
dysplastic foci with other nests of cells showing striking nuclear vacuolation. 
Capillary dilatation with margination of neutrophils was seen in the upper and 
mid-dermis. At 2 hours following treatment all 3 specimens showed capillary 
dilatation and red cell extravasation in the upper dermis with full thickness 
epidermal necrosis in one biopsy with the other specimens showing 
vacuolation of basal cells (Figure 4.1a).
All seven 1-2 hour samples were assessed for the presence of 
apoptosis and compared with 7 control biopsy specimens, selected at random 
from the pre-treatment specimens of lesions in the same study. Apoptotic 
cells were defined as individual cells exhibiting cytosol and chromatin 
condensation with significant cell shrinkage.157 Apoptotic cell counts were 
made in 10 random high power fields (x100) and a mean value calculated. 
The mean apoptotic cell counts ranged from 0.7-2.9 per high power field (hpf) 
in the control samples (mean 1.7) compared with 1.8-12.2/hpf (mean 5.1) for 
PDT-treated lesions (p=0.02 - Mann Whitney test). The presence of 
apoptosis in a PDT-treated lesion is demonstrated in Figure 4.1b.
By 24-48 hours full thickness coagulative necrosis was seen in 4/6 
specimens (Figure 4.2). In the remaining 2 specimens, there was focal 
necrosis in the superficial epidermis and preservation of the basal layer, but 
absence of dysplastic keratinocytes. Dilated capillaries in the dermal papillae 
showed loss of endothelial cells and contained thrombi in 3 specimens and 
all samples showed a lymphohistiocytic perivascular infiltrate. Patchy 
hyalanisation and swelling of collagen fibres in the upper and mid-reticular 
dermis was present in one biopsy at 48 hours (but no scar formation was 
subequently visible although no further histology is available).
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Figure 4.1 Bowen's disease 2 hours following ALA-PDT with (a) a striking 
basal cell vacuolation and inflammatory infiltrate in the upper 
dermis and (b) multiple apoptoses present in the epidermis.
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Figure 4.2 48 hours following ALA-PDT to a patch of Bowen's disease.
The epidermis is replaced by fibrin coagulum and there is 
thrombosis of some superficial vessels and a perivascular 
lymphohistiocytic infiltrate extending through the full thickness 
of the dermis.
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At 24-48 hours post-cryotherapy, full thickness necrosis of the 
epidermis was evident in all 4 specimens with necrosis of the dermis to 2mm 
in two lesions. The specimens also showed extensive loss of endothelial 
cells and red cell extravasation throughout the dermis. Thrombi in vessels to 
3mm were noted in two lesions. Although inflammatory infiltrate was less 
prominant, tissue damage was overall more extensive in the cryotherapy 
specimens than those samples derived from PDT treated lesions.
By 4-8 weeks post-PDT, the epidermis appeared normal and without 
dysplasia although scarring of the dermis was present in 2/4 specimens. This 
extended to the full thickness of the dermis and represented 2/3 ankle lesions 
in the open study of ALA-PDT (Section 3.4) where scarring was clinically 
evident (the remaining lesion was not biopsied post therapy). The remaining 
2 specimens showed no evidence of dermal scarring.
(c). Histopathology of the skin after PDT in basal cell carcinoma:
Post-therapy histopathological specimens were available from 29 
basal cell carcinomas following PDT. One hour post-therapy vacuolation of 
the basal cells in the normal epidermis was noted in 2/2 specimens. 
Vacuolation of tumour cells at the upper border of the tumour was also 
present with capillary dilatation in the dermis and an acute inflammatory 
infiltrate extending down 2mm.
Scarring of the dermis was present in 8/22 biopsies acquired 1-4 
months post-therapy, extending to 0.5mm in four specimens (Figure 4.3) and 
2mm in the remaining lesions. No scar formation was evident beyond 2mm 
and deeper structures were well preserved. In the remaining 14 biopsies, a 
chronic inflammatory infiltrate extended to 0.5 - 1mm. No scarring was also 
present in all 5 biopsies acquired between 6-12 months after PDT although 
there was persisting evidence of a mild superficial chronic inflammation in all 
samples.
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Figure 4.3 Histology 3 months post-therapy to the site of a BCC shows (a) 
superficial scar formation and (b) preservation of deep 
structures.
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4.3 - Conclusions
Topical ALA-PDT results in the development of oedema and erythema 
during therapy with occasional subsequent blister formation. Crusts form 
over lesions but without epidermal ulceration. Scar formation was site- 
specific in Bowen's disease occuring in lesions sited at the ankle. Minimal 
visible scar formation was observed in several BCCs.
The acute histopathological effects of topical ALA-PDT in Bowen's 
disease were of vacuolation of keratinocytes and their nuclei with capillary 
dilatation and an acute inflammatory infiltrate. Subsequently, a full thickness 
coagulative necrosis or focal necrosis developed by 24-48 hours. Scar 
formation was not evident microscopically other than in those sites where 
scar formation was obvious clinically. Topical ALA-PDT in BCC resulted in 
vacuolation of basal epidermal cells and tumour cells. Superficial fibrosis 
was evident in over a third of treatment sites 1-4 months following PDT, 
although scar formation was not noted in sites biopsied beyond 6 months 
from therapy.
The observed effects of topical ALA-PDT indicate that early 
vacuolation of treated cells is characteristic, but that other features including 
vascular changes and the development of a coagulative necrosis are not 
treatment specific. Cryotherapy typically results in homogenisation of the 
epidermis with loss of cellular outlines and a coagulative necrosis extending 
into dermis.156 In comparison with cryotherapy, ALA-PDT may cause less 
ulceration and bullae formation due to its greater specificity as observed by 
proportionally less epidermal necrosis and dermal damage. Cryotherapy 
caused a notably greater degree of tissue damage than PDT.
Although sample numbers were small, photodynamic therapy would 
appear to induce apoptosis in human keratinocytes in vivo in human tissue. 
This had previously only been shown in animal models.153'4 The reason
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for the development of apoptosis rather than necrosis following PDT remains 
unknown. As apoptosis requires cell membrane-bound enzymes, PDT using 
5-ALA as photosensitiser, which preferentially targets the mitochondria, may 
facilitate apoptosis. Cryotherapy, as with systemic lipophilic photosensitisers, 
through the direct destruction of the cell membrane, are instead likely to 
favour necrosis.
Treatment of an intra-epidermal neoplasm by PDT rarely resulted in 
either a visible or microscopic scar (although few late histology specimens 
were acquired). In contrast, destruction of a dermal tumour, whilst resulting 
in cosmetically acceptable 'wound' sites was associated with mild superficial 
dermal fibrosis on histopathological examination in over a third of specimens. 
A contribution of an initial pre-treatment biopsy to inducing scar formation 
extensively within the treatment field seems unlikely in the absence of this 
phenomenon with Bowen's disease sites. The absence of fibrosis in those 
sites sampled beyond 6 months may reflect a spontaneous improvement in 
early mild fibrosis although sample size is also likely to be relevant as 
minimal visible scar formation has been observed to remain at 12 months in 
certain of the larger BCCs.
ALA-PDT thus appears to achieve tumour destruction with less 
extensive tissue destruction than with cryotherapy, with apoptosis probably 
contributing to tumour cell kill. Fibrosis following ALA-PDT is reported for the 
first time, with its superficial distribution possibly reflecting the superficial 
extent of clinical ALA-PDT activity. The mild extent of fibrosis and the 
possible improvement with time, associated with the reduced initial extent of 
necrosis, probably both contribute to the excellent cosmesis observed 
following ALA-PDT.
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Chapter 5 - Photoproducts in ALA-PDT
5.1 - Introduction
Certain porphyrins, including haematoporphyrin, can produce a visible 
light emitting photoproduct following reaction with singlet oxygen.158,159 The 
role of this photoproduct, which has a strong absorbance around 680nm, is 
not known. The 630/635nm light used in Photofrin-PDT neglects to activate 
this potentially useful chemical. ALA-induced protoporphyrin IX is a relatively 
photolabile porphyrin, absorbing throughout the near ultraviolet and visible 
region30,133 (Figure 3.9). In vitro, PPIX readily forms several oxidized 
photoproducts, many of which absorb strongly in the same spectral region as 
PPIX.160'2 These arise from the action of photosensitized activated oxygen 
species, predominantly singlet oxygen, upon the surface of the PPIX 
molecule. Photobleaching of PPIX can give rise to products which do not 
absorb in the visible region, as observed both in v/'fro160"2 and in v/Vo.163,164
Several PPIX photoproducts possess measured singlet oxygen yields 
similar to the precursor agent suggesting a possible role for these products in 
ALA-PDT.161
Two main classes of PPIX derived photoproduct have been identified 
in vitro. Chlorin-type isomers, with absorption in the range 640-670nm, are 
the main product of PDT in simple solvents, with a lower yield of formyl- 
porphyrin products which have a similar but right-shifted spectrum to PPIX 
(640-650nm).165 The medium in which these reactions occur may influence 
whether other forms of activated oxygen, including superoxide, may be 
responsible for some photoproducts.
In vivo, fluorescence emissions have indicated PPIX photoproduct 
formation from both mouse163,164 and human tumours.166 A minor emission at 
660-670nm has been shown as a small contribution overlying the PPIX 
spectrum. Photoproduct formation emitting at 670nm has also been observed
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during irradiation of normal murine tissues, such as salivary gland, which 
accumulate PPIX.165
Where the time course of photoproduct formation has been followed in 
both mouse and human tissue, the relative contribution of the 670nm 
photoproduct increased relative to the PPIX emission at longer irradiation 
times.163,164 This is presumed to be due to the photobleaching of PPIX.
The potential contribution of photoproduct to efficacy in clinical PDT 
remains to be established. Beyond detection of fluorescence emissions, 
another method of assessing this contribution is to determine whether the 
efficacy of PDT is altered by the inclusion of activating wavelengths at 670nm 
in addition to 635nm.
5.2 - Photosensitization of murine skin by 5-ALA-induced porphyrin
Aim: To compare the phototoxicity in-vivo of 5-ALA induced porphyrins 
following PDT using light of 635nm and/or 670nm. The presence of 
additional tissue damage by incorporating 670nm light would provide 
evidence of a potentially useful photoprotoporphyrin with implications for 
clinical ALA-PDT.
Methods: The skin reactions of 30 female BALB/c mice, all 6-9 weeks old,
were studied using the previously described murine whole-foot response 
model for cutaneous porphyrin photosensitivity.167 Animals were given 
250mg/kg of 5-ALA by intraperitoneal injection and illuminated after 3 hours. 
The mice were restrained without anaesthesia in specially designed holders 
to permit illumination of both rear feet. This protocol was derived following 
review of a previous murine ALA-PDT dose-response study168 with the 
intention of optomising the likelihood of visible tissue response, but at a
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tolerated dose of photosensitizer. The feet were illuminated by 100J/cm2 of 
635±2nm and/or 670±2nm at 50mW/cm2 from two argon ion pumped dye 
lasers with sites receiving both wavelengths illuminated simultaneously.
The study, performed at Roswell Park Cancer Institute, Buffalo, was 
approved by the local regulatory authority.
The reaction of the murine feet to PDT was scored using the system 
summarized below:
Score Physical appearance
0 No apparent difference from normal
0.1 Very slight oedema
0.3 Slight oedema
0.5 Moderate oedema
0.75 Large oedema and/or slight erythema
1 Large oedema and/or erythema, with exudate
1.2 Moderate erythema, with slight crust or scale
1.5 Definite erythema, with scale or crust
1.65 Slight damage to toes
1.75 Definite damage and/or slight fusion of toes
2 Most toes fused, but general shape unchanged
2.5 Foot almost shapeless, but stubs of toes present
2.75 Foot shapeless with no toes
3 Only stub of foot remaining
The reactions were assessed at 24 hour intervals for up to 8 days following 
treatment until either the reaction had settled or a grade 2 or greater reaction 
was recorded at which point the mice was sacrificed. Each mouse was coded 
by a sequence of rings drawn on their tails, but the observer was blinded to 
the identity of each group during the period of follow-up.
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Results: No foot response reaction was noted on either feet of 5 mice
which received 5-ALA only and no light. Similarly, 5 mice received to each 
rear foot 635nm and or 670nm light in the absence of 5-ALA and no 
cutaneous reaction was observed.. The time course of the cutaneous 
reactions in each group is shown in Figure 5.1. The peak response was 
observed from days 4-8 with the greatest response noted in the 635+670nm 
group. A small response was noted for feet treated by 670nm alone.
The maximum reaction observed in each PDT group is summarized in 
Table 5.1. As numbers were small, statistical analysis was not performed, 
but 635nm light appeared to have its phototoxic effects enhanced by the 
addition of 670nm. Illumination during PDT with 670nm alone elicited a 
response in 7/10 mice ranging from slight oedema to toe fusion. The 
absence of a response from either foot in two mice in group 1 suggests that 
successful intraperitoneal injection of photosensitizer may not have been 
achieved.
Due to the design of the study, in all feet treated by 670nm alone, the 
contralateral foot received both wavelengths, providing an opportunity for 
photoproduct formation. Additional control groups of mice receiving 635nm to 
both feet or 670nm to both feet were not included due to limitations on the 
number of mice available in this initial study of the detection of photoproduct 
phototoxicity.
Summary: This was a pilot study to detect the presence of a 670nm
photoproduct using a murine model of cutaneous phototoxicity. A consistent 
pattern of results indicate that illuminating skin presumed to contain 5-ALA 
derived protoporhyrin IX achieved a greater phototoxic reaction when 670nm 
light was added to 635nm light. 670nm light alone also resulted in a small, 
but discernible reaction in 7/10 sites illuminated. The illumination of 
contralateral feet with 635 as well as 670nm light is the presumed source of
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Figure 5.1 Time course of the cutaneous phototoxicity in murine 
feet following ALA-PDT using 635 and/or 670nm light. 
Mean scores for the 10 feet treated in each group are 
shown with standard error bars.
635nm +/-670nm Irradiation, 100J/cm
2
635 nm 
670 nm 
635 + 670 nm 
ALA Only 
Light Only
1
0
0 2 4 6 8
Time (Days)
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Table 5.1 Maximum scores for reaction of murine feet to ALA-PDT using 
wavelengths of 635nm and/or 670nm.
Group, 
left/right foot
Wavelength(s)
(nm)
No. Scores Maximum response 
(median)
1L 635 10 o*,o*,0.25,1.2,1.5,
1.5,1.75,2,2,2
1.5
1R 635+670 10 0*,0*,1.5,2,2, 
2,2,2,2,2
2
2L 670 10 0,0,0,0.1,0.25,0.25,
0.25,0.5,1.2,2
0.25
2R 635+670 10 0.75,2,2,2,2, 
2,2,2,2,2
2
*No reaction on either foot of same 2 mice
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photoproduct formation although 635nm light in the ambient laboratory 
daylight may have contributed. The detection of cutaneous damage by 
incorporating 670nm light to ALA-PDT would suggest that a clinically useful 
photoproduct is present at this wavelength.
5.3 - Murine tumour destruction by 5-ALA-induced PDT
Aim: To determine whether the addition of 670nm light to ALA-PDT 
illumination with 635nm light improves tumour regression in vivo. A superior 
response using both wavelengths would indicate the presence of a 
therapeutically useful photoproduct of protoporphyrin IX.
Methods: Murine colon carcinoma (Colo 26) was propagated in 6-9 week-
old female BALB/c mice. Tumours were obtained by intradermal injection of 1 
x 106 cells, prepared from established tumours by enzymic digestion, into 
each flank of the animals. 169 Prior to tumour inoculation, all hair was 
removed from the region of the injection sites by shaving and depilation. 
Tumours were used for experimentation when they had reached a surface 
diameter of 4-6mm. The study, performed at Roswell Park Cancer Institute, 
Buffalo, was approved by the local regulatory authority.
ALA-PDT was administered to each tumour by the same protocol as 
outlined in Section 5.1. Mice were sacrificed 7 days following PDT. Tumours 
were then excised and tumour height was measured with callipers. The 
observer was blinded to the treatment group of an individual mouse. A ratio 
of tumour thickness to control thickness was calculated as this has previously 
been shown to produce a reliable indication of tumour regression in this 
murine model.168
117
Results: The response of tumours to ALA-PDT using the wavelengths
studied is summarized in Table 5.2. A total of 30 mice were available for 
study. No tumour developed in 2 injection sites and a further 4 tumours did 
not reach the initial 4mm minimum diameter for entry to the study. Following 
treatment, 4 mice died within 48 hours, all receiving PDT with combined 
wavelengths to one tumour and to the contralateral side either 635nm (n=3) 
or 670nm light (n=1). The combined intensity of photodynamic 
inflammation/destruction on both flanks was presumed to have contributed. 
Of the remaining 10 tumours treated with combined wavelengths, the tumour 
on the contralateral flank was illuminated by 635nm light in 2, by 670nm light 
in 4 and not illuminated in the remaining 4.
Whilst a reduction in tumour thickness occurred with 635nm and 
635+670nm light, 670nm light alone had no apparent beneficial effect. The 
presence of a PDT reaction with 635nm light on the contralateral flank made 
no difference to response in the 670nm light treated tumours. The combined 
wavelengths resulted in an overall 14% greater tumour regression than 
635nm alone, although this may not be a significant difference (statistics not 
performed due to the small study numbers).
Summary:
This pilot study to determine the importance of wavelength in ALA-PDT 
on tumour regression in vivo demonstrated a reduction in tumour thickness 
with 635nm light-mediated therapy which may have been augmented by the 
simultaneous illumination with 670nm. 670nm light-mediated PDT had no 
impact on regression either as monotherapy or when dual illumination was 
being applied to the contralateral tumour suggesting no circulating 
photoproduct was available for activation at 670nm. The apparent 
improvement in response using both wavelengths would indicate the
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Table 5.2 Tumour regression induced by ALA-PDT using 635±670nm in 
murine tumour model. Outcome is indicated by the ratio of 
mean tumour thickness at 7 days post treatment to mean control 
thickness (from tumours receiving no intervention).
Wavelength(s) (nm) No. Mean thickness (mm) 
(range)
Tumour/control 
thickness (%)
635 4 3.2(1.8-4.5) 89
635+670 10 2.7 (2.4-3.2) 75
670* 4 4.0 (3.6-4.6) 111
670** 6 4.0 (2.9-5.1) 111
light only (635±670nm) 8 3.6 (2.4-4.2) 100
5-ALA only 8 3.4 (2.7-4.2) 94
no intervention 6 3.6 (3.1-3.8)
*Contralateral tumour irradiated by 635+670nm.
**Contralateral tumour irradiated by 670nm.
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presence of a therapeutically useful photoproduct of protoporphyrin IX for 
local tumour destruction.
5.4 - Implications for clinical PDT
Two pilot studies are reported in this chapter with the aim of 
demonstrating the presence of a photoproduct of protoporhyrin IX that is 
activated by 670nm light. The relevance of this product to clinical ALA-PDT 
is not known but is thought to be due to the formation of a hydroxyaldehyde 
chlorin-type photoproduct.165 Despite discussion of the emission spectra of 
ALA-PDT induced derivatives, current opinion has been that photoproduct 
formation does not play a major role in PDT in neoplasia.170 This has been 
largely unsubstantiated, based on relative emission peaks without knowledge 
of singlet oxygen yields and the total quantity of photoproduct formation in a 
specific PDT protocol. We have not studied those products thought to be 
derived from PPIX but to have very similar activation wavelengths to the 
parent photosensitizer. Of potentially greater clinical relevance is the 
existence of products which would not routinely be activated in clinical PDT 
due to the narrowness of the bandwidths used.
The initial phototoxicity study demonstrated a greater phototoxic 
reaction when 670nm light was added to 635nm light in ALA-mediated PDT. 
Moreover, 670nm light alone had a small, but discernible reaction. A control 
group with 670nm light to both feet should have been included, but it is 
presumed that 635nm light was required to initially generate this 670nm 
photoproduct. Either ambient light or more likely circulating photoproduct 
was responsible for the tissue effects at 670nm illuminated sites. Apart from 
confirming these findings by repeating this study with all possible control 
groups to take account of the effects of treating both feet, an alternative
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model of murine ear swelling could be performed to assess cutaneous
• • 171phototoxicity.
The second study of the importance of wavelength in ALA-PDT 
demonstrated a reduction in tumour thickness with 635nm light-mediated 
therapy which was augmented by the simultaneous illumination with 670nm. 
The regression in tumour thickness to 75% of control tumour depth, 14% 
greater than the response of 635nm-mediated PDT, suggests that activation 
of a photosensitizing chemical using 670nm light may be clinically relevant. 
However, the apparent promoting effect of 670nm light alone in yielding 
thicker tumours than controls with a ratio of 111%, when either a nil or a 
minor tumour regression effect is anticipated, suggests that these results be 
cautiously interpreted in view of the small numbers in each group .
A possible additional complication to the interpretation of these studies 
is the small absorption that PPIX has at longer wavelengths than 635nm as 
shown in Figure 3.11. Unfortunately, as the phototoxicity study described 
above did not contain a 'control' group with 670nm illumination to both feet, 
the observed effect of unilateral illumination with 670nm (with 635nm applied 
to the opposite leg), could have arisen due to direct PPIX photodynamic 
activation rather than via a photoproduct. However, when the same protocol 
was used in the murine tumour study, no tumour regression was noted when 
670nm light was used to both flanks of 6 mice despite the absence of 
illumination by 635nm light which we presume normally will quench available 
PPIX. This suggests that 670nm activation of PPIX probably has a negligible 
effect and that the apparent increase in effect of the combined wavelengths is 
due to the photoproduct.
Traditional laser-based PDT excludes wavelengths outwith the narrow 
margin of 635±2nm. The prototype non-laser source assessed in this thesis 
provides light with its current filter of 615-645nm to ratify its efficacy 
alongside laser sources. The studies outlined above suggest the
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replacement of this by a filter which includes 670nm is justified, at least to 
enable study of the relative importance of incorporating wavelengths that will 
activate this photoproduct.
The relatively long irradiation times (average 30 minutes) using the 
prototype lamp may particularly favour the formation of this photoproduct 
which has been reported to increase substantially relative to protoporphyrin 
IX emission at longer irradiation times.163,164
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Chapter 6 - PDT in cutaneous T-cell lymphoma
6.1 - Introduction
Topical 5-ALA can promote the preferential accumulation of
protoporphyrin IX in malignant T-lymphocytes in comparison with normal 
118lymphocytes. Topical ALA-PDT has been used to treat 4 patients with
19either one or two plaques of cutaneous T-cell lymphoma. Svanberg et al
119achieved a clinical and histological clearance in 2/4 lesions and Wolf et al 
also achieved a complete response in all 3 plaques treated. The efficacy of 
topical ALA-PDT in patients with more extensive CTCL has not been 
reported, nor the possible differences in response between patch, plaque and 
tumour stage disease.
An open study and case report in this chapter outline the outcome of 
topical ALA-PDT, using laser and non-laser light sources, in patients with 
widespread and multi-stage CTCL.
6.2 - Patch, plaque and tumour stage disease - efficacy of PDT
Aim: This open study, conducted at the Department of Dermatology, 
Roswell Park Cancer Institute, Buffalo, was undertaken to determine 1. the 
efficacy of PDT in a group of patients with widespread and multi-stage CTCL, 
and 2. to determine the optimum treatment parameters.
Methods: Seven patients, each with histologically proven CTCL, were
referred for consideration for PDT. Six patients had received previous 
therapies with either recurrent disease or the development of lesions on new 
sites precipitating their referral. The previous therapies were; PUVA (n= 2),
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topical nitrogen mustard (n= 2), potent topical steroid (n= 3), a-interferon (n=
2), and radiotherapy (n=1, not to PDT sites).
Photosensitizer was administered via the topical application of 5- 
amino-laevulinic acid (5-30% in M55A cream vehicle - DUSA, NY) 24 hours 
prior to illumination. An argon pumped dye laser (A,=630nm) and a 1000W 
experimental quartz halogen lamp (X= 590-700nm) were the light sources 
used. Laser light was delivered to tissues through flexible quartz fibres fitted 
with microlenses. For large lesions (>3cm in diameter), overlapping fields of 
illumination were employed when using the laser, whilst the non-laser source 
could illuminate fields up to 17.5 cm in diameter. Individual lesions received 
10 - 300J/cm2 at an irradiance of 10-150mW/cm.2 Surface fluorescence was 
recorded immediately before illumination. Fluorescence was measured at 
690nm by dual wavelength excitation at 612nm and 633nm using 2 helium- 
neon lasers.
Clinical lesions were graded as either patch, plaque or tumour stage 
with patches defined as a minimally indurated erythematous macular lesions, 
plaques as indurated, elevated erythematous lesions, and tumours as 
nodules ± ulceration. All patients thus belonged to T1f T2 or T3 by TNM 
classification with erythroderma, or lymph node, peripheral blood or visceral 
involvement, reasons for initial exclusion from this study.
Treatments were performed at 3-4 week intervals with clinical 
response graded at the patient's return visits. Clinical response was 
expressed as complete clinical resolution (CCR), sub-complete (>90%) 
clinical response (sCCR), or partial response (PCR). Clearance was defined 
as clinical clearance following 1 or 2 treatments, with histological confirmation 
where doubt over clinical clearance existed. Epidermal toxic response (ETR) 
was also determined at 6-10 days following therapy by the scale: 0 = no 
change, 1 = minimal perceptible increase in erythema over baseline, 2 = 
significant erythema, 3 = scattered areas of desquamation within the lesion, 4
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= significant amount of desquamation in the lesion (>90%), 5 = epidermal 
necrosis with eschar formation. The requirement for local anaesthesia was 
also recorded. Patients were reviewed monthly for treatment of residual 
lesions and to observe for recurrent disease.
The data presented represents an interim analysis of the Roswell Park 
team's research on the response of CTCL. to ALA-PDT. The response of 
lesions following 1 or 2 treatments was initially assessed with the subsequent 
analysis of further treatments to non-responding lesions. Whilst all reported 
patients were examined by CAM, data was pooled from casenote records 
which detailed every treatment administered. Photographic records of all 
lesions treated (and clinical response) were viewed as part of the data 
collection which resulted in computerized records of all treatment episodes.
Results: The seven patients, aged 56-73 years old at enrolment,
received ALA-PDT to between 2 and 15 lesions (mean, 7). Two patients 
received concurrent therapy with topical nitrogen mustard application to sites 
not treated by PDT. Both patients were observed to obtain a better response 
with PDT than nitrogen mustard in comparable lesions in similar anatomical 
locations.
A total of 53 lesions received two treatments; 14 patch stage, 18 
plaque and 21 tumour stage lesions. Fluorescence was observed prior to 
illumination in all lesions treated. The overall clinical outcome of PDT is 
shown in Table 6.1.
Figure 6.1 demonstrates the response of patch, plaque, and tumour 
stage lesions to ALA-PDT. In each case depicted, histological confirmation 
of clearance was acquired with the histopathological clearance of a tumour 
lesion shown in Figure 6.2.
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Table 6.1 Response of CTCL lesions to topical ALA-PDT depending on 
lesion type and light source used.
Lesion type PCR
no.
sCCR
no.
CCR
no.
CCR
%
CCR - 
laser 
(%)
CCR - arc lamp 
(%)
Patch (n=14) 6 1 7 50 5/8 (62) 2/6 (33)
Plaque (n=18) 8 0 10 56 6/8 (75) 4/10 (40)
Tumour (n=21) 11 3 7 33 7/19(37) 0/2-
All (n=53) 25 4 24 45 18/35 (51) 6/18(33)
CCR = complete clinical resolution
sCCR = sub-complete (>90%) clinical response
PCR = partial (<90%) clinical response
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Figure 6.1- a+b A patch of histologically proven CTCL on the left wrist 
(a) before and (b) 6 months following topical ALA-PDT
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Figure 6.1- c+d Plaque stage disease on the wrist of another patient
(c) before and (d) 1 year following ALA-PDT.
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Figure 6.1- e+f Tumour stage disease (maximum depth 1,5cm) on the
abdomen (e) before and (f) 6 months following ALA-PDT.
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Figure 6.2- a+b Low power views of histopathological sections derived from 
biopsy of a tumour stage lesion (a) before and (b) 3 months 
following topical ALA-PDT using the laser source. A densely 
packed uniform upper dermal basophilic cell infiltrate in 
section (a) is absent from section (b). Both sections - H+E.
130
Figure 6.2- c Clearance of tumour infiltrate is evident on high power view of 
the post treatment biopsy section (H+E).
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The clearance rate of all three lesion types was superior following 
laser to that for the experimental broadband halogen lamp. Of the 18 lesions 
clearing following laser alone, 13 cleared following a single treatment. All 6 
lesions clearing following illumination with the halogen lamp required only 
one treatment.
Further ALA-PDT sessions were performed for those 29 lesions which 
failed to clear after 2 treatments. Six more lesions (1 patch, 1 plaque and 4 
tumours) cleared after 3,3,3,4,5 and 6 treatments, whilst the remaining 
lesions did not clear after a median of 4 treatments (range 3-12). Only 4/23 
lesions which failed to clear received 6 or more treatments.
The 8 patch stage lesions cleared after 1 (n=3), 2 (n=4), or 6 (n=1) 
treatments. The 11 plaques cleared following 1 (n=10) or 3 (n=1) treatments. 
The 11 tumour stage lesions cleared after 1 (n=6), 2 (n=1), 3 (n=2), 4 (n=1) 
or 5 (n=1) treatments.
The median size of all lesions clearing was 28cm2 (range 2.25cm2- 
144cm2) in comparison with 40mm2 (range 9cm2-168cm2) for those lesions 
which did not clear. Pre- and post- treatment biopsies, where available, 
indicated that tumour lesions up to 1.5cm in thickness had cleared.
The concentration of 5-ALA used for the 30 lesions which cleared was 
5% in 1, 10% in 5, and 20% in 24 lesions. For the 23 lesions not clearing, 
the majority of lesions also received 20% (n=14) whilst 7 received 10% and 2 
lesions, 30% 5-ALA. The irradiance used ranged from 30-150mW/cm2, 
median 100mW/cm2 and the average dose to achieve clearance was 
125J/cm2 (range 50-200J/cm2).
The clinical response of lesions following individual PDT sessions 
(Figure 6.3) was included in this study to establish the most favourable 
treatment parameters. Laser light at 10mW/cm2 was less effective, for both 
patch/plaque and tumour stage lesions, than 30-60mW/cm2 and 75- 
150mW/cm2, whilst the latter intensity treatments were broadly similar in
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Figure 6.3 Efficacy of ALA-PDT for patch/plaque and tumour stage CTCL 
using different, light dose/intensity regimens and different light 
sources, (a) Patch and plaque disease treated by laser (36 
treatments), (b) Tumour stage disease treated by laser (78 
treatments) and (c) All stages treated by halogen light (38 
treatments). Light intensities (10-150mW/cm2) are shown by 
symbol. Plot of mean ± SEM.
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efficacy. A plateau in the laser dose/response, with at least a 50% reduction 
in lesion size, was apparent from 30J/cm2 in patch/plaque disease, whilst 
50J/cm2 was required to achieve a similar outcome in tumour stage disease. 
Limited data from the halogen source (Figure 6.3c) suggests that optimal 
disease reduction is achieved at 100-150J/cm2 for treatments at irradiances 
of 40-150mW/cm2 although more data using lower light doses is required.
Local anaesthesia was required during the treatment of 23/53 lesions. 
The size of lesions requiring anaesthesia (36cm2, range 0.25-252cm2) 
differed little from that of lesions which did not (28cm2, range 4-252cm2), 
whilst the intensity of illumination was overall slightly higher for those lesions 
requiring anaesthesia (anaesthesia: 100mW/cm2, range 10-150mW/cm2; no 
anaesthesia: 80mW/cm2, range 30-150mW/cm2). The majority of treatments 
utilizing >10% 5-ALA with laser at any dose and power density required 
anaesthesia. For the halogen source, all treatments >50mW/cm2 required 
anaesthesia regardless of 5-ALA concentration or dose. One patient, with 15 
lesions, tolerated treatment without anaesthesia regardless of the dosimetry 
which may suggest that, within the regimens described, the requirement for 
local anaesthesia was patient rather than dosimetry dependent.
The phototoxic effect on epidermis (ETR) of ALA-PDT was assessed 
clinically on the scale described above, for individual treatments. Figure 6.4 
compares the ETR by lesion type, light source and dose. A similar pattern of 
response was evident for patch/plaque (Figure 6.4a) and tumour (Figure 
6.4b) stage lesions treated by laser, with ETR greater at the same dose for 
lower irradiance light (10mW/cm2 and 30-60mW/cm2). Scattered areas of 
desquamation (ETR = 3) results from illumination with 40-60J/cm2 at 75- 
150mW/cm2, the lowest plateau dose for maximum efficacy. Higher doses, 
up to 200J/cm2, have relatively little effect on ETR, which is much more 
dependent on irradiance intensity than dose. The non-laser source showed a 
gradual onset of epidermal damage and parallel response between
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Figure 6.4 Epidermal phototoxic response for different light dose and
intensity measurements observed during the treatment of (a) 
Patch and plaque disease by laser (36 treatments), (b) Tumour 
stage disease by laser (78 treatments), and (c) All stages 
treated by the halogen light (38 treatments). Light intensities 
(10-150mW/cm2) are shown by symbol. Plot of mean ± SEM.
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intermediate and high intensity treatments of all disease stages (Figure 6.4c). 
Widespread desquamation of the epidermis of lesions was noted at doses 
within the therapeutic window for PDT using this source and a 24 hour 
photosensitizer application time.
Five of the total of 30 lesions which had initially cleared, recurred 
during a 12 month follow-up period (range 6-20 months); four lesions at 3 
months, one at 10 months. This reduces the clearance rate to 47%.
Summary: Fourteen patch, 18 plaque and 21 tumour stage lesions
received topical ALA-PDT with complete clearance in 50%, 56% and 33 % of 
lesions respectively after two treatments. The clearance rate of all three 
lesion types was superior following laser to that for an experimental 
broadband halogen lamp. A further 6 cleared after 3,3,3,4,5 and 6 
treatments, whilst the remaining lesions did not clear after a median of 4 
treatments (range 3-12). The median size of all lesions clearing was 28cm2 
in comparison with 40mm2 for those lesions which did not clear. 24/30 
lesions which cleared had received 20% 5-ALA 24 hours prior to illumination. 
Light dose assessment with the laser indicated an optimal response with at 
least 40-60J/cm2at 30-150mW/cm.2 The non-laser halogen source showed a 
plateau in response from 125J/cm2 for treatments at 40-150mW/cm.2 The 
toxic effect on epidermis of ALA-PDT was greater for lower irradiance light. 
Five lesions recurred during a 12 month follow-up period.
6.3 - Case report - ALA-PDT, with the prototype lamp, in CTCL
A 47 year-old female with a 10 year history of mycosis fungoides was 
assessed for possible responsiveness to ALA-PDT during a flaring of her
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disease. Previous treatment with PUVA photochemotherapy (2 courses), 
alpha-interferon, oral retinoids, topical nitrogen mustard, potent topical 
steroids and radiotherapy had achieved only limited/short-term response to 
her plaque/tumour stage disease. Examination revealed in excess of 20 
plaques on her trunk and limbs. PDT using 125J/cm2 filtered red light , 4 
hours after 5-ALA application, revealed strong surface flourescence prior to 
treatment in a 6.5x3.2cm plaque. However, no response was clinically 
evident 4 weeks later when both the treated and a control plaque (measured, 
but not treated) showed increase in size over the month. The patient 
declined further treatment and was referred for assessment for radiotherapy.
6.4 - Conclusions
Topical ALA-PDT can achieve clearance of patch, plaque and tumour 
stage CTCL, with response rates of 50%, 56% and 33% respectively after 2 
treatments, and further PDT treatments clearing more lesions.
Careful interpretation of the data presented in this study is required 
due to the multiple parameters examined. As the study was on-going at the 
time of this interim analysis, clearance or not after two treatments was chosen 
as the first index of response to facilitate comparison of CTCL with earlier 
studies in this thesis. CTCL is less responsive that Bowen's disease or 
superficial BCC to ALA-PDT over 2 treatments compatible with their primary 
intradermal pathology and the anticipated greater depth of the majority of 
lymphoma lesions.
19 119Previous published case reports 1 indicate that 2-5 treatments might 
be expected to clear plaque stage disease with a presumption that thicker 
tumours would require more treatments. Thus the clearance of 30 lesions 
after 1-6 treatments may better reflect the response that can be achieved
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from ALA-PDT. Only 4/23 lesions which failed to clear received 6 or more 
treatments suggesting that a superior response might still be achieved by 
further treatments to the non-responders.
Both laser and non-laser sources can achieve lesion clearance. Laser 
appears superior in effect to the halogen lamp although fewer lesions were 
treated using the lamp which was introduced midway through the study and 
may have included a greater percentage of ineffective dose/irradiance 
combinations. A superior response of patch and plaque stages over tumour 
lesions is evident with laser treated lesions and is also suggested in the non­
laser group which failed to clear either of the 2 tumours treated.
Optimal response parameters indicate the use of 20% 5-ALA, followed 
by at least 40-60J/cm2 of laser light or 125J/cm2 non-laser light at 30- 
150mW/cm.2 Whilst most patch or plaque stage lesions will clear after 1 or 2 
treatments, there is a greater likelihood that more treatments will be required 
for treating thicker tumour lesions.
Whilst previous case reports19,119 indicated the efficacy of 4-6 hour 
topical application of 5-ALA, illumination at 4-5 hour is observed to produce 
relatively greater epidermal toxicity than when the photosensitizer is left for 
24 hours (unpublished data, Roswell Park C. I.).
Greater epidermal toxicity was evident using laser light at low 
intensities. As the PDT process consumes oxygen at a rate proportional to 
intensity, higher intensity treatments will deplete oxygen in the papillary 
dermis and hence the epidermis is left relatively hypoxic, sparing the 
keratinocytes from damage. In contrast, light intensity will be lower in the 
dermis preserving high oxygenation levels in the pericapillary zones of the 
papillary and deeper dermis, facilitating phototoxic reactions within CTCL 
lesions. A therapeutic window permitting an effective dose (40-60J/cm2) at 
an irradiance of 75-150mW/cm2 avoided maximum epidermal damage.
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A rise in tissue temperature with the halogen source, promoting 
vasodilatation and re-oxygenation of the epidermis, may account for the 
progressive, dose dependent increase in epidermal damage observed.
These observations suggest that for the treatment of epidermal lesions 
(Bowen's disease, BCC) where epidermal damage is desirable, lower 
intensity illumination may be preferable.
Experience in PDT of CTCL using the prototype non-laser source 
described in this thesis was limited to a single treatment in a patient with 
extensive and progressive disease, with only a 4 hour application time for 
20% 5-ALA. Lack of epidermal toxicity at 4 hours in this patient, combined 
with the response rates described above from the unique experience of the 
Buffalo unit, suggests that further evaluation of the lamp's use of ALA-PDT in 
CTCL in an appropriately designed pilot study is indicated. The prototype 
lamp, with its spectral output closer to that of the laser than the broadband 
halogen source, would be expected to achieve a similar response profile.
The request for anaesthesia by patients gives an indication of pain 
severity, although the tolerance of one patient to all dose and intensity 
combinations received, demonstrates patient variation in pain perception. 
Whilst epidermal toxicity is less with an application time for 5-ALA of 24 
hours, pain is more likely to be experienced (unpublished data, Roswell Park 
C.I.). This may result from the accumulation of PPIX in cutaneous nerve 
endings with prolonged 5-ALA application. Low intensity laser treatments 
caused less pain, but they were also less effective at clearing lesions. 
Treatments with the halogen source at a power density <50mW/cm2 were 
also minimally painful, but appear to be more effective, possibly due to the 
broadband illumination of the source although this requires further study.
The mechanism of action of ALA-PDT in CTCL is not fully understood. 
Direct tumour cell damage from the accumulation of PPIX117,118 may be 
complemented by host reactions associated with a PDT-induced inflammatory
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response (Chapter 1). This may explain the response of thick lesions to 
topical ALA-PDT, as adequate light/photosensitizer penetration is unlikely for 
tumours up to 1.5cm in depth.
The potential to clear CTCL by topical ALA-PDT, in patients with 
multiple lesions and multi-stage disease, requires further confirmation. An 
additional non-invasive therapy for CTCL, however, has been demonstrated 
by one unit, which has treated many lesions in several patients with follow-up 
times of up to 20 months. Patients receiving ALA-PDT to date have largely 
been non-responders to existing modalities or patients with rapidly 
progressing disease. Appropriate patient selection may therefore identify a 
group more responsive to ALA-PDT, although PDT will require to be 
compared with existing therapies in this group.
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Chapter 7 - Discussion
7.1 - Overview
The primary aim of this thesis was to critically evaluate the usefulness 
of ALA-PDT in skin cancer. Several open trials, with a variety of protocols, 
and limited histological/temporal evidence of clearance, were available at its 
commencement. Most of the published studies focused on systemically 
administered Photofrin and its precursors, and on the use of laser light to 
promote PDT. The place of topical administration of 5-ALA and the 
assessment of the potential for non-laser light in PDT of cutaneous 
malignancy, however, required further study.
Chapters 3 and 4 report the clinical trials and morphological effects of 
topical ALA-PDT using a prototype xenon source with an in vitro and in vivo 
efficacy comparable to laser. An initial open study in actinic keratoses and 
Bowens disease confirm the clinical efficacy of ALA-PDT using the prototype 
lamp. Three randomized, comparison trials focus on dose/wavelength 
response of Bowen's disease to ALA-PDT, and to its efficacy against 
cryotherapy for Bowen's disease. A comparison study of the importance of 
tumour thickness and duration of photosensitizer application on the response 
of BCC to ALA-PDT is also reported.
To further evaluate the potential of 5-ALA-PDT, in chapter 5, two 
murine studies report the presence of a photoproduct of PPIX that is 
activated by 670nm light and may alter therapeutic effectiveness.
In chapter 6, the potential for ALA-PDT in cutaneous lymphoma, 
previously restricted to 2 case reports, is described in detail for patch, plaque 
and tumour stage disease in patients with multiple lesions.
Adverse reactions, recurrence rates and the identification of those 
lesions that may particularly benefit from this new modality are identified from 
each of the clinical studies.
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The implications of the results reported in the preceeding chapters, 
along with the results of further relevant studies published during the follow- 
up period of the trials, are summarized below:
7.2 - Prototype non-laser source for PDT
The prototype lamp, incorporating a 300W xenon source, has been 
shown to be effective in PDT for human skin cancer. The lamp can deliver 
100J/cm2 of 630±15nm light at an intensity of 86mW/cm2 to a 3cm diameter 
field in approximately 20 minutes. This provides sufficient power, despite the 
long wavelength and narrow bandwidth employed, for it to be practical in 
clinical use. The simplicity of operation and ease by which light can be 
directed to any body site facilitate its use. Moreover, as a portable, reliable 
and relatively cheap source (approximately 1/10 the cost of a laser system), it 
has the potential for use outwith a hospital's laser suite.
The comparison of red with green light demonstrated that, with 
appropriate filters, output can be adjusted to permit evaluation of different 
wavelength/bandwidths and photosensitizers. No hyperthermic temperatures 
were recorded during this study supporting pre-clinical tests of the absence 
of infra-red emission.
7.3 - 5-ALA/PPIX as photosensitizer
5-ALA was used as a precursor for protoporphyrin IX throughout this 
thesis. Application of 20% 5-ALA in an oil in water emulsion 4 hours prior to 
illumination was effective in clearing actinic keratoses, Bowen's disease, and 
superficial BCC up to 1mm thick. A six hour application interval improves 
clearance of BCC 1-2mm thick. Twenty-four hour application of 20% 5-ALA 
in another oil in water emulsion promoted clearance of patch, plaque and 
tumour stage CTCL. Although numbers were limited, 5% and 10% 
preparations of 5-ALA also achieved clearance of CTCL lesions.
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Comparison with previous studies of actinic keratoses/Bowen's 
disease (Table 2.1) indicates that no benefit may have been attained from 
prolonging application to 6, 8, or 20 hours with initial 100% clearance rates 
and comparable recurrence rates achieved after only 4 hour application. In 
contrast, an increase from 4-6 hours improved BCC response for 
intermediate thickness lesions, an observation which could not be obtained 
from previous studies (Table 2.4) which failed to report individual tumour 
depth and the application times for each lesion. The study by Figan et a/02 
would suggest that even 20 hours remains insufficient time to clear more than 
60% of nodular lesions, although this study had reported a surprisingly low 
clearance rate for actinic keratoses and Bowen's disease also at 20 hours 
suggesting their broadband light delivery may have been sub-optimal.
Prolonging application to 24 hours in CTCL treatment, whilst intended 
to reduce epidermal toxicity, probably improves clearance rates. No 
response was evident after a single treatment, with a 4 hour 5-ALA 
application time, of PDT to a plaque of CTCL in one case report in this thesis 
although 5/7 lesions did clear with this protocol in two other case reports in 4
19 119patients with limited plaque disease. ’
The detection of surface fluorescence prior to illumination in all 
patients treated confirmed the presence of PPIX formation with the intensity 
at 4 or 6 hours strongly outlining areas of clinically diseased skin. Only 
where lesions abutted onto mucous membranes could a strong fluorescence 
in adjacent normal tissue be noted. The absence of the normal skin barrier 
from the non-keratinizing epithelium of the mucous membranes will promote 
uptake, hence care in limiting the field of illumination is required to minimise 
epidermal toxicity in PDT to these sites.
Fluorescence recording for CTCL lesions after 24 hour 5-ALA 
application whilst detecting fluorescence prior to illumination, often did not 
demonstrate a marked differential in intensity at the lesion/normal skin
143
interface consistent with the expected loss of differential uptake of 
photosensitizer by the normal/abnormal epidermis by this time.
No generalized phototoxic reactions, locally or generalized were noted 
throughout the studies performed in this thesis, although all lesions were 
protected from sunlight for 24 hours and patients were advised to avoid 
sitting out in the sun for the 24 hours following treatment. Blood and urine 
samples pre- and post-PDT were monitored in a recent study of actinic 
keratoses and Bowen's disease with no evidence that topical ALA-PDT alters 
systemic accumulation of porphyrins or porphyrin precursors.172
PPIX may not be the only active photosensitizer produced by 
exogenous administration of 5-ALA. In a study of explant pieces of normal 
skin, keratoacanthoma and BCC, porphyrin levels were measured after 
incubation with 5-ALA. Whilst PPIX preferentially accumulated in the BCC 
tissues, coproporphyrin accumulated in the keratoacanthomas suggesting 
that tumours may differ in their 5-ALA metabolism and that other porphyrin
173products may act as clinically relevant photosensitizers.
7.4 - Light/PDT dose
A wide variation in total light dose, from 30-540J/cm2 (Table 2.1), 
exists for Bowen's disease. The variety of different light sources, and hence 
wavelengths used, in part explains this wide variation. However, even where 
laser sources were used, dose levels varied between 60-250J/cm.2 Within 
individual studies, small numbers provided insufficient data for statistical 
interpretation of dose/response. Against this background, a large 
randomized study of 120 lesions was performed to establish a value for the 
minimum light dose which could achieve the optimal response. A significant 
reduction in the probability of clearance at 1 year was evident for lesions 
which received <100J/cm.2
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Dose ranges for BCC are similar, with 30-540J/cm2 used for non-laser 
studies and 40-250J/cm2 for laser trials. Dose/response was more difficult to 
evaluate with BCC due to smaller numbers of available lesions. A preliminary 
dose response comparison of two doses and 30 lesions showed no difference 
in outcome between 100J/cm2 or 150J/cm.2
Although initially time consuming, establishing that 100J/cm2 appears 
optimal for both Bowen's disease and BCC will avoid future unnecessary 
treatment time.
Total light energy, although the most easily measured, is only one 
component of the total PDT dose administered to tumours. The total 
photodynamic impact of a treatment session depends on the dose and 
wavelength of light reaching the tumour tissue, the concentration and 
absorption coefficient of the photosensitizer, and for 5-ALA, upon the cells' 
own preferential ability to synthesize protoporphyrin IX (+ other potentially 
relevant photosensitizers including photoproducts). Finally, this 
photodynamic process will be compromised if oxygen supply becomes limited 
and by self-shielding by superficially placed photosensitizer and 
photobleaching of the photosensitizer.
The clinical studies reported in this thesis have sought wherever 
possible to standardize these parameters to achieve a few large comparison 
trials. Whilst this has been achieved for Bowen's disease and BCC, the 
limited published experience of ALA-PDT for CTCL has restricted current 
study to initial efficacy assessment in patients who have failed on at least one 
previous therapy. ALA-PDT in CTCL will therefore require future randomized 
comparison of those parameters which appear most critical to lesion 
clearance.
A formula has also been derived to permit comparison of the output of 
coherent and non-coherent light sources and of different filter outputs in the 
same lamp. The total effective fluence (Chapters 1.4 and 3.11), however still
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requires estimation of the optical transmission of tissue at a particular 
wavelength of light through tissue and its absorption by photosensitizer. The 
output of the prototype lamp evaluated in this thesis, however, was limited to 
630±15nm (except for the provision of green light in the red/green 
comparison study) to permit valid comparison of efficacy with laser studies. 
An efficacy of this lamp comparable with laser is apparent from these studies 
(Tables 2.1, 2.4) and implies that its future detailed evaluation in CTCL 
should yield similar results to the argon laser. The output effective for ALA- 
PDT from the non-laser source used for a few CTCL lesions, along with that 
from the tungsten sources reported previously, remain difficult to compare 
due to their broadband outputs and the possibility that early sources may also 
have emitted significant amounts of infra-red with its own therapeutic action. 
The red/geen comparison and photoproduct studies provide evidence for the 
incorporation of certain wavelengths to optimise ALA-PDT that proVide a 
logical approach to the development of the most therapeutically effective 
wavelengths required for ALA-PDT.
7.5 - Lesion size/depth and fluence rate
The studies of Bowen's disease established a further, previously 
unrecognized, variable, lesion size, as having a significant effect on the 
probability of clearance. Despite restricting lesion size to 25mm in maximum 
diameter, two randomized trials (PDT vs. cryotherapy, Dose/response) 
revealed lesion size as significant. The cryotherapy treatment group also 
demonstrated this observation whilst size for red-light, but not green-light 
treated lesions in the third comparison study was almost significant. The 
response of large patches of Bowen's disease and of CTCL lesions also 
demonstrate this pattern (although with insufficient numbers for statistical 
analysis once other variables are included). BCC studies did not show this 
phenomenon, with tumour thickness the major variable influencing outcome.
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This implies that, providing other factors are near optimal, size will influence 
outcome, and requires consideration in future study designs.
Fluence rate and lesion size were linked variables in the Bowen's/BCC 
studies and hence assessment of fluence rate on response was confounded. 
An apparent improvement in response of Bowen's disease at or below 
48mW/cm,2 however, although not supported in the BCC study, is similar to 
the observed improvement in the response of CTCL lesions treated by the 
halogen (but not laser) source at <50 mW/cm.2 This further supports the 
observation, from study of systemic ALA-PDT145, that oxygen depletion starts 
to affect outcome at fluence rates above 50mW/cm.2 This variable may also 
only become apparent where treatment conditions are sub-optimal and 
fluence rate, rather than another variable, e.g. thickness or wavelength, 
become critical to maximizing photo-dynamic reactions within the tumour.
7.6 - Tumour thickness vs. response
Tumour thickness probably has a strong influence on the outcome of 
ALA-PDT in CTCL as well as BCC. Although few lesion depths are known, 
clearance rates for patch and plaque stage lesions were similar, whilst the 
rate dropped for tumour stage disease. However, documented clearance of 
tumours up to 1.5cm, with laser-PDT and 24 hour 5-ALA application, 
suggests a difference in achievable depth of treatment with CTCL compared 
with BCC. Whilst prolonging ALA may increase clearance rates, it is possible 
that the difference in cell type and/or tumour structure greatly affects 
outcome.
Malignant lymphocytes preferentially accumulate PPIX over normal, 
unstimulated lymphocytes.118 Most superficial, but few nodular BCC, 
demonstrate full thickness PPIX fluorescence by 6 hours. Svanberg et a/19 
demonstrated PPIX distribution following 4-6 hour 5-ALA application, by laser 
induced fluorescence, to show a demarcation between tumour and normal
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skin of 15:1 for BCC (and Bowen's disease), and 5:1 for CTCL. However, the 
tumour:normal tissue ratio at 24 hours is not known for either tumour. Doubts 
also remain over the potential of BCC cells to adequately absorb 5-ALA in the 
current oil in water emulsions used. Whilst Szeimes et a/134 proposed that 
increasing from 4-12 hours would promote uptake of 5-ALA to include deep 
dermal tumour cells, Roberts et a/9 indicated, although after only 4 hour 5- 
ALA application, that it was not depth but uptake beyond those tumour cells 
immediately adjacent to 'normal' dermis was limited. Thus adequate 
penetration into the tumour mass, when a topical route of photosensitizer 
delivery is used, may be more important to response and may not be 
accurately reflected by an intense surface fluorescence which may only 
represent the presence of PPIX in an outer rim of tumour cells.
Fluorescence measurement unfortunately is limited both by the depth 
of penetration of the wavelength used, permitting often only very superficial 
detection (e.g. UV light), and the inability if using a single wavelength of 
distinguishing its precise location in a tissue (e.g superficial vs. deep dermis). 
As knowledge of tumour depth is usually not known, in vivo fluorescence 
detection is thus at best only an estimation of PPIX distribution. Quantitative 
fluorescence microscopy of tissue samples is therefore required to achieve a 
better understanding of photosensitizer uptake by cells, but necessitates 
excision of tissue.
Current interpretation of the literature and above results thus suggest 
that thick tumours (nodular BCC and CTCL) benefit from longer 
photosensitizer application times thus making tumour depth a critical factor in 
response, but that additional factors, e.g. lipophilicity of 5-ALA vehicle, 
tumour cell mitotic rate, relative cellular iron deficiency, cell-to-cell adhesion, 
are likely to influence the preferential accumulation of PPIX between different 
tumour types and sub-types.
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7.7 - Mechanisms of action of ALA-PDT
Studies in this thesis have demonstrated: 1. The presence of both 
necrosis and apoptosis following ALA-PDT 2. That direct cell damage is the 
predominant route of tumour destruction 3. That the response of CTCL 
lesions may in part be immune-mediated 4. Microscopic scar formation is 
common following ALA-PDT to BCC.
A full thickness or focal coagulative necrosis was observed following 
ALA-PDT to Bowen's disease and BCC. Apoptosis were observed in high 
number in several sections 1 hour following therapy suggesting that both 
modalities of cell death are promoted by ALA-PDT.
The subcellular localization of PDT-induced photodamage may 
influence the rapid development of apoptosis, with cell membrane 
photodamage preventing apoptosis. When a photosensitizer (tin 
etiopurpurin) which targets mitochondria, was substituted by a drug analogue 
(tin octaethylpurpurin amidine) which also targets cell membranes, apoptoses 
were not observed until 24 hours after PDT, in comparison with <1hour with 
the original agent.174 PPIX also accumulates preferentially in the 
mitochondria, but also plasma and nuclear membranes. Apoptosis may thus 
occur if sufficient mitochondrial damage has occurred early on during PDT, 
but less specific mechanisms, including inflammation and hypoxia, may 
promote coagulative necrosis.
The importance of apoptosis to tumour cell death in PDT has recently 
been highlighted by a study of cells expressing the mitochondrial 
protooncogene Bcl-2, which inhibited not only apoptosis but overall PDT- 
induced cell kill in v/fro.175 Bcl-2 is thought to promote cell survival by 
inhibition of apoptosis.176 Thus cells expressing Bcl-2, which appear 
restricted to long-lived or proliferating cell populations,177 may be relatively 
resistant to PDT.
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Direct tumour damage appeared to be the primary route of cell kill from 
samples examined as endothelial damage to adjacent vessels was not noted 
to precede tissue damage. Assessment of histology following PDT remains a 
crude method of assessment, but is consistent with the observations of Wang 
et at26 that superficial blood flow increased post ALA-PDT to Bowen's disease 
and BCC, only returning towards pre-treatment levels on healing. However, a 
recent study demonstrated that endothelial cells in vitro accumulate 1.5-4 
times more PPIX when proliferating than when quiescent.178 Current 
evidence would suggest that this accumulation does not result in 
therapeutically significant vascular damage.
The hypothesis that clearance of deep tumour tissue is promoted in 
CTCL by a PDT-induced immune response suggests effects of PDT on tissue 
that extend beyond a non-specific inflammation. Evidence of a complex 
response is emerging of potentiation of antitumor immunity, but with inhibition 
of skin contact hypersensitivity and increased skin graft survival. A BALB/c 
mouse model has been used to demonstrate that PDT induces, in both 
normal and tumour tissue, interleukin (IL)-6 and IL-10 but not tumour necrosis 
factor-alpha.179 This suggests that the general inflammatory response 
induced by PDT may be mediated, at least in part, by IL-6. IL-6 may also 
modulate the local anti-tumour response. By contrast, the enhanced IL-10 
expression may promote the suppression of cell-mediated responses seen 
following PDT.
Clinical studies of ALA-PDT in the treatment of non-melanoma skin 
cancer and its precursor lesions report a good cosmetic outcome.19,91"5,105,113 
Whilst the studies reported in this thesis show similar cosmetically acceptable 
results, there was microscopic evidence of scar formation in 36% of treated 
BCCs after 1-4 months, although virtually absent following PDT to Bowen's 
disease. Nevertheless, scarring would appear less severe than might be 
expected from other therapies with scar formation clinically evident in 20% of
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sites of Bowen's disease treated by cryotherapy, another modality considered 
to have a relatively low scarring potential. Moreover, the absence of fibrosis 
from BCC sites biopsied at 6-12 months post-PDT may reflect spontaneous 
improvement when tissue repair is complete.
Recent evidence supports the a reduced potential for scarring by PDT. 
Heat shock protein 47, associated with collagen type I metabolism, increased 
following hyperthermia, but not PDT, in a study of normal murine 
fibroblasts.180 Preservation of the structural integrity of collagen has also 
been demonstrated in comparison with hyperthermia in rodent colon.149 This 
may not only preserve the integrity of tissue, but promote a good cosmetic 
outcome in PDT treated tissue.
7.8 - Is ALA-PDT carcinogenic?
Following over 20 years of experimentation of PDT, and 8 years of 
ALA-PDT, only one tumour has been reported to have possibly been induced 
by this therapy.60 This case report concerns an 82 year-old man who had 
received, over 4 years, 7 sessions of ALA-PDT to treat 28 actinic keratoses 
and 3 squamous cell carcinomas. Six months following his last treatment, a 
new pigmented lesion was noted and excised, to confirm a melanoma (Clark 
level 2, Breslow: 0.4mm). The site of the melanoma had been included in the 
treatment field of 4 of the PDT sessions. Whilst there is no proof of a causal 
association in this patient with a long history of cutaneous malignancy, 
concern remains that the PDT may have promoted, if not induced, the 
tumour, possibly by repeated Inflammation following each PDT session.
No tumours are known to have developed/metastasized following ALA- 
PDT administered in trials in this thesis, although follow-up intervals remain 
short (maximum 3 years) for the detection of malignancy.
PDT with systemic photosensitizers has been shown to be 
immunosuppressive.181 However, In-vitro studies with haematoporphyrin
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derivative and phthalocyanines, whilst demonstrating nuclear damage, have
59shown no mutagenic activity above background levels. Cell death is 
presumed to occur rather than the induction of mutagenic or carcinogenic 
phenotypes.
7.9 - Resistance to ALA-PDT
Certain cell populations and even certain people may be less sensitive 
to ALA-PDT than others, but evidence of precise explanations are still 
lacking. Patients may differ genetically in their response to PDT-mediated 
oxidative stress or following additional ingestion of anti-oxidants , e.g. 
vitamins C or E, which may render individuals temporarily less susceptible to 
PDT-induced intracellular reactions. As discussed above, cells expressing 
the proto-oncogene Bcl-2, may be relatively resistant to PDT. 5-ALA induced 
PPIX is known to accumulate primarily in epithelia and glands, but not 
mesenchymal tissues.10 Differences in the capacity of certain cell types to 
stimulate the haem cycle may be an important factor, with cells relatively low 
in intracellular iron able to preferentially accumulate PPIX, such as transferrin 
receptor positive activated lymphocytes.20
7.10 - Clinical indications for ALA-PDT in skin cancer
Indications for the use of topical ALA-PDT in clinical practice can now 
include Bowen's disease, following the addition of the first randomized 
comparison trial with established therapy, to the multiple open studies 
published. Other indications are less thoroughly evaluated, but may be of 
greater clinical use, offering advantages over existing therapies.
The potential indications for topical ALA-PDT are:
1. Actinic keratoses, especially widespread disease, not readily cleared by 
cryotherapy or topical 5-fluorouracil without great discomfort/multiple 
applications.
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2. Superficial (<1mm) BCC - especially multiple/large lesions.
3. Large patch Bowen's disease.
4. Patch/plaque stage CTCL, especially limited to a few lesions, where whole 
body photochemotherapy/systemic therapy may be inappropriate and local 
topical therapies have failed or are contra-indicated.
The number of treatment sessions of PDT required for certain lesion 
types will influence the viability of PDT in clinical practice. Although 3 
cryotherapy sessions may be required for small lesions of Bowen's disease in 
comparison with 1-2 PDT treatments, in view of longer treatment time and 
patient inconvenience, it is the superior adverse effect profile and the 
advantages of use in certain anatomical sites, that will cause clinicians to use 
ALA-PDT for these lesions. However, even the requirement of 3 or more 
treatments to certain lesions may still make PDT attractive if large patches of 
Bowens disease or superficial BCC can be cleared without surgery±grafting.
The clearance of 24/30 CTCL lesions in 1-2 treatments may also be 
practical for routine clinical therapy, but comparison with existing modalities 
and either improved response rates or early selection of lesions likely to 
respond, are still required before the full potential of ALA-PDT in CTCL can 
be correctly assessed.
Reproducible high clearance rates for BCC >1mm are also required 
before ALA-PDT can be introduced in practice for this indication.
The incidence of adverse events will also influence the introduction of 
ALA-PDT into wider clinical practice. Despite histological evidence of 
extensive epidermal damage, PDT was associated with no extensive 
epidermal ulceration as witnessed following 25% of lesions which received 
cryotherapy.
The requirement for anaesthesia was limited in the studies reported to 
large or ulcerated lesions of Bowen's disease or BCC, but was requested for 
the majority of lesions (excluding all lesions in one patient) receiving PDT for
153
CTCL with a 5-ALA application time of 24 hours. Thus, PDT can be tolerated 
without anaesthesia for small lesions (<3cm diameter) where 4-6 hour 
application times for 5-ALA are employed. Even the current requirement for 
anaesthesia for large lesions is possibly not a limitation as conventional 
therapy would likely also require anaesthesia or consist of several painful 
cryotherapy applications.
Pain associated with topical ALA-PDT may limit its therapeutic 
applications for multiple lesions. Uptake of 5-ALA by nerve endings may 
contribute to the requirement for anaesthesia, particularly following prolonged 
5-ALA application. In the absence of infrared emissions, however, pain may 
in part reflect the overall intensity of photodynamic activity as suggested by 
the requirement for anaesthesia in large lesions. Future improvements in the 
efficacy of PDT may unfortunately result in shorter, more successful, but 
more painful treatments. The application of topical local anaesthesia, 
possibly combined with the photosensitizer, may diminish this problem, 
although a vasodilatory agent, rather than a vasoconstrictive compound, 
should be used to minimise tissue hypoxia impeding photodynamic activity.
The low prevalence of clinically obvious scars, with preservation of 
tissue function, makes topical ALA-PDT particularly useful for lesions on the 
eyelids, ears and nose where disfigurement can result from conventional 
treatment modalities.
ALA-PDT may also be useful as an adjunctive/palliative therapy in 
extensive/ulcerated BCC or SCC. The use of ALA-PDT alone for squamous 
cell carcinoma, in view of the potential for metastases, should remain 
restricted to closely monitored research until efficacy has been proven in 
larger trials as only 2-6 lesions have been treated in each previous study 
(Table 2.2) and the case reported above (Chapter 3.10) indicated only a 
partial response of a large ulcerated tumour.
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Pigmented tumours also have the potential to respond to PDT, but 5- 
ALA, activated at 630/635nm is not an effective photosensitizer due to light 
absorption by melanin. Zinc napthalocyanine, illuminated by 77Arm light can 
reduce the size of B16 pigmented melanomas subcutaneously transplanted 
into mice by up to 40% in a pilot study.182
7.11 - Future Improvements - Light
Future improvements in the efficacy of ALA-PDT using the prototype 
source may be achieved by:
1. Combination of red and green light illumination,
2. Incorporation of 670nm light for photoproduct activation, or
3. Light fractionation.
The ability of green light to clear 48% of Bowen's disease (72% initial 
clearance), although inferior to red, suggests that combining these
wavelengths may permit the maintenance/improvement of the 88%-100% 
clearance rates reported in this thesis for red light, whilst shortening 
treatment times. In theory, one would anticipate green light acting
superficially, whilst proportionally more red could react with PPIX in the
deeper tissues.
Green light may allow higher light doses to be more safely
administered in tissues where tissue perforation could be catastrophic (e.g. 
intra-peritoneal PDT). However, light distribution within a cavity will also be 
altered by the wavelength, with experience of intra-peritoneal PDT indicating 
that green was less favourable than red in achieving whole peritoneal 
illumination using minimal access techniques.183
The reduced penetration of green light may make its use less painful 
than red-light ALA-PDT facilitating its use in large (but superficial) areas,
184such as for the treatment of diffuse 'field-change' actinic keratoses. Fritsch 
et al describe the improvement to the temples/foreheads of 6 patients with
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widespread facial actinic damage who received ALA-PDT with 30J/cm2 of 
green (543-8nm) light to one side and the same dose of 'red' (570-750nm) 
light to the other side of their faces. Each protocol appeared equally 
effective, but with less pain attributed to green-only treated lesions. It is not 
possible to compare the photodynamic activity of these two light energies in 
view of the broadband nature of the red light used. Nevertheless, this study 
supports a role for shorter wavelength light in superficial disease.
The relative absorptions of 540nm and 630nm light by PPIX would 
suggest that the doses used in this thesis, of 62.5 and 125J/cm2 respectively, 
are biologically equivalent, supported by the observed earlier loss of surface 
fluorescence from a sample of green and red treated lesions by, on average 
of 30 and 37J/cm2 respectively. Whilst green light alone may be effective for 
actinic keratoses, the higher recurrence rate of Bowen's disease and the 
critical importance of tumour depth in BCC clearance would suggest that it 
has limited application alone in ALA-PDT for use where either adnexal 
structures and/or dermis/subcutis are affected by dysplasia/tumour.
The clinical relevance of PPIX photoproducts remains disputed. Long 
irradiation times, as encurred using non-laser sources at low fluence rates, 
may favour the formation of 670nm photoproduct.163,164 The two murine 
studies presented, add to a limited literature (all based on laser studies), to 
suggest that further studies incorporating activation of this photoproduct are 
indicated.
At present the potential of light fractionation, with brief 'dark' intervals 
during illumination, in topical ALA-PDT for cutaneous malignancy remains 
unknown. Intercapillary spacing is theoretically the most important factor136 
although, in practice, longer intervals are probably required because of sub- 
optimal PDT activity due to low fluence rate or photosensitizer concentration. 
Fractionation may permit shorter overall treatment times by achieving a more 
efficient photodynamic reaction.
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7.12 - Future Developments - Photosensitizer
The relatively low lipophilicity of 5-ALA impedes its diffusion through 
biological membranes and hence high concentrations of the agent are 
required. Modification of 5-ALA by esterification with long chain (C6-C8) 
alcohols can reduce up to 150-fold the amount of ALA required to achieve the 
same level of PPIX (which itself is lipophilic).185 Clinical trials are required to 
confirm these in vitro observations.
Improved delivery of photosensitizer via iontophoresis may also 
facilitate improved tissue levels with lower concentrations of 5-ALA required 
although this is still to be verified as effective for application to the skin 
overlying lesions and may not be practical for routine use.186 Iron chelation 
continues to be evaluated to potentiate PPIX production with a reduced dose 
of 5-ALA , with a new agent, 1,2-diethyl-3-hydroxypyridin-4, recently
187confirmed in vivo to double PPIX production.
Local injection of photosensitizer into tumour might improve delivery, 
but would make ALA-PDT an invasive therapy. Nevertheless, if a high 
efficacy could be established for nodular BCC by this method, there may still 
be a therapeutic role for this non-surgical approach. A study to assess the 
viability of this approach has now been commenced.
Several new agents under evaluation for photodynamic therapy, BpD- 
MA, mTHPC, NPe6, SnET2, TPPS4, ZnPc, sulfonated aluminium 
phthalocyanines (AIPcSn), are more potent than current agents, with peak 
absorption wavelengths beyond 650nm which should facilitate the treatment 
of thicker tumours.22 The potential for topical application of these agents 
remains unknown.
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7.13 -Summary
Topical ALA-PDT is confirmed as an effective therapy for certain non­
melanoma skin cancers. PDT offers the advantages of being non-invasive, 
well tolerated in slow healing sites, and tissue sparing, leaving the skin 
surrounding the tumour intact and functional. ALA-PDT may be particularly 
useful for large superficial tumours and for lesions in anatomical sites where 
disfigurement from conventional therapies may be a particular risk. The 
novel non-laser source used, along with the topical application of 
photosensitizer, makes ALA-PDT a more easily accessible therapy. The 
protocols evaluated in this thesis also permit ALA-PDT to be a day/out­
patient procedure.
The adequacy of treatment depth remains a major limitation with 
nodular BCC inappropriate for ALA-PDT. Until it is possible to predict those 
thicker lesions which will respond to PDT, its practical role for such tumours, 
and particularly potentially metastatic cancers, such as squamous cell 
carcinoma, must be restricted to carefully monitored studies. New 
photosensitizers and refinement of current protocols may permit this 
development. A proportion of lesions are likely to remain resistant to PDT 
either through genetic or environmental factors.
This thesis confirms, in large open studies and where possible, in 
randomized comparison studies, certain applications for ALA-PDT delivered 
by a non-laser source. Modifications to photosensitizer application times and 
bandwidth/wavelength used should optimize treatment. An interim 
assessment of ALA-PDT in CTCL also suggests that this may be a useful 
additional therapy.
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7.14 - Principal observations
The principal observations derived from the studies in this thesis are:
1. A novel non-laser lamp is confirmed as an effective and practical light 
source for ALA-PDT.
2. Topical ALA-PDT is at least as effective as cryotherapy in Bowen's disease 
with fewer adverse reactions.
3. Topical ALA-PDT is most effective for the treatment of BCC up to 1mm in 
depth and efficacy for thicker lesions may be increased by prolonging 
photosensitizer application from 4-6 hours.
4. ALA-PDT can clear large lesions of Bowen's disease and BCC. Lesion 
size influenced outcome for Bowen's disease, whilst tumour thickness was 
the predominant influence in BCC clearance.
5. 100-125J/cm2 of red light (630±15nm) is more effective than lower doses at 
clearing Bowen's disease and minimising recurrence.
6. Red light (630±15nm) is more effective than green light (540±15nm) in the 
clearance of Bowen's disease.
7. Whilst there are no observed specific histological changes of ALA-PDT, 
both necrosis and apoptosis occur. Microscopic scar formation was observed 
in a few basal cell carcinomas, but rarely occurred after PDT to other lesions.
8. Evidence to support the existence of a photoproduct of PPIX, activated by 
670nm light, is complemented by a preliminary study that suggests that this 
may be a therapeutically useful agent.
9. Topical ALA-PDT can clear patch, plaque, and tumour stage CTCL lesions, 
although an overall response rate of 45% requires its comparison with 
existing modalities to determine the place of PDT in CTCL management.
10. ALA-PDT is a well tolerated non-invasive therapy. Anaesthesia was 
usually required only for large lesions or for prolonged photosensitizer 
application. A cosmetic outcome acceptable to patients was universal with 
only minimal scar formation clinically apparent.
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Appendix 1: Visual Analogue Score Sheet
Patient Assessment of Treatment No. Name
We would be grateful for your time in completing the questions below to help us 
assess whether or not you experienced discomfort following your treatment today in 
the Dermatology Department.
Please place a cross on each of the scale barrs below to reflect the SEVERITY of 
pain experienced following treatment (0 indicates no pain, 10 indicates very severe 
pain).
PAIN SEVERITY SCALE
0 10
First 24 Hours:
0_____________________________________________ 10
Day 2 after treatment:
0_____________________________________________ 10
Day 3 after treatment:
0_____________________________________________ 10
Day 4 after treatment:
0_____________________________________________ 10
Day 5 after treatment:
0_____________________________________________ 10
Day 6 after treatment:
0_________________________________________ 10
Day 7 after treatment:
0_________________________________________ 10
Day 8 after treatment:
0_____________________________________________ 10
Day 9 after treatment:
0_____________________________________________ 10
Day 10 after treatment:
0 10
Please comment on days when blistering was also noted. 
Thank you for your help in completing this assessment.
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Appendix 2: Consent Form for Bowen's Disease/ Actinic Keratoses Study
Your Doctor will have told you that your recent skin biopsy shows that you 
have an early, mild form of skin cancer which is normally easily cured by existing 
methods such as surgery or freezing with liquid nitrogen. You are invited to 
participate in a study assessing the value of a new alternative treatment called 
photodynamic therapy (PDT). PDT involves the application of a cream to the skin 
cancer followed 4 hours later by application of a strong light from an appropriate 
source. The light may cause a slight stinging sensation after treatment and swelling 
may occur. Rarely, it may be followed by blistering and crusting.
While preliminary results suggest that PDT is effective, it is also possible that 
it may not work but your participation in the trial may be of benefit to future patients 
who may receive PDT. If there is evidence that PDT is not working, you will , of 
course, have further treatment with freezing or surgery which is very likely to be 
effective.
If you wish to take part in this trial, your general practitioner will be advised of 
this and the clinical management that you will undergo. If you do participate in the 
trial, you will be asked to keep a chart assessing any discomfort in the 10 days 
following the new treatment and follow-up would be required for at least 1 year. 
You may be asked to donate a small further sample of skin from the treated area so 
that the response to treatment can be assessed accurately. This would involve a 
small skin biopsy similar to the one you had to make the diagnosis. As you know 
this might be slightly uncomfortable for a few days afterwards.
If you do not wish to participate in the trial or wish to withdraw at any time 
after commencing the trial, your care will in no way be affected. If you are pregnant 
or likely to become so, you should not participate in this trial.
Consent:
give my consent to the research procedures described above, the nature, purpose 
and possible consequences of which have been described to me by________
Signed_____________________  Date:____________
Witness:
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Appendix 3: Patient Information sheet - Bowen's Disease (Comparison Study)
Your Doctor will have told you that your recent skin biopsy shows that 
you have a skin condition called Bowens disease, in which a red/scaly patch 
develops on the skin which may become cancerous. You are invited to 
participate in a study assessing the value of a new alternative treatment 
called photodynamic therapy (PDT) comparing it to freezing with liquid 
nitrogen. If you participate, you will be randomised to receive either PDT or 
freezing. PDT involves the application of a cream to the skin lesion followed 
4 hours later by application of a strong light from an appropriate source. The 
light may cause a slight stinging sensation after treatment and swelling may 
occur. Rarely, it may be followed by blistering and crusting. We expect PDT 
to cause less pain and discomfort than freezing.
While preliminary results suggest that PDT is effective, further trials 
are needed. Your participation in the trial may be of benefit to future patients 
who may receive PDT. If there is evidence that PDT is not working after 2 
treatments, you will, of course, have further freezing treatment.
If you wish to take part in this trial, your general practitioner will be 
informed. If you do participate in the trial, you will be asked to keep a chart 
assessing any discomfort in the 10 days following the new treatment and 
follow-up would be required for at least 1 year. You may be asked for a small 
further sample of skin from the treated area so that the response to treatment 
can be assessed accurately. This would involve a small skin biopsy similar to 
the one you had to make the diagnosis.
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Appendix 4: Comparison Study - Patient Consent Form
Your Doctor will have told you that your recent skin biopsy shows that you 
have an early, mild form of skin cancer called Bowen's disease which is normally 
easily cured by existing methods such as freezing or surgery. You are invited to 
participate in a study assessing the value of a new alternative treatment called 
photodynamic therapy (PDT) comparing it to comparing it to freezing with liquid 
nitrogen. If you participate, you will be randomised to receive either PDT or 
freezing. PDT involves the application of a cream to the skin cancer followed 4 
hours later by application of a strong light from an appropriate source. The light 
may cause a slight stinging sensation after treatment and swelling may occur. 
Rarely, it may be followed by blistering and crusting.
While preliminary results suggest that PDT is effective, it is also possible that 
it may not work but your participation in the trial may be of benefit to future patients 
who may receive PDT. If there is evidence that PDT is not working after two 
treatments, you will , of course, have further treatment with cryotherapy or surgery, 
which is likely to be effective.
If you wish to take part in this trial, your general practitioner will be advised of 
this and the clinical management that you will undergo. If you do participate in the 
trial, you will be asked to keep a chart assessing any discomfort in the 10 days 
following the new treatment. Follow-up will be required for at least 1 year. This 
would also happen if you are allocated to cryotherapy or surgery. You may be 
asked to donate a small further sample of skin from the treated area so that the 
response to treatment can be assessed accurately. This would involve a small skin 
biopsy similar to the one you had to make the diagnosis. As you know this might be 
slightly uncomfortable for a few days afterwards.
If you do not wish to participate in the trial or wish to withdraw at any time 
after commencing the trial, your care will in no way be affected. If you are pregnant 
or likely to become so, you should not participate in this trial.
Consent:
give my consent to the research procedures described above, the nature, purpose 
and possible consequences of which have been described to me by________
Signed_____________________  Date:____________
Witness:
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Appendix 5: Patient Information sheet for Basal Cell Carcinoma Studies
Your Doctor will have told you that your recent skin biopsy shows that 
you have a skin condition called a rodent ulcer or basal cell carcinoma, which 
is the most common form of skin cancer in the U.K. and is normally easily 
cured by existing methods such as surgery. You are invited to participate in 
a study assessing the value of a new alternative treatment called 
photodynamic therapy (PDT). If you participate, you will be randomised to 
receive either PDT or freezing. PDT involves the application of a cream to 
the skin lesion followed a few hours later by application of a strong light from 
an appropriate source. The light may cause a slight stinging sensation after 
treatment and swelling may occur. Rarely, it may be followed by blistering 
and crusting. We expect PDT to cause less pain and discomfort than 
freezing.
While preliminary results suggest that PDT is effective, further trials 
are needed. Your participation in the trial may be of benefit to future patients 
who may receive PDT. If there is evidence that PDT is not working after 2 
treatments, you will, of course, have further freezing treatment.
If you wish to take part in this trial, your general practitioner will be 
informed. If you do participate in the trial, you will be asked to keep a chart 
assessing any discomfort in the 10 days following the new treatment and 
follow-up would be required for at least 1 year. You may be asked for a small 
further sample of skin from the treated area so that the response to treatment 
can be assessed accurately. This would involve a small skin biopsy similar to 
the one you had to make the diagnosis.
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Appendix 6: Consent Form for Basal Cell Carcinoma Studies
Your Doctor will have told you that your recent skin biopsy shows that you 
have a common form of skin cancer, called basal cell carcinoma (or a rodent ulcer) 
which is normally easily cured by existing methods such as surgery. You are invited 
to participate in a study assessing the value of a new alternative treatment called 
photodynamic therapy (PDT). PDT involves the application of a cream to the skin 
cancer followed 4 or 6 hours later by application of a strong light from an 
appropriate source. The light may cause a slight stinging sensation after treatment 
and swelling may occur. Rarely, it may be followed by blistering and crusting.
While preliminary results suggest that PDT is effective, it is also possible that 
it may not work but your participation in the trial may be of benefit to future patients 
who may receive PDT. If there is evidence that PDT is not working, you will , of 
course, have further treatment with surgery which is very likely to be effective.
If you wish to take part in this trial, your general practitioner will be advised of 
this and the clinical management that you will undergo. If you do participate in the 
trial, you will be asked to keep a chart assessing any discomfort in the 10 days 
following the new treatment and follow-up would be required for at least 1 year. 
You may be asked to donate a small further sample of skin from the treated area so 
that the response to treatment can be assessed accurately. This would involve a 
small skin biopsy similar to the one you had to make the diagnosis. As you know 
this might be slightly uncomfortable for a few days afterwards.
If you do not wish to participate in the trial or wish to withdraw at any time 
after commencing the trial, your care will in no way be affected. If you are pregnant 
or likely to become so, you should not participate in this trial.
Consent:
give my consent to the research procedures described above, the nature, purpose 
and possible consequences of which have been described to me by________
Signed_____________________  Date:____________
Witness:
